

Welcome to the world of Health and Wealth



95600 Square feet
of occupied land

28500 Square feet
of manufacturing
and utilities facility

More than 100
products

Active on Global
Scale

Manufacturing Facility
Making Legacy for Generations to Come

ANNUAL REPORT FOR THE YEAR ENDED JUNE 30, 2026

*"With a strengthened business platform, expanding high-value ventures and an aggressive international growth strategy, **Liven Pharma** is positioned to enter a new era of substantially higher profitability, stronger market leadership and exceptional long-term value creation"*

Table of contents

COMPANY'S INFORMATION	3
CHAIRMAN REVIEW REPORT	4
VISION AND MISSION STATEMENT	6
PROFILE OF DIRECTORS	7
CEO MESSAGE	9
DIRECTOR REPORT	10
ڈائریکٹرز کی رپورٹ	17
INDEPENDENT AUDITOR'S REPORT ON RIGHT ISSUE FUNDS UTILIZATION.....	24
INDEPENDENT AUDITOR'S REVIEW REPORT ON THE STATEMENT OF COMPLIANCE	28
STATEMENT OF COMPLIANCE WITH LISTED COMPANIES (CODE OF CORPORATE GOVERNANCE) REGULATIONS, 2019.....	29
NOTICE OF 35 th ANNUAL GENERAL MEETING.....	34
FORM OF PROXY	37
۳۵واں سالانہ عام اجلاس کا نوٹس	38
STATEMENT OF FREE FLOAT OF SHARES AND INDEPENDENT REASONABLE ASSURANCE REPORT THEREON	41
INDEPENDENT AUDITOR'S REPORT AND AUDITED FINANCIAL STATEMENTS	45

COMPANY'S INFORMATION

Board of Directors

Mr. Atif Hussain Siddiqi
Chairman

Mr. Kaashif Hussain
Chief Executive Officer

Ms. Firdous Shakir
Executive Director

Mr. Umar MujibShami
Non-Executive Director

Mr. Usman Mujib Shami
Non-Executive Director

Mr. Ahmad Shoaib Hashmi
Independent Director

Mr. Syed Raza Abbas
Independent Director

Audit Committee

Mr. Ahmad Shoaib Hashmi

Mr. Atif Hussain Siddiqi

Mr. Usman Mujib Shami

Human Resource & Remuneration Committee

Mr. Ahmad Shoaib Hashmi

Mr. Atif Hussain Siddiqi

Ms. Firdous Shakir

Chief Financial Officer

Mr. Muhammad Shah

Company Secretary

Mr. Muhammad Saeed

External Auditors

Reanda Haroon Zakaria Aamir Salman
Rizwan & Co Chartered Accountants

Legal Advisor

Saeed Associates

Share Registrar

F.D Registrar Services (pvt) Ltd

Bankers

Bank Al Habib Limited

Meezan Bank Limited

United Bank Limited

Bank Alfalah Limited

Registered Office

49-Km Lahore Multan Road Pakistan

+92-3-111-0-45836

info@liven-pharma.com

www.liven-pharma.com

CHAIRMAN REVIEW REPORT

ON BOARD'S OVERALL PERFORMANCE U/S 192 OF THE COMPANIES ACT 2017

This review is presented pursuant to the requirements of Section 192 of the Companies Act 2017 and reflects the Board's assessment of its overall performance, effectiveness and contribution towards the achievement of the Company's strategic, operational and governance objectives.

It is a privilege to present the Chairman's Review Report to the valued shareholders of Liven Pharma Limited for the financial year ended June 30, 2026. During the year, the Board remained focused on providing strategic direction, strengthening governance, enhancing operational performance and laying the foundation for sustainable growth and long-term value creation.

REVIEW OF OVERALL PERFORMANCE OF THE BOARD

During the year under review, the Board of Directors remained actively engaged in the formulation, review and execution of the Company's strategic priorities. The Board exercised effective oversight over the Company's affairs while maintaining a balanced focus on business growth, financial discipline, operational efficiency, regulatory compliance and long-term sustainability. Its deliberations were directed towards strengthening the Company's competitive position and preparing the business to respond effectively to emerging opportunities within the pharmaceutical and healthcare landscape.

Particular attention was given to expanding the Company's international business footprint, developing export opportunities, strengthening existing commercial relationships and exploring additional therapeutic and healthcare segments. The Board also maintained close oversight of cost structures, resource utilization, operational productivity and financial discipline, with the objective of improving efficiency while preserving the Company's commitment to quality and reliability.

The Board continued to attach significant importance to regulatory compliance, corporate governance, risk oversight and responsible business conduct. During the year, the Company further reinforced its compliance culture and continued to focus on applicable pharmaceutical, health, safety, environmental and corporate regulatory requirements. The Board recognizes that sustainable growth can only be achieved through strong governance, ethical conduct, accountability and responsible engagement with all stakeholders.

An important area of the Board's strategic focus during the year was diversification and the development of new business platforms. Progress was pursued in areas including Active Pharmaceutical Ingredients (API), Cosmetology, Consumer Care and Biological Products, with the objective of creating additional revenue channels, strengthening the Company's product portfolio, improving future profitability and positioning Liven Pharma Limited for participation in higher-growth segments of the healthcare industry.

The Board also continued to evaluate opportunities for strategic alliances, technology collaboration, new investments and business partnerships that may strengthen the Company's manufacturing capabilities, market access and long-term competitiveness. These initiatives reflect the Board's broader objective of transforming Liven Pharma Limited into a more diversified and resilient pharmaceutical and healthcare enterprise.

Following its comprehensive evaluation of the Board's own performance and that of its committees, the Board is satisfied that its overall performance during the financial year ended June 30, 2026 remained satisfactory, effective and aligned with the applicable legal and regulatory framework, sound corporate governance principles and recognized best practices. The Board remains committed to continuously improving its effectiveness, transparency, accountability and contribution to the sustainable development of the Company.

FUTURE OUTLOOK

The Board approaches the coming year with confidence, supported by the Company's evolving business platform, strengthening market relationships and the opportunities emerging across Pakistan's pharmaceutical and healthcare sectors. Liven Pharma Limited intends to build upon the foundations established during the year by pursuing disciplined expansion, greater market penetration, export development and carefully selected diversification opportunities.

The Company will continue to explore growth avenues in API, Biological Products, Consumer Care, Cosmetology and other promising healthcare segments, while simultaneously strengthening its core pharmaceutical operations. Strategic partnerships, international collaborations, manufacturing capabilities, product development and access to new markets will remain important components of the Company's forward-looking strategy.

The Board will continue to prioritize operational excellence, prudent financial management, quality enhancement, regulatory compliance and efficient deployment of capital. At the same time, the Company will remain attentive to changing market dynamics, technological developments and evolving customer and healthcare needs.

With a clear strategic direction and a continued emphasis on innovation, resilience and responsible growth, the Board believes that Liven Pharma Limited is well positioned to convert emerging opportunities into sustainable business performance. The Board remains committed to strengthening the Company's market position and generating enduring value for shareholders while maintaining the trust of all stakeholders.

ACKNOWLEDGMENT

On behalf of the Board of Directors, I sincerely acknowledge and appreciate the continued confidence and support extended by our valued shareholders throughout the year. Their trust remains a fundamental source of strength as the Company advances its strategic objectives.

I also place on record my appreciation for the dedication, professionalism and commitment demonstrated by the management and employees of Liven Pharma Limited. Their collective efforts, resilience and determination have contributed significantly to the progress achieved during the financial year ended June 30, 2026.

The Board further recognizes the valuable contribution of our business partners, customers, suppliers, financial institutions, regulatory authorities and other stakeholders whose continued cooperation has supported the Company's operations and development.

On behalf of the Board, I extend my sincere gratitude to all stakeholders and reaffirm our commitment to responsible leadership, sustainable growth, strong governance and the creation of lasting value for the shareholders of Liven Pharma Limited.



Atif Hussain Siddiqi
(Chairman)

VISION AND MISSION STATEMENT

Our Vision

Our business focus made explicit in this plan, renews our vision and strategic thinking on adding value to our target market segments. From average buyer to high-end institutions we will position ourselves in a manner to differentiate us from box pushers to serious minded totally committed purveyors of safe and reliable products.

Our marketing challenge is to position our product as the high-quality, high value-added yet affordable alternative to existing brands and similar products.

Our challenge is to strengthen our brand by giving the most effective and accurate product, rather than incentive based sales and marketing strategy.

From the import of the basic raw material to the procurement of excipients and packaging material our focus is to target the most reputed and prestigious manufacturers with concerned certifications as our vendors, so that what we produce for our customers is the compilation of the best what is available in the market.

We have long term targets and have set high goals for our short term results, that is why we believe in quality rather than quantity, perfection is our passion and so is the least required quality of our sector i.e. pharmaceutical manufacturing, but we take it seriously rather religiously we believe we have not chosen a business but a duty that is to endeavor ourselves in the service of humanity

Our Mission

Liven is a promise, a hope a life, a driving force more than just a pharmaceuticals manufacturing company endeavored in the business of cure, remedy and quality of life, our mission is to create a better world through our Business activities as well as our CSR activities. LIVEN is a name of a lively healthy and happy life. Welcome to the world of Liven Pharmaceuticals Ltd; where everybody is healthy wealthy and wise. LIVEN name means cause to be more lively, we creates to become more lively, rooted from a name itself we strive in providing healthcare, medicines, pharmaceuticals products and solutions to deprived, distressed and ailed to come to life and lively hood, leading by innovation to meet patient needs, and being a trusted partner for the healthcare community worldwide.

PROFILE OF DIRECTORS

MR. ATIF SIDDIQI - CHAIRMAN OF BOARD OF DIRECTORS

Mr. Atif, an accomplished industrialist, embarked on his professional career in 1999 with the establishment of his first venture, a manufacturing company specializing in empty glass ampoules for the pharmaceutical packaging industry. A graduate in BBA (Bachelors of Business Administration) from Premier College Lahore, he combines strong business acumen with extensive entrepreneurial experience.

Over the course of his career, he has successfully led multiple ventures, including Merchant's Glass, MG Construction, and Textile Temple, each of which has benefited from his strategic vision and hands-on leadership. His deep understanding of manufacturing operations, coupled with his commitment to operational excellence, has been a cornerstone of his professional success. Known for his industrious and perfectionist approach, Mr. Atif has consistently demonstrated the ability to deliver sustainable growth, innovation, and value creation throughout his career.

MR. KAASHIF HUSSAIN SIDDIQIE – CHIEF EXECUTIVE OFFICER & EXECUTIVE DIRECTOR

Mr. Kaashif Hussain is a visionary leader and entrepreneur with a strong academic background in Business Administration and Software Engineering, specializing in System Analysis and Design. He holds postgraduate degrees including an MBA and an MSc in Information Technology from Al-Khair University, Lahore.

He began his entrepreneurial journey in 1998 by establishing Heavenly Impex, an import business supplying glass packaging materials to pharmaceutical manufacturers in Pakistan. In 1999, he expanded the venture by founding Merchant's Glass, a manufacturing company. Over the years, Mr. Kaashif has also been associated with other successful ventures, including MG Constructions and Textile Temple.

Known for his analytical approach, decisiveness, and optimism, Mr. Kaashif has consistently demonstrated the qualities of a true leader, driving organizations toward growth and success.

MR. UMAR MUJIB SHAMI – NON-EXECUTIVE DIRECTOR

Mr. Umar Shami is an accomplished business leader with extensive experience in the oil, real estate, and media sectors. He holds an MBA from the Lahore University of Management Sciences (LUMS) and currently serves as a Director at New Life Developers Ltd., where he oversees real estate projects in Lahore and Gwadar. Under his leadership, Euro Oil has emerged as a growing brand in Pakistan's oil and gas industry. Prior to this role, he served as Chief Executive of Fuel Tech Ltd. A leading fuel distribution company catering to major national and multinational clients. Mr. Umar is widely recognized for his strategic vision and his ability to transform innovative ideas into successful business ventures.

MR. USMAN MUJIB SHAMI – NON-EXECUTIVE DIRECTOR

Mr. Usman Mujib Shami holds a Bachelor's degree from the Institute of Business Administration (IBA), Karachi, one of Pakistan's leading business schools. He further pursued a Master's degree in International Business from Hult International Business School, Shanghai.

In addition to serving as a Board Member of Euro Oil, Mr. Usman manages Pakistan's largest digital media house and acts as a marketing consultant for a premier housing development project in the emerging port city of Gwadar.

Mr. Usman is recognized for his analytical acumen, lean management practices, and dynamic leadership in business development, which distinguish him among top industry executives.

MR. AHMAD SHOAIB HASHMI – INDEPENDENT DIRECTOR

Mr. Ahmad Shoaib Hashmi is a distinguished businessman with extensive experience in the pharmaceutical industry. As a founding member of Mass Pharma, he has served for over 28 years in key leadership roles, including Director of Procurement and Director of International Business. With more than 35 years of professional expertise, his career encompasses pharmaceutical manufacturing, distribution, imports, and international trade.

Mr. Ahmed Shoaib is widely recognized for his strategic leadership and in-depth industry knowledge, having played a pivotal role in driving growth, developing global partnerships, and contributing to the advancement of the pharmaceutical sector. He is also among the pioneers who introduced innovative healthcare technologies in Pakistan, such as Enhanced External Counter pulsation (EECP) treatment for cardiac patients who are unable to undergo invasive procedures.

Ms. FIRDOUS SHAKIR – EXECUTIVE DIRECTOR

Ms. Shakir is a highly experienced professional with over 48 years of expertise in managing human resources and successfully operating small and medium enterprises. She has independently managed a dairy and protein farm, demonstrating strong leadership, organizational management, and operational skills.

Throughout her career, she has developed extensive knowledge in workforce management, supply chain oversight, and sustainable business practices, enabling her to build and maintain efficient business operations. Her ability to adapt to evolving market dynamics and her proven track record in entrepreneurship reflect her strategic mindset and commitment to long-term growth.

MR. SYED RAZA ABBAS JAFFERY – INDEPENDENT DIRECTOR

Mr. Syed Raza Abbas serves on the Board of the Company as a representative of National Investment Trust Limited (NITL), Pakistan's largest and oldest asset management company. He has been associated with NITL since 2001 and currently holds the position of Head of Equities, where he leads the equity investment team and oversees portfolio management across multiple funds. His responsibilities include developing investment strategies, conducting in-depth market research, and ensuring optimal asset allocation to maximize returns for investors.

Prior to joining NITL, Mr. Raza served as Manager Treasury at Doha Bank Limited (Pakistan), where he gained valuable experience in treasury operations, liquidity management, and financial risk mitigation.

Mr. Raza holds an MBA in Banking & Finance and also represents NITL on the boards of several other listed companies. Through his governance roles, he actively contributes to promoting transparency, accountability, and sustainable growth within these organizations.

CEO MESSAGE

It is with great pride that I present the performance of Liven Pharma Limited for the financial year ended June 30, 2026. The year was marked by geopolitical conflicts, regional wars, inflationary pressures, currency volatility, supply-chain disruptions and challenging economic conditions. Despite these headwinds, Liven Pharma remained resilient, protected its core business and continued to advance its strategic growth agenda.

Our response has been clear: strengthen, diversify and move forward. We continued to focus on operational efficiency, financial discipline, strategic alliances and opportunities for forward and backward integration, while strengthening our position in both domestic and international markets.

During FY 2026, we accelerated our focus on higher-value opportunities including APIs, oncology, biosimilars, biological products, consumer healthcare, cosmetology and veterinary pharmaceuticals. Progress towards our Bioequivalence & Research Center and veterinary pharmaceutical initiatives represents an important step in expanding our capabilities and creating new avenues for future growth.

International expansion remains a key priority. We intend to leverage strategic partnerships, develop new export markets and broaden our product portfolio to establish Liven Pharma as a more diversified and internationally competitive pharmaceutical company.

The disruptions of recent years have reinforced the importance of self-reliance, supply-chain security and operational control. We are therefore intended to invest strategically in APIs Manufacturing technology, enhancing present manufacturing capabilities, research and new business platforms designed to improve efficiency, reduce dependencies and strengthen our long-term profitability.

Our ambition is not incremental growth—it is transformational growth. The foundations being established today across pharmaceuticals, APIs, biologicals, research, consumer care, veterinary products and international markets are expected to create multiple engines of future revenue and profitability.

We remain firmly committed to sound governance, quality, regulatory compliance and responsible growth. At the same time, we will continue to pursue commercially attractive opportunities with discipline, speed and determination.

I am confident that Liven Pharma is entering a new phase of growth, diversification and value creation. With a strengthened platform, an expanding portfolio and a clear strategic roadmap, we are well positioned to capture the opportunities ahead and deliver sustainable value to our shareholders.

I sincerely thank our shareholders for their trust, our customers and partners for their continued confidence, and our employees for their dedication and commitment.

We have strengthened our foundations. We have expanded our vision. Now, we are ready to accelerate.

On behalf of the Board, I look forward to the next chapter of Liven Pharma Limited with confidence and determination.



Kaashif Hussain Siddique
(Chief Executive Officer)

DIRECTOR REPORT

We are pleased to present the annual report together with audited financial statements of the Company for the year ended June 30, 2026. The director report is prepared in accordance with section 227 of Companies Act, 2017 and Chapter XII of the Listed Companies (Code of Corporate Governance) Regulations, 2019.

Composition of Board

1.	Male	6
2.	Female	1
Sr. No.	Category	Name
1	Independent Director	1. Mr. Ahmad Shoaib Hashmi 2. Mr. Syed Raza Abbass
2	Non-Executive Director	1. Mr. Atif Hussain Siddiqi 2. Mr. Umar Mujib Shami 3. Mr. Usman Mujib Shami
3	Executive Director	1. Mr. Kaashif Hussain 2. Ms. Firdous Shakir (Female director)

PRINCIPAL ACTIVITIES

The principal activity of the company is manufacturing and sale of pharmaceutical products.

OVERVIEW OF ECONOMY AND BUSINESS

Macroeconomic Overview

The financial year ended 30 June 2026 reflected a modest recovery in Pakistan's economy. Real GDP grew by 3.7 percent, the highest in four years, supported by services, industry and agriculture. Inflation remained within the State Bank of Pakistan's target range in the first half of the year, and the policy rate was reduced to 10.5 percent in December 2025. However, the conflict in the Middle East raised global energy prices from March 2026, pushing inflation to 11.1 percent in June 2026 and the policy rate to 11.5 percent. Average inflation for the year was 7.1 percent. Foreign exchange reserves remained comparatively stable at around USD 17.2 billion.

Sector Performance

The pharmaceutical sector remained resilient, supported by steady demand for essential medicines and rising healthcare awareness. Disruption of Gulf shipping routes in the second half of the year increased freight and insurance costs for imported raw materials, although DRAP confirmed adequate stocks of essential medicines. Memoranda of understanding signed with Chinese companies in May 2026 for API manufacturing and technology transfer may reduce import dependence over time.

Industry Challenges

Delays in drug pricing and product registration, the sector's reliance on imported Active Pharmaceutical Ingredients (APIs) and packaging materials, and higher energy and financing costs remained the key challenges. During the year the Company paid PKR 2.820 million in registration fees to DRAP, but the registration certificates had not been issued by the reporting date. Constructive engagement with the Drug Regulatory Authority of Pakistan (DRAP) has remained a critical avenue for navigating these challenges.

Financial Highlights

During the year under review, the Company recorded a turnover of PKR 105.807 million (2025: PKR 127.272 million), including first export sales of PKR 14.148 million. Gross profit improved to PKR 26.646 million (2025: PKR 17.959 million), and the gross margin rose to 25.2 percent from 14.1 percent, as cost of sales declined faster than sales. A provision of PKR 36.760 million against obsolete finished goods has been recorded under other expenses.

The operating loss was PKR 77.140 million (2025: PKR 490.902 million). Last year's result included a one-off, non-cash listing expense of PKR 327.803 million arising from the reverse merger. Other expenses this year also include expected credit losses on trade debts of PKR 11.582 million and impairment of advances to suppliers of PKR 5.160 million. After a deferred tax credit of PKR 35.182 million, the Loss After Tax amounted to PKR 31.139 million (2025: PKR 584.460 million).

A revaluation surplus of PKR 188.911 million, net of deferred tax, was recognized in other comprehensive income. Total equity increased to PKR 985.458 million and total assets to PKR 1,216.042 million, mainly due to the rights issue and the revaluation surplus. Borrowings remain low, with a gearing ratio of 1.55 percent.

Related Party Transactions

The Company ensures compliance with Code of Corporate Governance for all the related party transactions. The details of these transactions are provided in note no. 35 of the annexed financial statements. During the year, the Chief Executive Officer and a director subscribed to right shares, and loans from directors of PKR 15.283 million, which are unsecured, interest-free and repayable on demand, remained outstanding at year end. The title of the freehold land is in the names of two directors and will be transferred to the Company once the related bank financing is settled.

Earning Per Share

The loss per share for the year is Rs. 0.28, basic and diluted, compared with Rs. 7.11 (restated) last year. The weighted average number of shares was 111,624,523, reflecting the issue of 20,000,000 right shares in January 2026. Last year's loss per share, originally reported as Rs. 8.37, has been restated for the bonus element of the rights issue. It was driven mainly by the non-cash listing expense and deferred tax. The pharmaceutical sector exhibited continued resilience, potentially supported by sustained demand for essential medicines and specialized formulations. Structural drivers such as rising healthcare awareness, demographic expansion, and ongoing regulatory engagement have collectively provided a framework conducive to sectoral continuity.

COMMITTEES OF THE BOARD

Audit committee

Audit committee comprises of three members from the Board. The chairman of the Committee is an independent director as required in the CCG Regulations 2019 while the remaining two are non-executive directors. The Board of Directors has set out terms of reference for the audit committee. The audit committee reviews the annual and quarterly financial statements and holds its meeting prior to the Board meetings. The following are the members of the audit committee.

Sr. No.	Name	Designation
i.	Mr. Ahmad Shoaib Hashmi	Chairman (Independent Director)
ii.	Mr. Atif Hussain Siddiqi	Member (Non-Executive Director)
iii.	Mr. Usman Mujib Shami	Member (Non-Executive Director)
iv.	Mr. Muhammad Saeed	Secretary

Meeting And Attendance

Board Audit Committee: Four (4) meetings have been convened during the financial year ended June 30, 2026.

Human Resource & Remuneration Committee

The committee consists of three members from the Board; one is independent director, one is non-executive director and the one is executive director. The Chairman of the committee is the independent non-executive director. The committee reviews and formulates the HR & management policies of the company. The Committee is also responsible for the remuneration of employees and ensures that it is aligned with the Company's business strategy and long-term interests. The following are the members of the Human Resource committee.

Sr. No.	Name	Designation
i.	Mr. Ahmad Shoaib Hashmi	Chairman (Independent Director)
ii.	Mr. Atif Hussain Siddiqi	Member (Non-Executive Director)
iii.	Ms. Firdous Shakir	Member (Executive Director)
iv.	Mr. Muhammad Saeed	Secretary

Meeting And Attendance

Human Resource and Remuneration Committee Meeting was held one (1) time during the financial year ended June 30, 2026.

Auditors

The present external auditors' Reanda Haroon Zakaria Aamir Salman Rizwan & Co Chartered Accountants, retire and being eligible, have offered themselves for re-appointment. The Board of Directors recommended the recommendation of the Audit Committee for their re-appointment as auditors of the Company for the financial year ending June 30, 2027 at a mutually agreed fee.

REMUNERATION POLICY

The non-Executive directors including independent Directors of the Company are entitled to a remuneration recommended by Human Resource and Remuneration Committee (HR&RC) and approved by the Board, based on market benchmark of the consumer healthcare industry and other similar style of business.

REMUNERATION OF THE CHIEF EXECUTIVE OFFICER, DIRECTOR AND EXECUTIVES

A detailed note on the remuneration of the Chief Executive Officer, Directors and Executives for the year 2026 are provided in note no. 36 of the annexed financial statements.

DIVERSITY, EQUITY AND INCLUSION

The Company is dedicated to promoting Diversity Equity and Inclusion (DE & I) throughout its operations. The Company has implemented policies and initiatives aimed at creating a diverse and inclusive workplace. The efforts are focused on ensuring equal opportunities for all employees and to ensure that all employees feel valued, respected and empowered, fostering an inclusive culture and supporting a wide range of perspectives. These measures are regularly reviewed and updated to align with Company's core values and contribute to the overall success and sustainability of the Company.

ENVIRONMENT, HEALTH AND SAFETY

The Company is committed to maintaining a safe and secure environment and believes, it is our responsibility to ensure that everyone working with us understands how to work safely and without risking their health. The health and safety of our employees and visitors is a top priority of the Company. So, we continuously identify, assess and manage any potential hazards associated with our operations to eliminate or minimize risks.

CORPORATE SOCIAL RESPONSIBILITY

As part of its CSR mandate, Liven Pharma Limited makes significant investments in community upliftment and the promotion of human rights. Our social initiatives primarily focus on areas surrounding our plant site, emphasizing education, livelihood opportunities, healthcare and vocational training for underprivileged individuals, as well as providing free medical services to those in need near our facility.

PATTERN OF HOLDING OF SHARES

No. of Shareholders	Shareholding From	Shareholding to	Total shares held
682	1	100	23,139
784	101	500	296,557
403	501	1000	339,852
777	1001	5000	1,952,262
197	5001	10000	1,432,506
70	10001	15000	866,401
41	15001	20000	733,982
19	20001	25000	436,117
11	25001	30000	302,308
8	30001	35000	263,810
6	35001	40000	231,678
7	40001	45000	293,572
9	45001	50000	445,216
4	50001	55000	211,522
4	55001	60000	230,639
2	60001	65000	127,790
2	70001	75000	147,000
1	90001	95000	92,922
1	95001	100000	100,000
1	100001	105000	105,000
1	110001	115000	111,895
1	115001	120000	119,666
1	120001	125000	122,086
2	150001	155000	307,437
1	160001	165000	162,604
1	195001	200000	200,000
1	200001	205000	202,213
1	225001	230000	230,000
1	230001	235000	230,482
1	445001	450000	447,867
1	555001	560000	556,726
1	3970001	3975000	3,970,960
1	8110001	8115000	8,113,131
1	8240001	8245000	8,241,633
2	40695001	40700000	81,391,394
3046			113,040,367

ADEQUACY OF INTERNAL FINANCIAL CONTROLS

These controls are designed to ensure accuracy, transparency, and integrity in financial reporting and operational processes. The effectiveness of these controls is periodically reviewed by management and overseen by the Audit Committee, which evaluates compliance and the need for any improvements or additional oversight measures.

COMPLIANCE WITH THE LISTED COMPANIES (CODE OF CORPORATE GOVERNANCE) REGULATIONS, 2019

The Board is familiar with the requirements of the Listed Companies (Code of Corporate Governance) Regulations, 2019 and has collaborated with Management to implement the necessary measures for compliance. For further details, please refer to the review report on the Statement of Compliance issued by the Company's external auditors in the Annual Report, as mandated by the Listed Companies (Code of Corporate Governance) Regulations, 2019.

STATE OF COMPANY'S AFFAIRS AND CORPORATE AND FINANCIAL REPORTING FRAMEWORK

The financial statements prepared by the management of the Company, represent fairly its state of affairs, the result of the operations, cash flows and changes in equity.

Appropriate accounting policies have been consistently applied in preparation of financial statements and accounting estimates are based on reasonable and prudent judgement.

Proper books of accounts have been maintained by the Company.

Financial reporting is based on the approved International Accounting Standards as applicable in Pakistan, have been followed in preparation of financial statements.

There is no significant doubt about the Company's ability to continue as a going concern.

The system of internal control is sound in design.

The process of monitoring internal controls will continue as an ongoing process with the objective to further strengthen the controls and bring improvements in the system.

MATERIAL CHANGES

During the financial year, the Company completed the right issue process. Pursuant to Central Depository Company (CDC) confirmation dated January 5, 2026, 19,979,786 right securities were credited into the Central Depository System, increasing the paid-up share capital to 113,040,367 ordinary shares. The reverse merger and change in principal business activity had been effected in the preceding period.

SUBSEQUENT EVENTS

No material events have occurred subsequent to June 30, 2026 that require adjustment or separate disclosure in the annual financial statements, based on information available up to the date of their approval.

DIVIDENDS

In light of the financial headwinds faced during the year, the Board—exercising judicious stewardship—has elected to withhold dividend distribution. This decision, though measured, is by no means indicative of future intent. With the Company now poised on the cusp of revitalized growth and strategic transformation, the prospect of shareholder rewards gleams promisingly on the horizon.

RISK OF MANAGEMENT

In the diligent execution of its fiduciary duties, the Board of Directors has maintained an unwavering commitment to the vigilant oversight of the socio-economic landscape, both domestically and internationally. This includes a rigorous appraisal of internal and external risk vectors that may impinge upon the Company's operational integrity and strategic objectives.

Throughout the year, the Board has demonstrated a proactive posture in identifying latent threats, evaluating their potential ramifications, and formulating robust countermeasures. These mitigation strategies are to be meticulously implemented under the auspices of the Audit Committee, thereby ensuring a seamless and comprehensive approach to risk governance, devoid of lacunae.

RISK ASSESSMENT

It is an undeniable reality that businesses, regardless of industry, face a spectrum of risks that may imperil their objectives. Unchecked, such vulnerabilities can lead to avoidable financial and reputational setbacks.

Acknowledging this, the Board has conducted a thorough evaluation of key macroeconomic pressures—including rising financing costs, energy price volatility, currency depreciation, and dwindling foreign reserves—all of which have intensified operational exposure. In response, the Board remains resolute in strengthening the Company's resilience through strategic foresight and sound governance.

FUTURE CHALLENGES & PROSPECTS

The Company enters the new year with a stronger balance sheet, including higher equity, minimal borrowings and cash and investments of PKR 181.551 million. The focus is on putting the right issue proceeds to work, including the dry powder injectables facility, product registrations with DRAP and expansion of the sales team. Production of 0.72 million units against an installed capacity of 12 million units shows the scale of the opportunity. The Company aims to widen its customer base, as two customers accounted for 58.98 percent of sales, and to build on its first export sales.

Higher energy and financing costs, import dependence and the uncertain outlook for inflation and global energy prices will continue to affect margins. Management will keep costs under close review, pursue recovery of old receivables and work towards sustainable profitability.

ACKNOWLEDGMENT

The Company expresses its gratitude to its shareholders, employees, business partners and all other stakeholders for their trust and support throughout our journey toward growth and prosperity. We anticipate another year of success and are committed to our mission of creating sustainable value for all our stakeholders.

For and on behalf of




Kaashif Hussain Siddique
(Chief Executive Officer)




Atif Hussain Siddiqi
(Chairman)

ڈائریکٹرز کی رپورٹ

ہمیں یہ رپورٹ پیش کرنے ہوئے خوشی محسوس ہوئی ہے کہ کمپنی کے سالانہ آڈٹ شدہ مالیاتی بیانات ہماہ مالی سال ختم شدہ 30 جون 2026 آپ کی خدمت میں پیش کیے جا رہے ہیں۔ یہ ڈائریکٹرز رپورٹ کمپنیز ایکٹ 2017 کے سیکشن 227 اور لسٹڈ کمپنیز (کوڈ آف کارپوریٹ گورننس) ریگولیشنز 2019 کے چپٹر XII کے مطابق تیار کی گئی ہے۔

نمبر شمار	زمرہ	نام	تعداد	بورڈ کی تشکیل صنف
1	آزاد ڈائریکٹر	(1) جناب احمد شعیب ہاشمی (2) جناب سید رضا عباس	6	مرد
2	نان ایگزیکٹو ڈائریکٹر	(1) جناب عاطف حسین (2) جناب عمر مجیب شامی (3) جناب عثمان مجیب شامی	1	خاتون
3	ایگزیکٹو ڈائریکٹر	(1) جناب کاشف حسین (2) محترمہ فردوس شاکر (خاتون ڈائریکٹر)		

بنیادی سرگرمیاں

کمپنی کی بنیادی سرگرمی دواسازی کی مصنوعات کی تیاری اور فروخت ہے۔

معیشت اور کاروبار کا جائزہ

معاشی جائزہ

30 جون 2026 کو ختم ہونے والے مالی سال میں پاکستان کی معیشت میں معمولی بحالی دیکھنے میں آئی۔ حقیقی جی ڈی پی میں 3.7 فیصد اضافہ ہوا، جو گزشتہ چار برسوں میں سب سے زیادہ ہے، اور اس میں خدمات، صنعت اور زراعت نے کردار ادا کیا۔ سال کی پہلی ششماہی میں مہنگائی اسٹیٹ بینک آف پاکستان کی ہدفی حد کے اندر رہی اور دسمبر 2025 میں پالیسی ریٹ کم کر کے 10.5 فیصد کر دیا گیا۔ تاہم، مشرق وسطیٰ میں جاری تنازع کے باعث مارچ 2026 سے عالمی توانائی کی قیمتوں میں اضافہ ہوا، جس کے نتیجے میں جون 2026 میں مہنگائی 11.1 فیصد اور پالیسی ریٹ 11.5 فیصد تک پہنچ گیا۔ سال کے دوران اوسط مہنگائی 7.1 فیصد رہی۔ زرمبادلہ کے ذخائر نسبتاً مستحکم رہے اور تقریباً 17.2 ارب امریکی ڈالر کی سطح پر برقرار رہے۔

دواسازی کے شعبے کی کارکردگی

دواسازی کا شعبہ مضبوط رہا، جسے ضروری ادویات کی مستقل طلب اور صحت کے بارے میں بڑھتی ہوئی آگاہی کا سہارا حاصل رہا۔ سال کی دوسری ششماہی میں خلیجی بحری راستوں میں خلل کے باعث درآمدی خام مال کے لیے مال برداری اور انشورنس کے اخراجات بڑھ گئے، تاہم ڈرگ ریگولیٹری اتھارٹی آف پاکستان (ڈریپ) نے ضروری ادویات کے وافر ذخائر کی تصدیق کی۔ مئی 2026 میں چینی کمپنیوں کے ساتھ ایکٹو فارماسیوٹیکل انگریڈینٹس (APIs) کی تیاری اور ٹیکنالوجی کی منتقلی کے لیے دستخط کی گئی مفاہمتی یادداشتیں وقت کے ساتھ درآمدی انحصار کم کرنے میں مددگار ثابت ہو سکتی ہیں۔

صنعتی چیلنجز

ادویات کی قیمتوں کے تعین اور مصنوعات کی رجسٹریشن میں تاخیر، ایکٹو فارماسیوٹیکل انگریڈینٹس (APIs) اور پیکنگ میٹیریل کی درآمد پر شعبے کا انحصار، اور توانائی اور مالی اخراجات میں اضافہ بنیادی چیلنجز رہے۔ سال کے دوران کمپنی نے ڈریپ کو رجسٹریشن فیس کی مد میں 2.820 ملین روپے ادا کیے، تاہم رپورٹنگ کی تاریخ تک رجسٹریشن سرٹیفکیٹ جاری نہیں ہوئے تھے۔ ڈرگ ریگولیٹری اتھارٹی آف پاکستان (ڈریپ) کے ساتھ تعمیری روابط ان چیلنجز سے نمٹنے کا ایک اہم ذریعہ رہے ہیں۔

مالیاتی کارکردگی

زیر جائزہ سال کے دوران کمپنی نے 105.807 ملین روپے کی فروخت (2025: 127.272 ملین روپے) ریکارڈ کی، جس میں 14.148 ملین روپے کی پہلی برآمدی فروخت بھی شامل ہے۔ مجموعی منافع بہتر ہو کر 26.646 ملین روپے (2025: 17.959 ملین روپے) ہو گیا، اور مجموعی منافع کا مارجن 14.1 فیصد سے بڑھ کر 25.2 فیصد ہو گیا، کیونکہ فروخت کی لاگت میں کمی فروخت میں کمی سے زیادہ رہی۔ متروک تیار شدہ مال کے مقابل 36.760 ملین روپے کی پراویژن دیگر اخراجات میں شامل کی گئی ہے۔

آپریٹنگ نقصان 77.140 ملین روپے رہا (2025: 490.902 ملین روپے)۔ گزشتہ سال کے نتائج میں ریورس مرجر کے نتیجے میں پیدا ہونے والا 327.803 ملین روپے کا ایک مرتبہ کا غیر نقد لسٹنگ خرچ شامل تھا۔ اس سال دیگر اخراجات میں تجارتی قرضوں پر متوقع کریڈٹ نقصانات کے 11.582 ملین روپے اور سپلائرز کو دیے گئے ایڈوانسز کی قدر میں کمی (امپیئرمنٹ) کے 5.160 ملین روپے بھی شامل ہیں۔ 35.182 ملین روپے کے موخر ٹیکس کریڈٹ کے بعد بعد از ٹیکس نقصان 31.139 ملین روپے رہا (2025: 584.460 ملین روپے)۔

جائیداد، پلانٹ اور آلات کی ازسرنو تشخیص (ری ویلیویشن) سے حاصل ہونے والا 188.911 ملین روپے کا فاضل، موخر ٹیکس کے بعد، دیگر جامع آمدن میں تسلیم کیا گیا۔ کل ایکویٹی بڑھ کر 985.458 ملین روپے اور کل اثاثے بڑھ کر 1,216.042 ملین روپے ہو گئے، جس کی بنیادی وجہ رائٹ ایشو اور ری ویلیویشن سرپلس ہے۔ قرضے کم رہے اور گینرنگ ریشو 1.55 فیصد رہا۔

متعلقہ فریقین سے لین دین

کمپنی متعلقہ فریقین سے تمام لین دین کے سلسلے میں کوڈ آف کارپوریٹ گورننس کی تعمیل کو یقینی بناتی ہے۔ ان لین دین کی تفصیلات منسلکہ مالیاتی گوشواروں کے نوٹ نمبر 35 میں دی گئی ہیں۔ سال کے دوران چیف ایگزیکٹو آفیسر اور ایک ڈائریکٹر نے رائٹ شیئرز کی خریداری کی، اور ڈائریکٹرز سے لیے گئے 15.283 ملین روپے کے قرضے، جو غیر محفوظ، بلا سود اور طلب پر قابل واپسی ہیں، سال کے اختتام پر بقایا رہے۔ فری ہولڈ زمین کی ملکیت کا اندراج دو ڈائریکٹرز کے نام پر ہے اور متعلقہ بینک فنانسنگ کی ادائیگی کے بعد یہ کمپنی کے نام منتقل کر دی جائے گی۔

فی شیئر نقصان

سال کے لیے بنیادی اور تخفیف شدہ فی شیئر نقصان 0.28 روپے ہے، جبکہ گزشتہ سال یہ 7.11 روپے (ازسرنو ترتیب شدہ) تھا۔ حصص کی اوسط وزنی تعداد 111,624,523 رہی، جو جنوری 2026 میں 20,000,000 رائٹ شیئرز کے اجراء کی عکاسی کرتی ہے۔ گزشتہ سال کا فی شیئر نقصان، جو ابتدا میں 8.37 روپے ظاہر کیا گیا تھا، رائٹ ایشو کے بونس عنصر کے مطابق ازسرنو ترتیب دیا گیا ہے۔ یہ نقصان بنیادی طور پر غیر نقد لسٹنگ خرچ اور موخر ٹیکس کی وجہ سے ہوا تھا۔

بورڈ کی کمیٹیاں

آڈٹ کمیٹی

آڈٹ کمیٹی بورڈ کے تین اراکین پر مشتمل ہے۔ کمیٹی کے چیئرمین آزاد ڈائریکٹر ہیں، جیسا کہ سی سی جی ریگولیشنز 2019 کے تحت لازم ہے، جبکہ باقی دو اراکین نان ایگزیکٹو ڈائریکٹرز ہیں۔ بورڈ آف ڈائریکٹرز نے آڈٹ کمیٹی کے لیے باقاعدہ دائرہ اختیار (Terms of Reference) مقرر کیا ہے۔ آڈٹ کمیٹی سالانہ اور سہ ماہی مالیاتی گوشواروں کا جائزہ لیتی ہے اور اس کا اجلاس بورڈ کے اجلاس سے پہلے منعقد کیا جاتا ہے۔ آڈٹ کمیٹی کے اراکین درج ذیل ہیں:

نمبر شمار	نام	عہدہ
i	جناب احمد شعیب ہاشمی	چیئرمین (آزاد ڈائریکٹر)
ii	جناب عاطف حسین صدیقی	رکن (نان ایگزیکٹو ڈائریکٹر)
iii	جناب عثمان مجیب شامی	رکن (نان ایگزیکٹو ڈائریکٹر)
iv	جناب محمد سعید	سیکرٹری

اجلاس اور حاضری

30 جون 2026 کو ختم ہونے والے مالی سال کے دوران بورڈ آڈٹ کمیٹی کے چار (4) اجلاس منعقد ہوئے۔

ہیومن ریسورس اور معاوضہ کمیٹی

یہ کمیٹی بورڈ کے تین اراکین پر مشتمل ہے، جن میں ایک آزاد ڈائریکٹر، ایک نان ایگزیکٹو ڈائریکٹر اور ایک ایگزیکٹو ڈائریکٹر شامل ہیں۔ کمیٹی کے چیئرمین آزاد نان ایگزیکٹو ڈائریکٹر ہیں۔ کمیٹی کمپنی کی ہیومن ریسورس اور مینجمنٹ پالیسیوں کا جائزہ لے کر انہیں تشکیل دیتی ہے۔ یہ کمیٹی ملازمین کے معاوضے کی بھی ذمہ دار ہے اور اس بات کو یقینی بناتی ہے کہ یہ کمپنی کی کاروباری حکمت عملی اور طویل مدتی مفادات سے ہم آہنگ ہو۔ ہیومن ریسورس کمیٹی کے اراکین درج ذیل ہیں:

نمبر شمار	نام	عہدہ
i	جناب احمد شعیب ہاشمی	چیئرمین (آزاد ڈائریکٹر)
ii	جناب عاطف حسین صدیقی	رکن (نان ایگزیکٹو ڈائریکٹر)
iii	محترمہ فردوس شاکر	رکن (ایگزیکٹو ڈائریکٹر)
iv	جناب محمد سعید	سیکرٹری

اجلاس اور حاضری

30 جون 2026 کو ختم ہونے والے مالی سال کے دوران ہیومن ریسورس اور معاوضہ کمیٹی کا ایک (1) اجلاس منعقد ہوا۔

آڈیٹرز

کمپنی کے موجودہ بیرونی آڈیٹرز، ریندا ہارون زکریا عامر سلمان رضوان اینڈ کمپنی، چارٹرڈ اکاؤنٹنٹس، ریٹائر ہو رہے ہیں اور اہل ہونے کے باعث انہوں نے از خود دوبارہ تقرری کے لیے خود کو پیش کیا ہے۔ بورڈ آف ڈائریکٹرز نے آڈٹ کمیٹی کی سفارش کے مطابق 30 جون 2027 کو ختم ہونے والے مالی سال کے لیے باہمی طور پر طے شدہ فیس پر ان کی دوبارہ تقرری تجویز کی ہے۔

معاوضہ پالیسی

کمپنی کے نان ایگزیکٹو ڈائریکٹرز، بشمول آزاد ڈائریکٹرز، کو معاوضہ ہیومن ریسورس اور معاوضہ کمیٹی کی سفارش اور بورڈ کی منظوری کے بعد ادا کیا جاتا ہے، جو کنزیومر ہیلتھ کیئر انڈسٹری اور اسی نوعیت کے دیگر کاروباروں کے مارکیٹ بینچ مارک کے مطابق ہے۔

چیف ایگزیکٹو آفیسر، ڈائریکٹرز اور ایگزیکٹوز کا معاوضہ

مالی سال 2026 کے لیے چیف ایگزیکٹو آفیسر، ڈائریکٹرز اور ایگزیکٹوز کو ادا کیے گئے معاوضے کی تفصیلات مالیاتی گوشواروں کے نوٹ نمبر 36 میں فراہم کی گئی ہیں۔

تنوع، مساوات اور شمولیت

کمپنی اپنے تمام امور میں تنوع (Diversity)، مساوات (Equity) اور شمولیت (Inclusion) کے فروغ کے لیے پُر عزم ہے۔ کمپنی نے ایک متنوع اور جامع کام کی جگہ کے قیام کے لیے پالیسیاں اور اقدامات نافذ کیے ہیں۔ ان کوششوں کا مرکز تمام ملازمین کے لیے مساوی مواقع کو یقینی بنانا ہے، اور یہ کہ تمام ملازمین خود کو قابلِ قدر، محترم اور بالاختیار محسوس کریں، شمولیت پر مبنی ثقافت کو فروغ دیا جائے اور مختلف نقطہ نظر کو سہارا دیا جائے۔ ان اقدامات کا باقاعدگی سے جائزہ لیا جاتا ہے اور انہیں کمپنی کی بنیادی اقدار کے مطابق اپ ڈیٹ کیا جاتا ہے، تاکہ یہ کمپنی کی مجموعی کامیابی اور پائیداری میں اپنا کردار ادا کریں۔

ماحول، صحت اور حفاظت

کمپنی ایک محفوظ اور مامون ماحول کو برقرار رکھنے کے لیے پُر عزم ہے اور سمجھتی ہے کہ یہ ہماری ذمہ داری ہے کہ ہمارے

ساتھ کام کرنے والا ہر فرد یہ جانتا ہو کہ اپنی صحت کو خطرے میں ڈالے بغیر محفوظ طریقے سے کام کیسے کیا جائے۔ ہمارے ملازمین اور مہمانوں کی صحت اور حفاظت کمپنی کی اولین ترجیح ہے۔ اسی لیے ہم اپنے آپریشنز سے وابستہ ممکنہ خطرات کی مسلسل نشاندہی، جائزہ اور انتظام کرتے ہیں تاکہ خطرات کو ختم یا کم سے کم کیا جاسکے۔

کارپوریٹ سماجی ذمہ داری (CSR)

اپنی سماجی ذمہ داری کے تحت، لیون فارما لمیٹڈ کمیونٹی کی فلاح و بہبود اور انسانی حقوق کے فروغ کے لیے نمایاں سرمایہ کاری کرتی ہے۔ ہماری سماجی سرگرمیاں بنیادی طور پر پلانٹ کے اطراف کے علاقوں پر مرکوز ہیں، جن میں تعلیم، روزگار کے مواقع، صحت کی سہولیات اور پسماندہ افراد کے لیے پیشہ ورانہ تربیت پر زور دیا جاتا ہے، نیز ہماری سہولت کے قریب ضرورت مند افراد کو مفت طبی خدمات بھی فراہم کی جاتی ہیں۔

اندرونی مالیاتی کنٹرولز کی مناسبت

یہ کنٹرولز کمپنی کی مالیاتی رپورٹنگ اور آپریشنل عمل میں درستگی، شفافیت اور دیانت داری کو یقینی بنانے کے لیے وضع کیے گئے ہیں۔ ان کنٹرولز کی افادیت کا مینجمنٹ کی جانب سے وقتاً فوقتاً جائزہ لیا جاتا ہے اور آڈٹ کمیٹی ان کی نگرانی کرتی ہے، جو تعمیل اور کسی بھی بہتری یا اضافی نگرانی کی ضرورت کا جائزہ لیتی ہے۔

لسٹڈ کمپنیز (کوڈ آف کارپوریٹ گورننس) ریگولیشنز، 2019 کی تعمیل

بورڈ کو لسٹڈ کمپنیز (کوڈ آف کارپوریٹ گورننس) ریگولیشنز، 2019 کے تقاضوں کا بخوبی علم ہے اور اس نے مینجمنٹ کے ساتھ مل کر تعمیل کے لیے ضروری اقدامات اختیار کیے ہیں۔ مزید تفصیلات کے لیے براہ کرم سالانہ رپورٹ میں شامل کمپنی کے بیرونی آڈیٹرز کی جانب سے جاری کردہ اسٹیٹمنٹ آف کمپلائنس کی ریویو رپورٹ سے رجوع کریں، جیسا کہ مذکورہ ریگولیشنز کے تحت لازم ہے۔

کمپنی کے امور کی کیفیت اور کارپوریٹ و مالیاتی رپورٹنگ فریم ورک

کمپنی کی انتظامیہ کے تیار کردہ مالیاتی گوشوارے اس کی مالی حالت، آپریشنز کے نتائج، نقد بہاؤ اور ایکویٹی میں تبدیلیوں کو درست طور پر ظاہر کرتے ہیں۔

مالیاتی گوشواروں کی تیاری میں موزوں اکاؤنٹنگ پالیسیاں مستقل طور پر اپنائی گئی ہیں اور اکاؤنٹنگ تخمینے معقول اور محتاط فیصلے پر مبنی ہیں۔

کمپنی نے کتب حسابات درست اور مکمل طور پر برقرار رکھی ہیں۔

مالیاتی رپورٹنگ پاکستان میں قابل اطلاق منظور شدہ بین الاقوامی اکاؤنٹنگ معیارات کے مطابق کی گئی ہے اور مالیاتی گوشواروں کی تیاری میں ان کی پیروی کی گئی ہے۔

کمپنی کے ایک جاری ادارے کے طور پر چلتے رہنے کی صلاحیت کے بارے میں کوئی قابل ذکر شبہ نہیں ہے۔

داخلی کنٹرول کا نظام ڈیزائن کے لحاظ سے مضبوط ہے۔

داخلی کنٹرولز کی نگرانی کا عمل مستقل طور پر جاری رہے گا، تاکہ نظام کو مزید مضبوط اور بہتر بنایا جاسکے۔

اہم تبدیلیاں

مالی سال کے دوران کمپنی نے رائٹ ایشو کا عمل مکمل کیا۔ سینٹرل ڈیپازٹری کمپنی (CDC) کی 5 جنوری 2026 کی تصدیق کے مطابق، 19,979,786 رائٹ سیکیورٹیز سینٹرل ڈیپازٹری سسٹم میں جمع (کریڈٹ) کی گئیں، جس سے ادا شدہ شیئر کیپٹل بڑھ کر 113,040,367 عام حصص تک پہنچ گیا۔ ریورس مرجر اور بنیادی کاروباری سرگرمی میں تبدیلی کا عمل گزشتہ مدت میں ہی مکمل ہو چکا تھا۔

بعد از تاریخ توازن نامہ واقعات

30 جون 2026 کے بعد کوئی ایسا اہم واقعہ پیش نہیں آیا جس کے لیے سالانہ مالیاتی گوشواروں میں ایڈجسٹمنٹ یا علیحدہ انکشاف کی ضرورت ہو؛ یہ بات ان گوشواروں کی منظوری کی تاریخ تک دستیاب معلومات کی بنیاد پر کہی گئی ہے۔

منافع منقسمہ (ڈیویڈنڈ)

سال کے دوران درپیش مالی چیلنجز کے پیش نظر بورڈ نے محتاط اقدام کرتے ہوئے منافع منقسمہ تقسیم نہ کرنے کا فیصلہ کیا ہے۔ یہ فیصلہ اگرچہ محتاط ہے، لیکن کسی بھی طرح مستقبل کے ارادے کی عکاسی نہیں کرتا۔ کمپنی اب بحال شدہ ترقی اور حکمت عملی کی تبدیلی کی دہلیز پر ہے، اور مستقبل میں شیئر ہولڈرز کے لیے بہتر منافع کے امکانات روشن نظر آتے ہیں۔

رسک مینجمنٹ

اپنی امانتی (فٹیشری) ذمہ داریوں کی انجام دہی میں بورڈ آف ڈائریکٹرز نے ملکی اور بین الاقوامی سماجی و معاشی صورتحال کی مسلسل اور چوکس نگرانی جاری رکھی ہے۔ اس میں کمپنی کی آپریشنل سالمیت اور حکمت عملی کے اہداف پر اثر انداز ہو سکنے والے داخلی اور خارجی خطرات کا سخت جائزہ بھی شامل ہے۔

سال بھر بورڈ نے ممکنہ خطرات کی نشاندہی، ان کے ممکنہ نتائج کے جائزے اور مؤثر جوابی اقدامات کی تیاری میں فعال کردار ادا کیا۔ ان تخفیفی حکمت عملیوں پر آڈٹ کمیٹی کی نگرانی میں باقاعدگی سے عمل درآمد کیا جائے گا، تاکہ رسک گورننس کا ایک جامع نظام، بغیر کسی خلا کے، یقینی بنایا جا سکے۔

رسک کا جائزہ

یہ ایک ناقابل تردید حقیقت ہے کہ ہر صنعت کے کاروبار کو مختلف خطرات کا سامنا ہوتا ہے جو ان کے اہداف کو خطرے میں ڈال سکتے ہیں۔ ان کا تدارک نہ کیا جائے تو یہ قابلِ اجتناب مالی اور ساکھ کے نقصانات کا باعث بن سکتے ہیں۔

اسی تناظر میں بورڈ نے بڑھتی ہوئی مالی لاگت، توانائی کی قیمتوں میں اتار چڑھاؤ، کرنسی کی قدر میں کمی اور زرمبادلہ کے ذخائر میں کمی جیسے بنیادی معاشی دباؤ کا بغور جائزہ لیا ہے، جن سے آپریشنل خطرات میں اضافہ ہوا ہے۔ اس کے جواب میں بورڈ دور اندیشی اور مضبوط گورننس کے ذریعے کمپنی کی لچک کو مزید مضبوط بنانے کے لیے پُر عزم ہے۔

مستقبل کے چیلنجز اور امکانات

کمپنی نئے سال میں ایک زیادہ مضبوط بیلنس شیٹ کے ساتھ داخل ہو رہی ہے، جس میں زیادہ ایکویٹی، کم سے کم قرضے، اور 181.551 ملین روپے کی نقد رقم اور سرمایہ کاری شامل ہیں۔ کمپنی کی توجہ رائٹ ایشو سے حاصل ہونے والی رقم کو مؤثر طور پر استعمال کرنے پر ہے، جس میں ڈرائی پاؤٹر انجیکٹیلز کی سہولت کا قیام، ڈریپ کے پاس مصنوعات کی رجسٹریشن

اور سیلز ٹیم میں توسیع شامل ہے۔ 12 ملین یونٹس کی نصب شدہ پیداواری صلاحیت کے مقابلے میں 0.72 ملین یونٹس کی پیداوار کمپنی کے لیے موجود کاروباری امکانات کی وسعت کو ظاہر کرتی ہے۔ کمپنی اپنے کسٹمر بیس کو وسیع کرنے اور اپنی پہلی برآمدی فروخت کی بنیاد پر مزید ترقی کرنے کا ارادہ رکھتی ہے، جبکہ دو صارفین نے مجموعی فروخت کا 58.98 فیصد حصہ حاصل کیا۔

توانائی اور مالیاتی اخراجات میں اضافہ، درآمدات پر انحصار، اور افراط زر اور عالمی توانائی کی قیمتوں کے غیر یقینی رجحانات آئندہ بھی منافع کے مارجن کو متاثر کرتے رہیں گے۔ انتظامیہ اخراجات کا قریبی جائزہ جاری رکھے گی، پرانے قابل وصول رقوم کی وصولی کے لیے اقدامات کرے گی اور پائیدار منافع کے حصول کے لیے کام کرے گی

اظہار تشکر

کمپنی اپنے شیئر ہولڈرز، ملازمین، کاروباری شراکت داروں اور دیگر تمام اسٹیک ہولڈرز کا ترقی اور خوشحالی کے سفر میں ان کے اعتماد اور تعاون پر شکریہ ادا کرتی ہے۔ ہم آئندہ سال کو مزید کامیاب تصور کرتے ہیں اور اپنے تمام اسٹیک ہولڈرز کے لیے پائیدار قدر پیدا کرنے کے اپنے مشن کے لیے پُر عزم ہیں۔

بورڈ آف ڈائریکٹرز کی جانب سے



کاشف حسین صدیقی (چیف ایگزیکٹو آفیسر)



عاطف حسین صدیقی (چینرمن)



**REPORT OF FACTUAL FINDINGS ON UTILIZATION OF PROCEEDS OF RIGHT
ISSUE FOR LIVEN PHARMA LIMITED AS AT JUNE 30, 2025**

The Board of Directors

Liven Pharma Limited

49-KM, Multan Road, Phool Nagar District Kasur,

Lahore.

October 03, 2026

**REPORT OF FACTUAL FINDINGS ON UTILIZATION OF PROCEEDS OF RIGHT
ISSUE FOR LIVEN PHARMA LIMITED AS AT JUNE 30, 2026**

Honorable Members of the Board,

We are pleased to enclose herewith our report on the above referred engagement.

We take this opportunity to thank your staff for the courtesy and cooperation extended to us in the course of our engagement.

Yours faithfully,



CHARTERED ACCOUNTANTS

Enclosed as above

Reanda Haroon Zakaria Aamir Salman Rizwan & Company
Chartered Accountants

Office No. 275, H-1 Block, M.A. Johar Town, Lahore – 54782, Pakistan

Tel: +92 (42) 3531 1524

Email: info@hzasrhr.pk | Web: www.hzasr.pk

Other offices in Karachi and Islamabad



REPORT OF FACTUAL FINDINGS ON UTILIZATION OF PROCEEDS OF RIGHT ISSUE FOR LIVEN PHARMA LIMITED (THE COMPANY) AS AT JUNE 30, 2026

Report to the Board of Directors of the Company.

Purpose of this Agreed-Upon Procedures Report

Our report is issued solely in our capacity as the statutory auditors of the Company, for the purpose of assisting the Company in complying with the requirements of section 10(5) of the Further Issue of Shares Regulations, 2020, and may not be suitable for any other purpose.

Responsibilities of the Engaging Party

The Company has acknowledged that the agreed-upon procedures are appropriate for the purpose of the engagement.

The Company is responsible for the subject matter on which the agreed-upon procedures are performed.

Practitioner's Responsibilities

We have conducted the agreed-upon procedures engagement in accordance with the International Standard on Related Services (ISRS) 4400 (Revised), Agreed-Upon Procedures Engagement. An agreed-upon procedures engagement involves our performing the procedures that have been agreed with the Company and reporting the findings, which are the factual results of the agreed-upon procedures performed. We make no representation regarding the appropriateness of the agreed-upon procedures.

This agreed-upon procedures engagement is not an assurance engagement. Accordingly, we do not express an opinion or an assurance conclusion.

Had we performed additional procedures, other matters might have come to our attention that would have been reported.

Professional Ethics and Quality Management

We have complied with the ethical requirements as prescribed by the Institute of Chartered Accountants of Pakistan. For the purpose of this engagement, there are no independence requirements with which we are required to comply.

Our firm applies International Standard on Quality Management 1, which requires the firm to design, implement and operate a system of quality management including policies or procedures regarding compliance with ethical requirements, professional standards and applicable legal and regulatory requirements.

Procedures and Findings

We have performed the procedures described below, which were agreed upon with the Company in the terms of our engagement letter, for the purpose as stated above:

Sr. No.	Procedure	Findings
01	Obtained the schedule of utilization of right share proceeds and verified, on test	The proceeds amounting to rupees 16.19 million have been utilized in accordance

Attest



Sr. No.	Procedure	Findings
	basis, the item-wise breakup of utilization in terms of amounts and percentages of total allocation and compared it with the utilization plan earlier disclosed to the members in the offer letter for the period from July 1, 2025 to June 30, 2026.	with the utilization plan outlined in the offer letter, Rs. 11.19 million for procurement of vehicles, Rs. 2.82 million for DRAP related registration and licensing cost, Rs. 0.84 million for expansion of sales team and Rs. 1.33 million for additional working capital requirements.
02	Reviewed the utilization schedule against the purposes earlier disclosed to the members to identify any deviations in the use of proceeds and obtained management's explanation where any deviations were noted.	Exceptions were noted, In addition to actual utilized proceeds of Rs. 16.19 million, the Company has utilized an amount of Rs. 15.17 million, out of the right issue proceeds, for purposes other than those disclosed in the right offer document. Further, the Company utilized Rs. 1.26 million, out of total utilization of Rs. 2.82 million, on registration of medicines which were not listed in the right offer document.
03	Obtained the detailed schedule of utilization of right share proceeds and inspected supporting documents including bank statements, invoices, and contracts to verify that the proceeds were utilized for the purposes disclosed in the final offer document. Further, examined the related disclosures in the financial statements to confirm that a progress report on utilization has been incorporated until such time the proceeds are fully utilized or the intended purpose is achieved.	Keeping in view the planned utilization of right issue proceeds, 8.09% utilization has been achieved till June 30, 2026. We have obtained supporting evidence and bank statements evidencing payments for such expenditure No disclosure was made in the half-yearly financial statements as right issue was completed after December 31, 2025 ; however, the disclosure has been included in the annual financial statements.


CHARTERED ACCOUNTANTS
DATED: October 03, 2026
Engagement Partner: Ahmad Salman Arshad

PROGRESS REPORT ON UTILIZATION OF PROCEEDS OF RIGHT ISSUE AS OF 30-JUNE-2026:

With reference to the right issue completed by Liven Pharma Limited (Company) on January 05, 2026, following is the progress report on utilization of the proceeds of the right subscription amount, in accordance with the requirement contained in Regulation 10(2) of the Companies (Further Issue of Shares) Regulations, 2020.

UTILIZATION STATUS

Purpose of the issue	Proceeds utilization plan (Rs. million)	Actual utilized proceeds (Rs. million)	Utilization (%)	Balance (Rs. million)
Establishment of dry powder injectables (dpi) facility	40.00	-	0.0%	40.00
Procurement of vehicles	49.00	11.19	22.8%	37.81
DRAP related registration and licensing cost	6.00	2.82	47.0%	3.18
Expansion of sales team and promotional activities	65.00	0.84	1.3%	64.16
Additional working capital requirements	40.00	1.33	3.3%	38.67
Total	200.00	16.19	8.09%	183.81

Deviation

In addition to actual utilized proceeds of Rs. 16.19 million, the Company has utilized an amount of Rs. 15.17 million, out of the right issue proceeds, for purposes other than those disclosed in the right offer document.

Further, the Company utilized Rs. 1.26 million, out of total utilization of Rs. 2.82 million, on registration of medicines which were not listed in the right offer document.




INDEPENDENT AUDITOR'S REVIEW REPORT ON THE STATEMENT OF COMPLIANCE



INDEPENDENT AUDITOR'S REVIEW REPORT

To the members of Liven Pharma Limited

Review Report on the Statement of Compliance contained in Listed Companies (Code of Corporate Governance) Regulations, 2019

We have reviewed the enclosed Statement of Compliance with the Listed Companies (Code of Corporate Governance) Regulations, 2019 (the Regulations) prepared by the Board of Directors of Liven Pharma Limited for the year ended June 30, 2026 in accordance with the requirements of regulation 36 of the Regulations.

The responsibility for compliance with the Regulations is that of the Board of Directors of the Company. Our responsibility is to review whether the Statement of Compliance reflects the status of the Company's compliance with the provisions of the Regulations and report if it does not and to highlight any non-compliance with the requirements of the Regulations. A review is limited primarily to inquiries of the Company's personnel and review of various documents prepared by the Company to comply with the Regulations.

As a part of our audit of the financial statements we are required to obtain an understanding of the accounting and internal control systems sufficient to plan the audit and develop an effective audit approach. We are not required to consider whether the Board of Directors' statement on internal control covers all risks and controls or to form an opinion on the effectiveness of such internal controls, the Company's corporate governance procedures and risks.

The Regulations require the Company to place before the Audit Committee, and upon recommendation of the Audit Committee, place before the Board of Directors for their review and approval, its related party transactions. We are only required and have ensured compliance of this requirement to the extent of the approval of the related party transactions by the Board of Directors upon recommendation of the Audit Committee.

Based on our review, nothing has come to our attention which causes us to believe that the Statement of Compliance does not appropriately reflect the Company's compliance, in all material respects, with the requirements contained in the Regulations as applicable to the Company for the year ended June 30, 2026.

Further, we highlight below instances of non-compliance with requirements of the Regulations as reflected in the paragraphs referred below where these are stated in the Statement of Compliance:

	Paragraph Reference	Description
(i)	18	The company is in non-compliance with certain requirements, other than regulation 3, 6, 7, 8, 27, 32, 33 and 36 of the Regulations and explanations is given.

Chartered Accountants

Place: Lahore

Date: October 03, 2026

UDIN: CR202610384cyDAOCRZz

Reanda Haroon Zakaria Aamir Salman Rizwan & Company
Chartered Accountants

Office No. 275, H-1 Block, M.A. Johar Town, Lahore - 54782, Pakistan

Tel: +92 (42) 3531 1524

Email: info@hzasr.pk | Web: www.hzasr.pk

Other offices in Karachi and Islamabad

Page 1 of 1

**Statement Of Compliance with Listed Companies (Code of Corporate Governance)
Regulations, 2019**

Name of company: LIVEN PHARMA LIMITED
Year ending: JUNE 30, 2025

The company has complied with the requirements of the Regulations in the following manner:-

1. The total number of directors are seven (7) as per the following,-

Male	Six (6)
Female	One (1)

2. The composition of the Board is as follows:

Sr. No.	Category	Names
i.	Independent directors	Ahmad Shoaib Hashmi Syed Raza Abbas Jaffery
ii.	Non-Executive Directors	Atif Hussain Siddiqi (Chairman) Usman Mujib Shami Umer Mujib Shami
iii.	Executive Director	Kaashif Hussain Siddiquie
	Female Director	Firdous Shakir

*Determination of number of independent directors under Regulation 6 arrives at 2.33 (rounded to 2) which is based on seven directors. The fraction is not rounded up since the two (2) independent directors possess requisite competencies, skills, knowledge and experience to hold the office as such and discharge and execute their responsibilities as per applicable laws and regulations.

3. The directors have confirmed that none of them is serving as a director on more than seven listed companies, including this company;

4. The company has prepared a code of conduct and has ensured that appropriate steps have been taken to disseminate it throughout the company along with its supporting policies and procedures;

5. The Board has developed a vision/mission statement, overall corporate strategy and significant policies of the company. The Board has ensured that complete record of particulars of the significant policies along with their date of approval or updating is maintained by the company;

6. All the powers of the Board have been duly exercised and decisions on relevant matters have been taken by the Board/ shareholders as empowered by the relevant provisions of the Act and these Regulations;




7. The meetings of the Board were presided over by the Chairman and, in his absence, by a director elected by the Board for this purpose. The Board has complied with the requirements of Act and the Regulations with respect to frequency, recording and circulating minutes of meeting of the Board;

8. The Board have a formal policy and transparent procedures for remuneration of directors in accordance with the Act and these Regulations;

9. The Board has not arranged Directors' Training program during the year.

10. The Board has approved appointment of chief financial officer and company secretary, including their remuneration and terms and conditions of employment and complied with relevant requirements of the Regulations;

11. Chief financial officer and chief executive officer duly endorsed the financial statements before approval of the Board;

12. The Board has formed committees comprising of members given below.

Audit committee

Sr. No.	Name	Designation
i.	Mr. Ahmad Shoaib Hashmi	Chairman (Independent Director)
ii.	Mr. Atif Hussain Siddiqi	Member (Non-Executive Director)
iii.	Mr. Usman Mujib Shami	Member (Non-Executive Director)
iv.	Mr. Muhammad Saeed	Secretary

HR and Remuneration Committee:

Sr. No.	Name	Designation
i.	Mr. Ahmad Shoaib Hashmi	Chairman (Independent Director)
ii.	Mr. Atif Hussain Siddiqi	Member (Non-Executive Director)
iii.	Ms. Firdous Shakir	Member (Executive Director)
iv.	Mr. Muhammad Saeed	Secretary

13. The terms of reference of the aforesaid committees have been formed, documented, and advised to the committee for compliance;

14. The frequency of meetings of the committees were as per the following:

- i. Audit committee: 4 meetings
- ii. HR and Remuneration Committee: 1 meeting




15. The Board has neither set up an effective internal audit function nor has outsourced the internal audit function to suitably qualified and experienced for the purpose and are conversant with the policies and procedures of the company;

16. The statutory auditors of the company have confirmed that they have been given a satisfactory rating under the Quality Control Review program of the Institute of Chartered Accountants of Pakistan and registered with Audit Oversight Board of Pakistan, that they and all their partners are in compliance with International Federation of Accountants (IFAC) guidelines on code of ethics as adopted by Institute of Chartered Accountants of Pakistan and that they and the partners of the firm involved in the audit are not close relatives (spouse, parent, dependent and non-dependent children) of the chief executive officer, chief financial officer, head of internal audit, company secretary, or director of the company;

17. The statutory auditors or the persons associated with them have not been appointed to provide other services except in accordance with the Act, these Regulations, or any other regulatory requirement, and the auditors have confirmed that they have observed IFAC guidelines in this regard;

18. We confirm that all requirements of regulations 3, 6, 7, 8, 27, 32, 33, and 36 of the Regulations have been complied with;

19. Explanation for non-compliance with requirements (other than regulations 3, 6, 7, 8, 27, 32, 33, and 36) are below:

Sr. No.	Requirement	Explanation for Non-Compliance	Reg. No.
i.	Formal Policy: The Board shall have in place a formal policy and transparent procedure for fixing the remuneration packages of individual directors for attending meetings of the Board and its committees.	In accordance to the Policy approved by the Board, the Company do not offer any remuneration to the members of the BOD to attend the meetings	16
ii.	Anti-Harassment Policy: The Board is required to approve anti-harassment policy to safeguard the rights and well-being of employees.	Currently, the management is assessing this amendment and compliance thereof, as applicable, will be performed in due course of time.	10(4) (xvi)
iii.	Annual Evaluation of Board: The Board shall implement a formal and effective mechanism for the annual evaluation of its own performance, including that of individual members and committees. It is further encouraged to undergo an independent external evaluation at least once every three years.	The Board is in process of formation and implementation of effective mechanism for evaluation of Board and of its committees.	10(3) (v)



Sr. No.	Requirement	Explanation for Non-Compliance	Reg. No.
iv.	Audio and visual recordings: The chairman of the Board is encouraged to take necessary steps for recording the entire proceedings other general meeting(s) by audio and Visual Which Shall be archived and made available to the Commission and PSX when required.	The management is taking the necessary measures and will comply with this requirement in due course of time.	10(7)
v.	Role of board and its members to address Sustainability Risks and Opportunities: The Board is responsible for setting the company's sustainability strategies, priorities and targets to create long term corporate value. The Board may establish a dedicated sustainability committee having at least one female director.	The requirements relating to Environmental, Social and Governance (ESG) are being worked out and shall be complied with in due course of time.	10(A)
vi.	Director's Training: It is encouraged that by June 30, 2022 all the directors on their Boards have acquired the prescribed certification under any director training program offered by institutions, local or foreign, that meet the criteria specified by the Commission and approved by it.	The Company is committed to arrange such trainings/courses for its directors that are more relevant to their job descriptions and beneficial for the Company. However, the Company may/will consider required training, if and when necessary, on case-to-case basis.	19
vii.	Nomination Committee: The Board may constitute a separate committee, designated as the Nomination Committee, of such number and class of directors, as it may deem appropriate in its circumstances.	The Board through its HR & Remuneration Committee effectively discharges all the responsibilities of Nomination Committee as recommended by the Code. It regularly monitors and assesses the requirements with respect to any changes needed on Board's committees including chairmanship of those committees. The Board also actively monitors requirements regarding its structure, size and composition and timely reviews and adapts any necessary changes in that regard.	29(1)



Sr. No.	Requirement	Explanation for Non-Compliance	Reg. No.
viii.	Risk Management Committee: The Board may constitute the Risk Management Committee, of such number and class of directors, as it may deem appropriate in its circumstances, to carry out a review of effectiveness of risk management procedures and present a report to the Board.	The Audit Committee itself and through its senior officers annually reviews business risks facing the Company to ensure that a sound system of risk identification, risk management and related systemic and internal controls is being maintained to safeguard assets. All material controls (financial, operational, compliance) are monitored and reviewed. The Board ensures that risk mitigation measures are robust.	30(1)
ix.	Internal Audit Function: There shall be an internal audit function in every company. The board shall appoint head of internal Audit.	At present, the Company does not have head of internal audit and internal audit function. The Board of Directors are committed to strengthening the internal control environment and intend to establish an internal audit function and appoint head of internal audit in the next financial year. The Company is in the restructuring phase as such the internal audit function is carried out by CFO.	31,20
x.	Disclosure of significant policies on website: The Company may post key elements of its significant policies, brief synopsis of terms of reference of the Board's committees on its website and key elements of the directors' remuneration policy.	Although these are well circulated among the relevant employees and directors, the Board shall consider posting such policies and synopsis on its website in near future.	35


Signature
ATIF HUSSAIN SIDDIQI
Chairman


NOTICE OF 35th ANNUAL GENERAL MEETING

Notice is hereby given that Annual General Meeting of the Members of Liven Pharma Limited ('the Company') will be held on **Monday, October 26, 2026 at 11:00 am at the registered office of the company situated at 49 Km Lahore - Multan road Pakistan.** and through weblink meeting, to transact the following businesses:

Ordinary Business:

- To Confirm the minutes of the Annual General Meeting (AGM) held on November 26, 2025;
- To receive, consider and adopt the six-month audited accounts (transition period) of the Company for the financial year ended June 30, 2026, together with the Directors' and Auditors' Reports thereon;

Weblink	QR Code
https://liven-pharma.com/financial-statements/	

- To appoint Statutory Auditors of the Company for the financial year ending June 30, 2027 and to fix their remuneration. The present auditors, being eligible, have offered themselves for re-appointment.
- To transact any other business with the permission of the Chair.

By order of the Board

Company Secretary

Lahore October 2nd, 2026

NOTES:

- The Share Transfer Books of the Company will remain closed for the period from October 19 to October 26, 2026 (both days inclusive) and no transfer of shares will be accepted for registration during this period. Transfers received in order at the Office of Company's Share Registrar M/s. F.D. Registrar Services (Private) Ltd, Office#1705, 17th Floor, Saima Trade Tower A, I.I. Chundrigar Road Karachi, Pakistan ('Registrar') at the close of business on October 18 2026 the last working day before the start of the book closure date will be considered in time to attend and vote at the Meeting.
- Any member who wants to attend the meeting via video link must send their particulars (Name, copy of CNIC, Folio number, cell number through email at info@liven-pharma.com at least 48 hours before the time of the meeting. After due verification of the said particulars, a video link/ login details will be sent through email to connect the meeting.
- A member of the Company entitled to attend and vote at this meeting, may appoint another person as his/her proxy to attend and vote instead of him/her. An instrument of the proxy and the power of attorney or other authority (if any) under which it is signed, or a notarially certified copy of such power or authority, in order to be effective, must be received at the Registered Office of the Company not less than 48 hours before the time for holding the meeting.
- CDC shareholders entitled to attend and vote at the meeting must bring his/her Participant ID and Account/Sub-Account number along with original CNIC or original passport to authenticate his/her identity. In case of Corporate entity, resolution of Board of Directors/Power of Attorney with specimen signature of the nominee shall be produced (unless provided earlier) at the time of the meeting.
- For appointing the proxy; CDC shareholders shall submit the proxy form as per above requirements together with attested copy of CNIC or Passport of the beneficial owner and proxy. In case of corporate entity, the Board of Directors' resolution/power of attorney, along with the specimen signature of the nominee, shall be submitted along with the proxy form to the Company.

- The proxy form shall be witnessed by two witnesses with their names, addresses, and CNIC numbers. The proxy shall produce his/her original CNIC or original Passport at the time of meeting.

6. Members are requested to notify/submit the following information/documents, in case of book entry securities in CDS to their respective participants and in case of physical shares to the registrar of the Company by quoting their folio numbers and name of the Company at the above mentioned address, if not earlier notified/submitted:

- Change in their addresses, if any.
- Members, who have not yet submitted attested photocopy of their valid CNIC are requested to submit the same along with folio numbers at earliest, directly to the Company's Share Registrar M/s. F.D. Registrar Services (Pvt) Ltd.

7. In accordance with regulation 4(7) of the Companies (Distribution of Dividends) Regulations, 2017, shareholders are requested to provide required dividend mandate information (IBAN) to their respective CDS accounts through their participants or to the Share Registrar (if shares are in physical form) for direct credit of cash dividends into their designated bank accounts through electronic modes.

8. The shareholders of the Company are hereby informed that as per provisions of Section 72 of the Companies Act, 2017 ('the Act'), the companies are required to replace their physical shares with book-entry-form within a period not exceeding four years from the date of the commencement of the Act. The Securities and Exchange Commission of Pakistan ('SECP'), vide their letter File no. CSD/ED/Misc./2016-639-640 dated 26th March, 2021, has advised all listed companies to pursue their such shareholders who still hold their shares in physical form for converting the same into CDC. Therefore as advised by SECP, the shareholders who hold physical shares are requested to convert the same into book-entry-form as soon as possible.

9. The Government of Pakistan through Finance Act, 2020, has made certain amendments in section 150 of the Income Tax Ordinance, 2001, whereby different rates have been prescribed for deduction of withholding tax on the amount of dividend paid by the companies. These tax rates are as under:

- (a) For filers of income tax returns: 15%
 (b) For non-filers of income tax returns: 30%

To enable the Company to make tax deduction on the amount of cash dividend @ 15% instead of 30%, all shareholders whose names are not entered in the Active Tax-Payers List (ATL) provided on the website of the Federal Board of Revenue (FBR), despite the fact that they are filers, are advised to make sure that their names are entered into the ATL at the earliest possible (as and when declared), otherwise tax on their cash dividend will be deducted @ 30%. For shareholders holding their shares jointly as per the clarification issued by the FBR withholding tax will be determined separately on 'Filer/Non-Filer' status of Principal Shareholder as well as joint-holder(s) based on their shareholding proportions.

Therefore, all shareholders who hold shares jointly are required to provide shareholding proportions of Principal Shareholder and Joint-holder(s) in respect of shares held by them, as follows:

Folio / CDC Account No.	Total Shares	Principal Shareholder		Joint Shareholder(s)	
		Name and CNIC No.	Shareholding Proportion No. of Shares)	Name And CNIC No.	Shareholding Proportion (No. of Shares)

In case of non-receipt of above information, the shareholding will be divided among the joint-holders equally.

10. As per the provisions of Section 244 of the Companies Act, 2017, any shares issued or dividends declared by the Company, which remain unclaimed or unpaid for a period of three years from the date they became due and payable shall vest with the Federal Government after compliance of procedures prescribed under the Act. In compliance with the above, those shareholders who have not yet collected their pending entitlements are once again advised to lodge their claims with the Company's Share Registrar.

11. Pursuance to the SECP's SRO No. 389(i)/2023 dated 21 March 2023 the Company has sought approval from members in the EOGM held on December 20, 2024. Therefore, audited financial statement for the financial year ended June 30, 2026 will be circulated through **QR enabled code and web link**. However, hard copies of the financial statements along with all respective report can be provided on written demand of the members at their registered address. Furthermore, aforesaid Financial Statements and reports will also be available at the website of the Company <https://liven-pharma.com/financial-statements/> at least twenty-one days before the date of meeting.
12. All corporate members are requested to provide list of ultimate beneficial shareholding having 5% and above controls in their organization.
13. In adherence to the regulatory requirements set forth by the SECP, it is hereby stated that no gifts will be distributed at the meeting.

FORM OF PROXY

I/We _____ of _____ being a member of LIVEN PHARMA LIMITED and holder (Number of Shares) _____ Ordinary Shares as per share Register Folio No. _____ and/or CDC Participant I.D. No. _____ and Sub Account No. _____ hereby appoint _____ of _____ or failing him/ her of _____ as my proxy to vote for me/us and on my/our behalf at the Annual General Meeting of the Company to be held on the 26th day of October 2026 and at any adjournment thereof.

Signed this _____ day of _____ 2026.

WITNESSES:

1) Signature: _____. Name: _____. Address: _____. CNIC or: _____.
 Passport No: _____.

2) Signature: _____. Name: _____. Address: _____. CNIC or: _____.
 Passport No: _____.

_____.

Signature

(Signature should agree with the specimen registered with the Company)

Note:

Proxies, in order to be effective, must be received by the Company not less than 48 hours before the meeting. A Proxy holder may not need to be a member of the Company.

CDC Shareholders and their proxies are each requested to attach an attested photocopy of their Computerized National Identity Card or Passport with this proxy form before submission to the Company.

۳۵واں سالانہ عام اجلاس کا نوٹس

بذریعہ ہذا مطلع کیا جاتا ہے کہ لیون فارما لمیٹڈ ("کمپنی") کے اراکین کا سالانہ عام اجلاس بروز پیر، 26 اکتوبر 2026 کو صبح 11:00 بجے کمپنی کے رجسٹرڈ آفس واقع 49 کلومیٹر لاہور- ملتان روڈ، پاکستان پر اور ویب لنک کے ذریعے منعقد ہوگا، جس میں درج ذیل امور نمٹائے جائیں گے:

عام کاروبار:

- (1) 26 نومبر 2025 کو منعقد ہونے والے سالانہ عام اجلاس (AGM) کی کارروائی کی توثیق کرنا؛
- (2) 30 جون 2026 کو ختم ہونے والے مالی سال کے لیے کمپنی کے چھ ماہ کے آڈٹ شدہ حسابات (عبوری مدت) بمعہ ڈائریکٹرز اور آڈیٹرز کی رپورٹس وصول کرنا، زیر غور لانا اور منظور کرنا؛
- ویب لنک / کیو آر کوڈ: <https://liven-pharma.com/financial-statements/>
- (3) 30 جون 2027 کو ختم ہونے والے مالی سال کے لیے کمپنی کے قانونی آڈیٹرز کا تقرر کرنا اور ان کا معاوضہ مقرر کرنا۔ موجودہ آڈیٹرز، اہل ہونے کے باعث، دوبارہ تقرری کے لیے خود کو پیش کر چکے ہیں؛
- (4) چیئر کی اجازت سے کوئی اور کاروبار انجام دینا۔

بحکم بورڈ

کمپنی سیکریٹری

لاہور، 2 اکتوبر 2026

نوٹس:

- (1) کمپنی کی شیئر ٹرانسفر کتابیں 19 اکتوبر سے 26 اکتوبر 2026 تک (دونوں دن شامل) بند رہیں گی اور اس مدت کے دوران حصص کی منتقلی رجسٹریشن کے لیے قبول نہیں کی جائے گی۔ کمپنی کے شیئر رجسٹرار، میسرز ایف ڈی رجسٹرار سروسز (پرائیویٹ) لمیٹڈ، آفس نمبر 1705، 17 ویں منزل، صائمہ ٹریڈ ٹاور اے، آئی آئی چندریگر روڈ، کراچی، پاکستان ("رجسٹرار") کے دفتر میں 18 اکتوبر 2026 کو، جو بک کلوزر کی تاریخ سے پہلے آخری کاروباری دن ہے، کاروبار کے اوقات کے اختتام تک موصول ہونے والی درست منتقلیاں اجلاس میں شرکت اور ووٹ دینے کے لیے بروقت تصور کی جائیں گی۔
- (2) کوئی بھی رکن جو ویڈیو لنک کے ذریعے اجلاس میں شرکت کرنا چاہتا ہے، وہ اپنی تفصیلات (نام، شناختی کارڈ کی کاپی، فوٹیو نمبر، موبائل نمبر) اجلاس کے وقت سے کم از کم 48 گھنٹے قبل info@liven-pharma.com پر ای میل کے ذریعے ارسال کرے۔ ان تفصیلات کی مناسب تصدیق کے بعد اجلاس سے منسلک ہونے کے لیے ویڈیو لنک / لاگ ان کی تفصیلات ای میل کے ذریعے بھیج دی جائیں گی۔
- (3) کمپنی کا وہ رکن جو اس اجلاس میں شرکت اور ووٹ دینے کا اہل ہو، اپنی جگہ شرکت کرنے اور ووٹ دینے کے لیے کسی دوسرے شخص کو اپنا پروکسی مقرر کر سکتا ہے۔ پروکسی کا فارم اور پاور آف اٹارنی یا دیگر اختیار نامہ (اگر کوئی ہو) جس کے تحت اس پر دستخط کیے گئے ہوں، یا اس اختیار کی نوٹری سے تصدیق شدہ نقل، مؤثر ہونے کے لیے اجلاس کے انعقاد کے وقت

سے کم از کم 48 گھنٹے قبل کمپنی کے رجسٹرڈ آفس میں موصول ہو جانی چاہیے۔

(4) اجلاس میں شرکت اور ووٹ دینے کے اہل سی ڈی سی شیئر ہولڈرز اپنی شناخت کی تصدیق کے لیے اپنا پارٹیسپنٹ آئی ڈی اور اکاؤنٹ / سب اکاؤنٹ نمبر، اصل شناختی کارڈ یا اصل پاسپورٹ کے ہمراہ ساتھ لائیں۔ کارپوریٹ ادارے کی صورت میں، بورڈ آف ڈائریکٹرز کی قرارداد / پاور آف اٹارنی بمعہ نامزد شخص کے نمونہ دستخط اجلاس کے وقت پیش کیے جائیں (اگر پہلے فراہم نہ کیے گئے ہوں)۔

(5) پروکسی مقرر کرنے کے لیے: سی ڈی سی شیئر ہولڈرز مذکورہ تقاضوں کے مطابق پروکسی فارم، بینیفیشل اونر اور پروکسی کے شناختی کارڈ یا پاسپورٹ کی تصدیق شدہ نقول کے ہمراہ جمع کرائیں۔ کارپوریٹ ادارے کی صورت میں، بورڈ آف ڈائریکٹرز کی قرارداد / پاور آف اٹارنی بمعہ نامزد شخص کے نمونہ دستخط پروکسی فارم کے ساتھ کمپنی کو جمع کرائے جائیں۔

- پروکسی فارم پر دو گواہوں کے دستخط ہونے چاہییں، جن کے نام، پتے اور شناختی کارڈ نمبر درج ہوں۔ پروکسی اجلاس کے وقت اپنا اصل شناختی کارڈ یا اصل پاسپورٹ پیش کرے گا۔

(6) اراکین سے گزارش ہے کہ سی ڈی ایس میں بک انٹری سیکیورٹیز کی صورت میں اپنے متعلقہ پارٹیسپنٹس کو، اور فزیکل شیئرز کی صورت میں کمپنی کے رجسٹرار کو، مندرجہ بالا پتے پر اپنے فولیو نمبر اور کمپنی کا نام درج کرتے ہوئے درج ذیل معلومات / دستاویزات سے آگاہ کریں / جمع کرائیں، اگر پہلے آگاہ / جمع نہ کرائی گئی ہوں:

- اپنے پتے میں تبدیلی، اگر کوئی ہو۔

- وہ اراکین جنہوں نے اب تک اپنے درست شناختی کارڈ کی تصدیق شدہ فوٹو کاپی جمع نہیں کرائی، ان سے درخواست ہے کہ وہ اسے فولیو نمبر کے ہمراہ جلد از جلد براہ راست کمپنی کے شیئر رجسٹرار، میسرز ایف ڈی رجسٹرار سروسز (پرائیویٹ) لمیٹڈ کو جمع کرائیں۔

(7) کمپنیز (ڈسٹریبیوشن آف ڈیویڈنڈز) ریگولیشنز، 2017 کے ضابطہ 4(7) کے مطابق، شیئر ہولڈرز سے درخواست ہے کہ وہ نقد منافع منقسمہ کی براہ راست الیکٹرانک ذرائع سے اپنے نامزد بینک اکاؤنٹس میں منتقلی کے لیے مطلوبہ ڈیویڈنڈ مینڈیٹ کی معلومات (IBAN) اپنے متعلقہ سی ڈی ایس اکاؤنٹس میں اپنے پارٹیسپنٹس کے ذریعے، یا (فزیکل شیئرز کی صورت میں) شیئر رجسٹرار کو فراہم کریں۔

(8) کمپنی کے شیئر ہولڈرز کو مطلع کیا جاتا ہے کہ کمپنیز ایکٹ، 2017 ("ایکٹ") کی دفعہ 72 کی رو سے، کمپنیاں ایکٹ کے نفاذ کی تاریخ سے چار سال سے زائد نہ ہونے والی مدت کے اندر اپنے فزیکل شیئرز کو بک انٹری فارم سے تبدیل کرنے کی پابند ہیں۔ سیکیورٹیز اینڈ ایکسچینج کمیشن آف پاکستان ("ایس ای سی پی") نے اپنے خط فائل نمبر CSD/ED/Misc./2016-639-640 مورخہ 26 مارچ 2021 کے ذریعے تمام لسٹڈ کمپنیوں کو ہدایت کی ہے کہ وہ ایسے شیئر ہولڈرز کو، جو اب بھی فزیکل شکل میں حصص رکھتے ہیں، انہیں سی ڈی سی میں تبدیل کرانے کے لیے آمادہ کریں۔ لہذا ایس ای سی پی کی ہدایت کے مطابق، فزیکل شیئرز رکھنے والے شیئر ہولڈرز سے درخواست ہے کہ وہ انہیں جلد از جلد بک انٹری فارم میں تبدیل کرا لیں۔

(9) حکومت پاکستان نے فنانس ایکٹ، 2020 کے ذریعے انکم ٹیکس آرڈیننس، 2001 کی دفعہ 150 میں بعض ترامیم کی ہیں، جن کے تحت کمپنیوں کی جانب سے ادا کیے جانے والے منافع منقسمہ کی رقم پر ودہولڈنگ ٹیکس کی کٹوتی کے لیے مختلف شرحیں مقرر کی گئی ہیں۔ ٹیکس کی یہ شرحیں درج ذیل ہیں:

(الف) انکم ٹیکس ریٹرن فائل کرنے والوں (فائلرز) کے لیے: 15 فیصد

(ب) انکم ٹیکس ریٹرن فائل نہ کرنے والوں (نان فائلرز) کے لیے: 30 فیصد

تاکہ کمپنی نقد منافع منقسمہ کی رقم پر 30 فیصد کے بجائے 15 فیصد کی شرح سے ٹیکس کی کٹوتی کر سکے، وہ تمام شیئر ہولڈرز جن کے نام فیڈرل بورڈ آف ریونیو (ایف بی آر) کی ویب سائٹ پر فراہم کردہ ایکٹو ٹیکس پینرز لسٹ (ATL) میں درج نہیں ہیں، خواہ وہ فائلر ہی کیوں نہ ہوں، انہیں مشورہ دیا جاتا ہے کہ وہ جلد از جلد اپنے نام ATL میں درج کرانا یقینی بنائیں (جب اور جیسے ہی اعلان کیا جائے)، بصورت دیگر ان کے نقد منافع منقسمہ پر ٹیکس 30 فیصد کی شرح سے کاٹا جائے گا۔ مشترکہ طور پر حصص رکھنے والے شیئر ہولڈرز کے لیے، ایف بی آر کی جاری کردہ وضاحت کے مطابق، ودہولڈنگ ٹیکس کا تعین پرنسپل شیئر ہولڈر اور جوائنٹ ہولڈر (ز) کی ان کے شیئر ہولڈنگ کے تناسب کی بنیاد پر 'فائلر / نان فائلر' حیثیت کے لحاظ سے الگ الگ کیا جائے گا۔ لہذا، وہ تمام شیئر ہولڈرز جو مشترکہ طور پر حصص رکھتے ہیں، ان سے درخواست ہے کہ وہ اپنے حصص میں پرنسپل شیئر ہولڈر اور جوائنٹ ہولڈر (ز) کا شیئر ہولڈنگ کا تناسب درج ذیل کے مطابق فراہم کریں:

فولیو / سی ڈی سی اکاؤنٹ نمبر	کل حصص	پرنسپل شیئر ہولڈر: نام اور شناختی کارڈ نمبر	شیئر ہولڈنگ کا تناسب (حصص کی تعداد)	جوائنٹ شیئر ہولڈر (ز): نام اور شناختی کارڈ نمبر	شیئر ہولڈنگ کا تناسب (حصص کی تعداد)

مذکورہ معلومات موصول نہ ہونے کی صورت میں، شیئر ہولڈنگ کو جوائنٹ ہولڈرز میں برابر تقسیم کیا جائے گا۔

(10) کمپنیز ایکٹ، 2017 کی دفعہ 244 کی شرائط کے مطابق، کمپنی کی جانب سے جاری کردہ کوئی بھی حصص یا اعلان کردہ منافع منقسمہ، جو واجب الادا ہونے کی تاریخ سے تین سال کی مدت تک غیر دعویٰ شدہ یا ادا نہ ہوئے ہوں، ایکٹ میں مقررہ طریقہ کار کی تکمیل کے بعد وفاقی حکومت کے سپرد ہو جائیں گے۔ مذکورہ بالا کی تعمیل میں، وہ شیئر ہولڈرز جنہوں نے اب تک اپنے زیر التوا استحقاق وصول نہیں کیے، انہیں ایک بار پھر مشورہ دیا جاتا ہے کہ وہ کمپنی کے شیئر رجسٹرار کے پاس اپنے دعوے جمع کرائیں۔

(11) ایس ای سی پی کے ایس آر او نمبر 2023/389(I) مورخہ 21 مارچ 2023 کے تحت کمپنی نے 20 دسمبر 2024 کو منعقدہ غیر معمولی عام اجلاس (EOGM) میں اراکین سے منظوری حاصل کی ہے۔ لہذا، 30 جون 2026 کو ختم ہونے والے مالی سال کے آڈٹ شدہ مالیاتی گوشوارے کیو آر کوڈ اور ویب لنک کے ذریعے ارسال کیے جائیں گے۔ تاہم، اراکین کے تحریری مطالبے پر مالیاتی گوشواروں کی بارڈ کاپیاں، تمام متعلقہ رپورٹس کے ہمراہ، ان کے رجسٹرڈ پتے پر فراہم کی جا سکتی ہیں۔ مزید برآں، مذکورہ مالیاتی گوشوارے اور رپورٹس کمپنی کی ویب سائٹ <https://liven-pharma.com/financial-statements> پر اجلاس کی تاریخ سے کم از کم اکیس دن پہلے بھی دستیاب ہوں گی۔

(12) تمام کارپوریٹ اراکین سے درخواست ہے کہ وہ اپنے ادارے میں 5 فیصد اور اس سے زائد کنٹرول رکھنے والے حتمی مستفید ہونے والے شیئر ہولڈرز (Ultimate Beneficial Owners) کی فہرست فراہم کریں۔

(13) ایس ای سی پی کی جانب سے مقرر کردہ ریگولیٹری تقاضوں کی پاسداری میں، یہ بیان کیا جاتا ہے کہ اجلاس میں کوئی تحائف تقسیم نہیں کیے جائیں گے۔

LIVEN PHARMA LIMITED STATEMENT OF FREE FLOAT SHARES

	Quarter-1 30/09/2025	Quarter-2 31/12/2025	Quarter-3 31/03/2026	Quarter-4 30/06/2026
Total Outstanding Shares	93,040,367	93,040,367	113,040,367	113,040,367
Less: Government Holdings	-	-	-	-
Less: Shares held by Directors/Sponsors / Senior Management Officers and their associates	80,916,785	80,123,374	97,855,823	97,746,252
Less: Shares in Physical Form	4,326,500	4,326,500	4,346,714	4,346,714
Less: Shares held by Associate Companies / Group Companies (Cross holdings)	-	-	-	-
Less: Shares issued under Employees Stock Option Schemes that cannot be sold in the open market in normal course.	-	-	-	-
Less: Treasury Shares	-	-	-	-
Less: Any other category that are barred from selling at the review date	-	-	-	-
Free Float	7,797,082	8,590,493	10,837,830	10,947,401

Basis of Preparation: This statement is prepared in accordance with the requirements of Regulation No. 5.7.2 (b)(ii) of Pakistan Stock Exchange Limited Regulation (PSX Regulations).



**CONFIRMATION OF CDC's NOMINEE HOLDING IN MEMBERS' /
CERTIFICATE HOLDERS' REGISTER**

Chief Compliance Officer
 Central Depository Company of Pakistan Limited
 CDC House, 99-B, Block-B
 F.M.C.R.S. Main Shahr-e-Faisal Karachi

Dear Sir,

In compliance with CDC Regulation No. 13.7.1, we are writing to confirm as follows:

Financial Year End	30/06/2026	
Name of Auditor	Reanda Haroon Zakaria Aamir Salman Rizwan & Co., Chartered Accountants	
Security Name	LIVEN PHARMA LIMITED	
Security Symbol	LIVEN	
	Note	Number of Securities
Balance at the end of period / year in the CDC's Nominee Holding in Members' / Certificate holders' Register	N-1	108,693,653
Balance of book entry security in the Central Depository Register at the end of period / year	N-2	108,693,653
Difference, if any		0

N-1: Movement in the CDC's Nominee Holding in Members' / Certificate holders' Register

Number of Securities

Balance at the beginning of the year in the CDC's Nominee Holding in Members' / Certificate holders' Register	88,713,867
Add: Additions during the period / year	19,979,786
Less: Deletions during the period / year	0
Balance at the end of year / period in the CDC's Nominee Holding in Members' / Certificate holders' Register	108,693,653

N-2: Movement in the Central Depository Register

Number of Securities

Balance at the beginning of the year in the Central Depository Register	88,713,867
Add: Additions during the period / year	19,979,786
Less: Deletions during the period / year	0
Balance at the end of year / period in the Central Depository Register	108,693,653

Reason for Difference and discrepancy (if any):



Authorized Signatory (ies) / Company Secretary



Handwritten signature: Reanda Haroon Zakaria

This reconciliation would be stamped, signed and dated by the External Auditor here





INDEPENDENT REASONABLE ASSURANCE REPORT ON STATEMENT OF FREE FLOAT OF SHARES

To the Chief Executive of the Liven Pharma Limited

1. Introduction

We have been engaged to perform a reasonable assurance engagement on the annexed Statement of Free Float of Shares (the 'Statement') of Liven Pharma Limited (the Company) as of September 30, 2025, December 31, 2025, March 31, 2026 and June 30, 2026.

2. Applicable Criteria

The criteria against which the Statement is assessed is Regulation No. 5.7.2.(b)(ii) of Pakistan Stock Exchange Limited Regulations (PSX Regulations) which requires every listed company to submit directly to Pakistan Stock Exchange (PSX) an annual Free-Float Certificate duly verified by the auditor along with the annual audited accounts as prescribed under regulation 5.6.9.(a) of the PSX Regulations.

3. Management's Responsibility for the Statement

Management is responsible for the preparation of the Statement as of September 30, 2025, December 31, 2025, March 31, 2026 and June 30, 2026 in accordance with the applicable criteria. This responsibility includes maintaining adequate records and internal controls as determined necessary to enable the preparation of the Statement such that it is free from material misstatement, whether due to fraud or error.

4. Our Independence and Quality Control

We have complied with the independence and other ethical requirements of the Code of Ethics for Chartered Accountants (Revised 2019) issued by the Institute of Chartered Accountants of Pakistan, which is founded on fundamental principles of integrity, objectivity, professional competence and due care, confidentiality and professional behavior.

The firm applies International Standard on Quality Management (ISQM) 1 "Quality Management for Firms that Perform Audits or Reviews of Financial Statements, or Other Assurance or Related Services Engagements", which requires the firm to design, implement and operate a system of quality management including policies or procedures regarding compliance with ethical requirements, professional standards and applicable legal and regulatory requirements.

5. Our responsibility and summary of the work performed

Our responsibility is to carry out an independent reasonable assurance engagement and to express an opinion as to whether the Statement is prepared in accordance with the applicable criteria, based on the procedures we have performed and the evidence we have obtained.

We conducted our reasonable assurance engagement in accordance with International Standard on Assurance Engagements 3000 (Revised), 'Assurance Engagements other than audits or reviews of historical financial statements' (ISAE 3000) (Revised) issued by the International Auditing and Assurance Standards Board. That standard requires that we plan



Reanda Haroon Zakaria Aamir Salman Rizwan & Company
Chartered Accountants

Office No. 275, H-1 Block, M.A. Johar Town, Lahore – 54782, Pakistan

Tel: +92 (42) 3531 1524

Email: info@hzasr.pk | Web: www.hzasr.pk

Other offices in Karachi and Islamabad



and perform this engagement to obtain reasonable level of assurance about whether the Statement is free from material misstatement.

A reasonable assurance engagement in accordance with ISAE 3000 (Revised) involves performing procedures to obtain evidence about the free float of shares and related information in the Statement. The nature, timing and extent of procedures selected depend on the practitioner's judgment, including the assessment of the risks of material misstatement, whether due to fraud or error, in the Statement. In making those risk assessments, we considered internal control relevant to Liven Pharma Limited's preparation of the Statement. A reasonable assurance engagement also includes assessing the applicable criteria used and significant estimates made by management, as well as, evaluating the overall presentation of the Statement.

We have carried out the procedures considered necessary for the purpose of providing reasonable assurance on the Statement. Our assurance procedures performed included verification of information in the Statement with the underlying data and record comprising of Central Depository Company statements, forms submitted by the Company with Securities & Exchange Commission of Pakistan relating to its pattern of shareholding and other related information. Verification that the computation of free float of shares is in accordance with the PSX regulation also forms part of our assurance procedures.

With respect to identification of associates of an individual as defined in section 2(ii)(a) of the Securities Act, 2015, we have obtained and relied on management's representations that are based on written declarations from individuals (i.e. directors, sponsors and senior management officers of the company) about their associates.

We believe that the evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

6. Opinion

In our opinion, the Statement as of September 30, 2025, December 31, 2025, March 31, 2026 and June 30, 2026 is prepared, in all material respects, in accordance with the PSX Regulations.

7. Restriction on use and distribution

This report is issued in relation to the requirements as stipulated under Regulation No 5.7.2.(b)(ii) of the PSX Regulations and is not to be used or distributed for any other purpose. This report is restricted to the facts stated herein and the attachments.



Chartered Accountants
 Place: Lahore
 Date: October 01, 2025



INDEPENDENT AUDITOR'S REPORT

To the members of Liven Pharma Limited

Report on the Audit of the Financial Statements

Opinion

We have audited the annexed financial statements of Liven Pharma Limited (the Company), which comprise the statement of financial position as at June 30, 2026, and the statement of profit or loss, the statement of comprehensive income, the statement of changes in equity, the statement of cash flows for the year then ended, and notes to the financial statements, including material accounting policy information and other explanatory information, and we state that we have obtained all the information and explanations which, to the best of our knowledge and belief, were necessary for the purposes of the audit.

In our opinion and to the best of our information and according to the explanations given to us, the statement of financial position, statement of profit or loss, the statement of comprehensive income, the statement of changes in equity and the statement of cash flows together with the notes forming part thereof conform with the accounting and reporting standards as applicable in Pakistan and give the information required by the Companies Act, 2017 (XIX of 2017), in the manner so required and respectively give a true and fair view of the state of the Company's affairs as at June 30, 2026 and of the loss and other comprehensive income, the changes in equity and its cash flows for the year then ended.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) as applicable in Pakistan. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' *Code of Ethics for Professional Accountants* as adopted by the Institute of Chartered Accountants of Pakistan (the Code) and we have fulfilled our other ethical responsibilities in accordance with the Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

R. May

Reanda Haroon Zakaria Aamir Salman Rizwan & Company
Chartered Accountants

Office No. 275, H-1 Block, M.A. Johar Town, Lahore – 54782, Pakistan
 Tel: +92 (42) 3531 1524
 Email: info@hzasr.hr.pk | Web: www.hzasr.pk

Other offices in Karachi and Islamabad

Page 1 | 6



Following are the Key audit matters:

Sr.no.	Key audit matters	How the matter was addressed in our audit
(i)	Revenue Recognition Refer notes 4.12 & 25 to the financial statements. The Company's revenue is generated from sales of pharmaceutical products. The Company recognized revenue of Rs. 105.807 million from the sale of goods to local as well as export customers during the year ended June 30, 2026 which has decreased by 16.87% as compared to last year. We identified the recognition of revenue as a key audit matter because revenue is one of the key performance indicators of the Company and give rise to an inherent risk that revenue could be subject to misstatement to meet expectations or targets.	Our audit procedures included the following: • Obtained an understanding of the Company's process with respect to revenue recognition and evaluated controls relevant to such process; • Inspected contracts on selected samples to obtain an understanding of contract terms particularly relating to timing and the customer's acceptance of the products and assessing the Company's accounting policies for recognition of revenue with reference to the requirements of the prevailing accounting standards; • Performed substantive audit procedures over revenue transactions along with inspection of related supporting documents, on test basis; • Compared a sample of revenue transactions recorded around the year end and post year end with the underlying documentation to assess if the related revenue was recorded in the appropriate accounting period; and • Assessed the adequacy of disclosure made in the financial statements in accordance with the applicable accounting and reporting standard as applicable in Pakistan.
(ii)	Stock in Trade Refer notes 4.3 & 8 to the financial statements. As at 30 June 2026, the Company's stock in trade amounted to Rs 92.902 million.	Our audit procedures included the following: • Obtained an understanding of policies and procedures followed by the Company with respect to valuation of inventories;

R/Mee

REANDA

Sr.no.	Key audit matters	How the matter was addressed in our audit
	We have considered this area as a key audit matter due to significance of amounts involved, complex valuation processes and estimates involved in the determination of provision for obsolescence of stock in trade and the NRV.	- Assessed appropriateness of the Company's accounting policies for valuation of inventories and compliance of those policy with the applicable financial reporting framework; - Attended management's inventory counts and observing the process, including the process implemented by management to identify and monitor obsolete stock; - Performed recalculation of net realizable value (NRV), on a sample basis, for closing stock in trade; - Tested provision recorded for slow moving, obsolete and near to expiry stock in trade to assess that it was as per the policy of the Company; and - Assessed the adequacy of related financial statements disclosures in accordance with the applicable financial reporting framework.
(iii)	Surplus on revaluation on property, plant and equipment Refer to notes 4.1, 5 and 14 to the financial statements. The entity follows the revaluation model for subsequent measurement of freehold land, buildings on freehold land, plant and machinery, furniture and fixture and motor vehicles. The fair value of these assets is determined on regular intervals by an independent valuer. Latest revaluation was undertaken as at 30 June 2026.	Our audit procedures included the following: - Obtaining and inspecting the results of valuation carried out by management of the Company through an externally appointed expert on which the management assessment of valuation of property, plant and equipment was based; - Evaluating the externally appointed expert's competence, capabilities and objectivity; - Evaluating the completeness and appropriateness of information used in the valuation by inspecting the relevant underlying documentation;

R0264



Sr.no.	Key audit matters	How the matter was addressed in our audit
	We considered revaluation of property, plant and equipment as key audit matter due to significant management's judgments and estimations involved in determination of valuation.	- Evaluating the appropriateness of key methodology used by the management, reasonableness of key estimates and assumptions used by the management in valuation exercise; - Evaluating whether the results of the valuation exercise have been appropriately accounted for in accordance with the requirements of accounting and reporting regulations as applicable in Pakistan; and - Assessing the appropriateness of financial statements' disclosures in accordance with the requirements of the applicable financial reporting framework.

Information Other than the Financial Statements and Auditor's Report Thereon

Management is responsible for the other information. The other information comprises the information included in the annual report, but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Board of Directors for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with the accounting and reporting standards as applicable in Pakistan and the requirements of Companies Act, 2017 (XIX of 2017) and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern

RHAC



and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Board of directors are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs as applicable in Pakistan will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs as applicable in Pakistan, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

RMU



We communicate with the board of directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the board of directors with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.


From the matters communicated with the board of directors, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

Based on our audit, we further report that in our opinion:

- proper books of account have been kept by the Company as required by the Companies Act, 2017 (XIX of 2017);
- the statement of financial position, the statement of profit or loss, the statement of comprehensive income, the statement of changes in equity and the statement of cash flows together with the notes thereon have been drawn up in conformity with the Companies Act, 2017 (XIX of 2017) and are in agreement with the books of account and returns;
- investments made, expenditure incurred and guarantees extended during the year were for the purpose of the Company's business; and
- no Zakat was deductible at source under the Zakat and Ushr Ordinance, 1980 (XVIII of 1980).

The engagement partner on the audit resulting in this independent auditor's report is Ahmad Salman Arshad.


 Chartered Accountants
 Place: Lahore
 Date: October 03, 2026
 UDIN: AR202610384vd2BbE6ar

Liven Pharma Limited
STATEMENT OF FINANCIAL POSITION
AS AT JUNE 30, 2026

	Note	2026 (Rupees)	2025 (Rupees)
ASSETS			
NON-CURRENT ASSETS			
Property, plant and equipment	5	918,164,718	666,512,380
Intangible assets	6	4,796,922	8,440,679
Total non-current assets		922,961,640	674,953,059
CURRENT ASSETS			
Trade debts	7	11,115,542	9,402,578
Stock in trade	8	92,902,365	123,324,881
Tax refund due from Government	9	733,459	-
Prepayments, deposits and advances	10	6,777,661	7,339,727
Short term investments	11	163,300,000	-
Cash and bank balances	12	18,250,894	7,884,396
Total current assets		293,079,921	147,951,582
TOTAL ASSETS		1,216,041,561	822,904,641
EQUITY AND LIABILITIES			
Share capital and reserves			
Share capital			
Issued, subscribed and paid-up share capital	13	1,130,403,670	930,403,670
Capital reserve			
Surplus on revaluation on property, plant and equipment	14	188,911,397	-
Revenue reserve			
Accumulated loss		(333,857,053)	(296,543,276)
Total equity		985,458,014	633,860,394
LIABILITIES			
NON-CURRENT LIABILITIES			
Lease liabilities	15	2,338,379	1,247,868
Long term financing	16	2,520,472	5,098,065
Deferred taxation	17	114,451,738	92,272,765
Total non-current liabilities		119,310,589	98,618,698
CURRENT LIABILITIES			
Trade and other payables	18	82,390,515	61,720,121
Loan from related parties	19	15,282,580	14,047,263
Running finance	20	9,117,046	11,185,166
Mark up accrued	21	304,745	386,020
Current portion of long term liabilities	22	4,178,072	3,086,979
Provision for taxation	23	-	-
Total current liabilities		111,272,958	90,425,549
Total liabilities		230,583,547	189,044,247
TOTAL EQUITY AND LIABILITIES		1,216,041,561	822,904,641
CONTINGENCIES AND COMMITMENTS			
	24		

The annexed notes 1 to 49 form an integral part of these financial statements.

Rabir

[Signature]
 Chief Executive

[Signature]
 Director

[Signature]
 Chief Financial Officer

Liven Pharma Limited
STATEMENT OF PROFIT OR LOSS
FOR THE YEAR ENDED JUNE 30, 2026

	Note	2026 (Rupees)	2025 (Rupees)
Sales	25	105,806,555	127,271,949
Cost of sales	26	(79,160,938)	(109,313,168)
Gross profit		26,645,617	17,958,781
Administrative and general expenses	27	(37,712,939)	(373,563,504)
Selling and distribution expenses	28	(9,761,800)	(17,606,673)
Other expenses	29	(53,771,704)	(116,904,602)
Finance costs	30	(2,539,511)	(785,675)
Operating loss		(77,140,337)	(490,901,673)
Other income	31	12,218,820	305,814
Loss before levies and taxation		(64,921,517)	(490,595,859)
Levies	32	(1,399,506)	(1,590,899)
Loss before taxation		(66,321,023)	(492,186,758)
Taxation	33	35,182,336	(92,272,765)
Loss after taxation		(31,138,687)	(584,459,523)
Loss per share - Basic and diluted (restated)	34	(0.28)	(7.11)

The annexed notes 1 to 49 form an integral part of these financial statements.

Army




Chief Executive




Director




Chief Financial Officer

Liven Pharma Limited

STATEMENT OF COMPREHENSIVE INCOME

FOR THE YEAR ENDED JUNE 30, 2026


	Note	2026 (Rupees)	2025 (Rupees)
Loss after taxation		(31,138,687)	(584,459,523)
Other comprehensive income			
Items that may be reclassified subsequently to profit or loss (net of tax):		-	-
Items that will not be reclassified to profit or loss (net of tax):			
Surplus on revaluation on property, plant and equipment		188,911,397	-
Total other comprehensive income for the year		188,911,397	-
Total comprehensive income/(loss) for the year		<u>157,772,710</u>	<u>(584,459,523)</u>

The annexed notes 1 to 49 form an integral part of these financial statements.

Attested



 Chief Executive



 Director



 Chief Financial Officer

Liven Pharma Limited
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED JUNE 30, 2026


	Share capital	Capital reserve	Revenue reserve	Total equity
Particulars	Issued, subscribed and paid-up share capital	Surplus on revaluation of property, plant and equipment	Accumulated (loss)/profit	
Rupees				
Balance as at July 01, 2024	400,000	589,507,658	159,784,726	749,692,384
Effect of scheme of arrangement/ merger (note 1.2)	-	(461,376,137)	-	(461,376,137)
Transfer to retained earnings	-	(128,131,521)	128,131,521	-
Transactions with owners:				
Deemed issued during the year	121,237,000	-	-	121,237,000
Issued against loan to directors	142,500,000	-	-	142,500,000
Issued as a result of merger scheme	666,666,670	-	-	666,666,670
Adjustment of share capital of LPL	(400,000)	-	-	(400,000)
	930,003,670	-	-	930,003,670
Comprehensive income for the year:				
Loss for the year	-	-	(584,459,523)	(584,459,523)
Other comprehensive income	-	-	-	-
Total comprehensive loss for the year	-	-	(584,459,523)	(584,459,523)
Transfer to accumulated loss on account of incremental depreciation (net of tax)	-	-	-	-
Balance as at June 30, 2025	930,403,670	-	(296,543,276)	633,860,394
Balance as at July 01, 2025	930,403,670	-	(296,543,276)	633,860,394
Transactions with owners:				
Issuance of right shares	200,000,000	-	-	200,000,000
Share issuance cost - net of tax	-	-	(6,175,090)	(6,175,090)
	200,000,000	-	(6,175,090)	193,824,910
Comprehensive income for the year:				
Loss for the year	-	-	(31,138,687)	(31,138,687)
Other comprehensive income	-	188,911,397	-	188,911,397
Total comprehensive income for the year	-	188,911,397	(31,138,687)	157,772,710
Transfer to accumulated loss on account of incremental depreciation (net of tax)	-	-	-	-
Balance as at June 30, 2026	1,130,403,670	188,911,397	(333,857,053)	985,458,014

The annexed notes 1 to 49 form an integral part of these financial statements.

R. Khurana



Chief Executive



Director



Chief Financial Officer

Liven Pharma Limited
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED JUNE 30, 2026

	Note	2026 (Rupees)	2025 (Rupees)
CASH FLOWS FROM OPERATING ACTIVITIES			
Loss before taxation		(66,321,023)	(492,186,758)
Adjustments for non cash and other items:			
Depreciation on property, plant and equipment	5.5	26,088,954	23,276,063
Depreciation on right of use assets	5.6	1,112,405	1,394,478
Amortization on intangible assets	6.2	3,643,757	2,963,319
Listing expense	27.1	-	327,803,230
Bad debt written off	29	-	29,658,026
Allowance for expected credit loss	29	11,582,140	87,214,758
Provision for impairment on advance to supplier	29	5,160,109	-
Gain on sale of property, plant and equipment	31	(4,665,920)	-
Provision for obsolete stock	29	36,760,211	-
Workers' welfare fund (WWF) payable	29	26,452	31,818
Additional charge on unpaid balance of WWF	30	4,773	-
Finance costs	30	2,534,738	785,675
Operating profit / (loss) before working capital changes		15,926,596	(19,059,391)
Working capital changes			
Decrease / (increase) in current assets:			
Stock in trade		(6,337,695)	458,856
Trade debts		(13,295,104)	(21,524,966)
Prepayments, deposits and advances		(4,598,043)	(522,090)
(Decrease) / increase in current liabilities:			
Trade and other payables		20,639,169	39,396,735
Cash generated from / (used in) from operations	A	12,334,923	(1,250,855)
Finance costs paid		(2,616,013)	(473,655)
Taxes paid		(733,459)	-
Net cash generated from / (used) in operating activities		8,985,451	(1,724,510)
CASH FLOWS FROM INVESTING ACTIVITIES			
Payments against acquisition of property, plant and equipment		(29,661,895)	(22,836,069)
Proceeds from disposal of property, plant and equipment		7,148,500	-
Payments against acquisition of intangible asset		-	(10,000,000)
Purchase of short term investments		(646,572,000)	-
Proceeds of disposal of short term investments		483,272,000	-
Net cash used in investing activities	B	(185,813,395)	(32,836,069)
CASH FLOWS FROM FINANCING ACTIVITIES			
Payments against lease liabilities		(697,852)	(1,357,822)
Proceeds from issuance of right shares		200,000,000	-
Payments against transaction cost for issuance of right issue		(8,697,310)	-
Proceeds from loan from director		1,643,465	14,047,263
Repayments of loan from director		(408,148)	-
Proceeds from running finance		90,779,215	154,672,254
Repayments against running finance		(92,847,335)	(156,143,152)
Proceeds from long term finance		-	6,680,000
Repayments against long term finance		(2,577,593)	(441,679)
Net cash generated from financing activities	C	187,194,442	17,456,864
Net increase/(decrease) in cash and cash equivalents	A+B+C	10,366,498	(17,103,715)
Cash and cash equivalents acquired as a result of merger		-	32,782
Cash and cash equivalents at the beginning of the period		7,884,396	24,955,329
Cash and cash equivalents at the end of the period	12.1	18,250,894	7,884,396

The annexed notes 1 to 49 form an integral part of these financial statements.

Rohay

Liven
 Chief Executive
 C.E.O.

Fair
 Director
 Director

Shah
 Chief Financial Officer
 C.F.O.

Liven Pharma Limited

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED JUNE 30, 2026

1 STATUS AND NATURE OF BUSINESS

- 1.1 Liven Pharma Limited (Formerly: Landmark Spinning Industries Limited) (the Company) was registered on October 21, 1991 under the repealed Companies Ordinance, 1984 (now the Companies Act, 2017) as a private limited company in Pakistan and subsequently converted into public limited company as on April 30, 1992. The shares of the Company are quoted on Pakistan Stock Exchange Limited (PSX). The principal activity of the Company was trading, manufacturing, and selling of yarn. The Company changed its principle line of business under the scheme of arrangement sanctioned by the Honorable High Court of Sindh, Karachi and the principal line of business has been changed from "Textile Spinning" to "Pharmaceuticals." The Company changed its registered office under the arrangement sanctioned by the Honorable High Court of Sindh, Karachi from Sindh to Punjab. The registered office and manufacturing facility of the Company is located at 49-KM, Multan Road, Phool Nagar District Kasur. The regional office of the Company is located at apartment no. 303, third floor, regency plaza, 120-P, M-M Alam road, mini market, Gulberg-II Lahore.
- 1.2 The operations of the Company were suspended on November 29, 2002, to forestall the recurring losses on account of power breakdowns / frequent load shedding and had been in suspension since then. As a result, the Securities and Exchange Commission (SECP) in its order dated March 20, 2019, granted sanction to the Registrar, Company Registration Office (CRO), Karachi, to present winding up petition against the Company before the Court under clause (b) of section 304 of the Companies Act, 2017. The Company filed an appeal against the said order, however, the same was refused by the Commission vide letter No. 5(10) Misc/ABR/19 dated April 22, 2019. The winding-up against the Company has not yet been filed.
- In response to the continuous effort by the management to revive the Company, on October 28, 2021, the Company received a proposal from Liven Pharmaceutical (Private) Limited, prompting the Board of Directors to authorize management to explore the feasibility of a potential reverse merger. The Company communicated the same to the PSX along with the requisite documents in accordance with Rule 5.22 of the PSX Rule Book "Reverse Merger Regulations" and subsequently received confirmation from the PSX that the proposed
- The Board of Directors of the Company in their meeting dated April 13, 2022 duly approved the scheme of merger whereby the Liven Pharmaceuticals (Private) Limited will be merged with and into Landmark Spinning Industries Limited in exchange of issuance ordinary shares of Landmark Spinning Industries Limited against the shares of Liven Pharmaceuticals (Private) Limited.
- The petition for the scheme of arrangement (the scheme) was filed on May 17, 2022, with the High Court of Sindh. Additionally, the shareholders of the Company have approved the scheme of merger in the Extra Ordinary General Meeting held on June 27, 2022.
- During the previous year, the Scheme of Arrangement dated April 25, 2022, for the amalgamation of the entire business and operations of Liven Pharmaceuticals (Private) Limited ("LPL") into the Company was sanctioned by the Honorable High Court of Sindh, Pakistan, on September 2, 2024. As a result of the Court's approval, all assets, rights, liabilities, and obligations of LPL have been amalgamated, transferred, and vested into the Company. This included adjustments for the factory land, building, plant, and machinery located at Winder Industrial Estate, Sector C, District Lasbella, Baluchistan, which have been settled against the loan from related parties associated with the Company's current sponsors in accordance with the Scheme of Arrangement. Accordingly, the former shareholders of LPL were issued 87% of the issued shares in the merged entity.

R. M. M. M.

Liven Pharma Limited

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2026

Owing to the implementation of Scheme of Arrangement sanctioned by the Honorable High Court of Sindh, Karachi :

- the name of the Company changed from "Landmark Spinning Industries Limited" to "Liven Pharma Limited."
- the principal line of business of the Company changed from "textile spinning" to "pharmaceuticals."
- the registered office of the Company changed from "Sindh" to "Punjab."
- Authorized share capital of the Company increased to Rs. 1 billion.

Furthermore, as a result of the Court's sanction of the Scheme of Arrangement, the Company will continue its pharmaceutical manufacturing business. The management believes that the SECP's prior winding-up order has now become infructuous, as the underlying issue has been resolved and the Scheme of Arrangement was approved with the SECP's comments considered.

- 1.3 The merger transaction has been accounted for in accordance with the reverse acquisition principles contained in IFRS 3 "Business Combinations" and the guidance provided by the IFRS Interpretations Committee on reverse acquisitions that do not constitute a business. Since the listed company did not meet the definition of a business under IFRS 3, the transaction falls outside the scope of that standard. Therefore, paragraph 10-12 of IAS 8 "Changes in accounting estimates and errors", and IFRS 2 "Share-based payment" have been applied to account for the merger transactions. Accordingly, the private company (Liven Pharmaceuticals (Private) Limited) has been identified as the accounting acquirer, and the listed company (Landmark Spinning Industries Limited) as the accounting acquiree.

For accounting purposes, these financial statements represent a continuation of the financial statements of the accounting acquirer. Comparative figures have been restated to present the results, financial position, and cash flows of the accounting acquirer as if it had always been the reporting entity. The impact of the fair value of shares deemed to have been issued and the fair value of the identifiable net liabilities of the legal parent has been recognized as a listing expense in profit or loss in accordance with IFRS 2.

The identifiable assets and liabilities of Landmark Spinning Industries Limited as at the effective date were as follows:

Assets	
Cash and bank	32,782
Long term deposits	25,000
	<u>57,782</u>
Liabilities	
Accrued liabilities	1,733,482
	<u>1,733,482</u>

- 1.4 The Board of Directors of Liven Pharma Limited (the Company), in its meeting held on Friday, 12th September, 2025 at 49-Km Multan Road, Lahore, resolved to increase the paid-up share capital of the Company by issue of further 20,000,000 (Twenty million) shares, having face value of Rs. 10/- (Rupees Ten) each, as right shares, to be offered to the members of the Company in proportion of approximately 21.496 right shares for every 100 ordinary shares held i.e, approximately 21.496% at a price of Rs. 10/- (Rupees Ten) per right shares.
- 1.5 On January 05, 2026, the Company has issued 20,000,000 ordinary shares, at a price of Rs. 10 per share, aggregating to Rs. 200 million. In this regard, share issuance cost was incurred amounting to Rs 8.697 million, which is directly charged to equity net of tax. These funds will be utilized in establishment of dry powder injectables (DPI) facility, procurement of vehicles, DRAP related registration and licensing cost, expansion of sales team and promotional activities and additional working capital requirements.

Ramey

Liven Pharma Limited

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2026

2 BASIS OF PREPARATION

2.1 Statement of compliance

These financial statements have been prepared in accordance with the accounting and reporting standards as applicable in Pakistan. Accounting and reporting standards applicable in Pakistan comprise:

- IFRS Accounting Standards issued by the International Accounting Standards Board (IASB) as notified under the Companies Act, 2017; and
- Provisions of, directives and notifications issued under the Companies Act, 2017.

Where provisions of, directives and notifications issued under the Companies Act, 2017 differ from the IFRS Accounting Standards, the provisions of, directives and notifications issued under the Companies Act, 2017 have been followed.

2.2 Basis of measurement

These financial statements have been prepared under the historical cost convention using accrual basis of accounting except for cashflow information, certain items of property, plant and equipment at revalued amounts and otherwise specified in respective notes to the financial statements.

2.3 Functional and presentation currency

Items included in the financial statements are measured using the currency of the primary economic environment in which the Company operates. These financial statements are presented in Pakistani Rupees which is also the functional currency of the Company. All financial information presented in Pakistani Rupees has been rounded to nearest rupee, unless otherwise stated.

2.4 Significant accounting estimates and judgments

The preparation of financial statements requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. The estimates and associated assumptions and judgments are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the result of which forms the basis of making judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Subsequently, actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised and in any future periods affected.

- Useful lives, residual values and depreciation method of property, plant and equipment - Note 4.1 & 5
- Revaluation of property, plant and equipment - Note 4.1 & 5
- Useful lives, residual values and amortization method of intangible assets - Note 4.2 & 6
- Provision for impairment of inventories - Note 4.3
- Impairment loss of non-financial assets other than inventories - Note 4.2
- Current income tax expense, provision for current tax and recognition of deferred tax asset (for carried forward tax losses) - Note 4.9, 32, 33 & 17
- Estimation of lease liabilities and right of use assets - Note 4.7, 5, 15 & 22
- Pricing of revenue from contracts with customers - Note 4.12
- Estimation of borrowing cost - Note 4.15
- Estimation of provisions - Note 4.17
- Provision for expected credit losses - Note 4.19.1 & 7
- Estimation of contingent liabilities - Note 4.18.1.2 & 24

There have been no critical judgments made by the Company's management in applying the accounting policies that would have significant effect on the amounts recognized in these financial statements except for determining the realizable / settlement values of assets and liabilities, residual values and useful lives of property, plant and equipment.

RP/My

Liven Pharma Limited

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2026

3 NEW STANDARDS, AMENDMENTS TO APPROVED ACCOUNTING STANDARDS AND NEW INTERPRETATIONS

3.1 New accounting standards, amendments and IFRS interpretations that are effective for the year ended June 30, 2026

The following standards, amendments and interpretations are effective for the year ended June 30, 2026. These standards, amendments and interpretations are either not relevant to the Company's operations or did not have significant impact on the financial statements other than certain additional disclosures.

	Effective date (annual reporting periods beginning on or after)
Amendments to IAS 21 'The Effects of Changes in Foreign Exchange Rates' - Lack of Exchangeability	January 01, 2025
3.2 New accounting standards, amendments and interpretations that are not yet effective	
The following standards, amendments and interpretations are only effective for accounting periods, beginning on or after the date mentioned against each of them. These standards, amendments and interpretations are either not relevant to the Company's operations or are not expected to have significant impact on the Company's financial statements other than certain additional disclosures.	
Amendments to IFRS 7 'Financial Instruments: Disclosures' - Amendments regarding the classification and measurement of financial instruments	January 01, 2026
Amendments to IFRS 9 'Financial Instruments' - Amendments regarding the classification and measurement of financial instruments	January 01, 2026
Annual Improvements to IFRS Accounting Standards—Volume 11	January 01, 2026
IFRS 17 Insurance Contracts	January 01, 2027
IFRS 18 'Presentation and Disclosures in Financial Statements'	January 01, 2027
IFRS 19 'Subsidiaries without Public Accountability: Disclosures'	January 01, 2027
IAS 28 Investments in associates and joint ventures: Amendments to provide clarity about which entities are eligible to measure investments using the fair value option	January 01, 2027
Amendments to IAS 21 - Translation to a Hyperinflationary Presentation Currency	January 01, 2027
IFRS 1 'First-time Adoption of International Financial Reporting Standards' has been issued by IASB effective from July 01, 2009. However, it has not been adopted yet locally by Securities and Exchange Commission of Pakistan (SECP).	
IFRS 17 - 'Insurance contracts' has been notified by the IASB to be effective for annual periods beginning on or after January 1, 2023. However SECP has notified the timeframe for the adoption of IFRS - 17 which will be adopted by January 01, 2026.	

Ritmay

Liven Pharma Limited

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2026

IFRS 18 'Presentation and Disclosures in Financial Statements' has been issued by IASB effective from January 01, 2027. However, it has not been adopted yet locally by SECP.

IFRS 20 Regulatory Assets and Regulatory Liabilities has been notified by the IASB to be effective for annual periods beginning on or after January 1, 2029. However it has not been adopted yet locally by Securities and Exchange Commission of Pakistan (SECP).

3.3 Sustainability Disclosure

IFRS S1: General Requirements for Disclosure of Sustainability-related Financial Information. IFRS S1 sets out overall requirements for sustainability-related financial disclosures with the objective to require an entity to disclose information about its sustainability-related risks and opportunities that is useful to primary users of general purpose financial reports in making decisions relating to providing resources to the entity. IFRS S2: Climate-related Disclosures' IFRS S2 sets out the requirements for identifying, measuring and disclosing information about climate related risks and opportunities that is useful to primary users of general purpose financial reports in making decisions relating to providing resources to the entity. 'As per the current scenario, the Company will fall in Phase-III of the criteria as per the order from Securities and Exchange Commission of Pakistan (SECP) dated 31 December, 2024. Therefore the effective date of these two sustainability standards for the Company is for annual reporting periods beginning on or after 01 July, 2027

4 MATERIAL ACCOUNTING POLICY INFORMATION

The material accounting policies adopted in the preparation of these financial statements are set out below. These policies have been consistently applied.

4.1 Property, plant and equipment

Items of property, plant and equipment other than freehold land, buildings on freehold land, plant and machinery, furniture and fixtures and motor vehicles are measured at cost less accumulated depreciation and impairment loss (if any). freehold land, buildings on freehold land, plant and machinery, furniture and fixtures and motor vehicles are measured at the revalued amount less accumulated depreciation and impairment loss (if any). Cost comprises purchase price, import duties and non-refundable purchase taxes, after deducting trade discounts and rebates, and includes other costs directly attributable to the acquisition or construction, erection and installation.

Subsequent costs, if reliably measurable, are included in the asset's carrying amount, or recognized as a separate asset as appropriate, only when it is probable that future economic benefits associated with the cost will flow to the Company. The carrying amount of any replaced parts as well as other repair and maintenance costs, are charged to profit or loss account during the period in which they are occurred.

Depreciation is charged to statement of profit or loss by applying the reducing balance method so as to write down the assets over their estimated useful lives at the rates specified in note 5 to these financial statements. The assets' residual values, useful lives and methods are reviewed, and adjusted if appropriate, at each financial year end.

An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

Impairment loss, if any, or its reversal, is also charged to profit or loss account for the year. Where an impairment loss is recognized, the depreciation charge is adjusted in future periods to allocate the asset's revised carrying amount, less its residual value, over its estimated useful life.

Revaluation of property, plant and equipment is carried out by independent professional valuer. The frequency of revaluations depends upon the changes in fair values of the items of property, plant and equipment being revalued.

Attag

Liven Pharma Limited

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2026

Any revaluation increase arising on the revaluation of assets is recognized in other comprehensive income and presented as a separate component of equity as "Surplus on revaluation on property, plant and equipment", except to the extent that it reverses a revaluation decrease for the same asset previously recognized in profit or loss, in which case the increase is credited to profit or loss to the extent of the decrease previously charged. Any decrease in carrying amount arising on the revaluation of assets is charged to profit or loss to the extent that it exceeds the balance, if any, held in the "Surplus on revaluation on property, plant and equipment" relating to a previous revaluation increase of that asset. The surplus on revaluation in respect of revalued assets to the extent of incremental depreciation charged (net of deferred tax) is transferred to unappropriated profit.

In respect of additions and deletions of assets during the year, full month depreciation is charged from the month of acquisition and up to the month preceding the deletion, respectively.

An item of property, plant and equipment and any significant part initially recognised is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. The gain or loss arising on derecognition of an item of property, plant and equipment is determined as the difference between the sales proceeds and the carrying amounts of the asset and is recognised in as other income in the statement of profit or loss. In case of the derecognition of a revalued property, the attributable revaluation surplus remaining in the surplus on revaluation is transferred directly to the unappropriated profit.

Judgment and estimates

The useful lives, residual values and depreciation method are reviewed on a regular basis. The effect of any changes in estimate is accounted for on a prospective basis. Further, the key assumptions used to determine the fair value of property, plant and equipment are provided in note 5.

4.2 Intangible assets

- Intangible assets acquired separately are initially recognized at cost. After initial recognition, these are measured at cost less accumulated amortization and accumulated impairment losses. Costs associated with routine maintenance of intangible assets are recognized as an expense when incurred. However, costs that are directly attributable to identifiable intangible assets and which enhance or extend the performance of intangible assets beyond the original specification and useful life is recognized as capital improvement and added to the original cost of the intangible.
- Amortization is charged so as to allocate the cost of assets over their estimated useful lives, using the straight-line method on patents and using the diminishing balance method on ERP system at the rates specified in note 6 to the financial statements.
- Company accounts for impairment, where indications exist, by reducing asset's carrying amount to the recoverable amount.

Judgment and estimates

The useful lives, residual values and amortization method are reviewed on a regular basis. The effect of any changes in estimate accounted for on a prospective basis.

Impairment of non-financial assets

Assets that have an indefinite useful life are not subject to depreciation and are tested annually for impairment. Assets that are subject to depreciation are reviewed for impairment at each reporting date, or wherever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized wherever the carrying amount of the asset exceeds its recoverable amount. The recoverable amount is higher of an asset's fair value less costs to sell and value in use.

R. D. D. D.

Liven Pharma Limited

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2026

For the purposes of assessing impairment, assets are grouped at the lowest levels, for which there are separately identifiable cash flows. Non-financial assets that suffered an impairment, are reviewed for possible reversal of the impairment at each reporting date. Reversals of the impairment loss are restricted to the extent that asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss has been recognized. An impairment loss or reversal of impairment loss is recognized in profit or loss for the year.

4.3 Stock in trade

Raw materials, packing materials, stores and spares, work in process and finished goods are stated at the lower of cost and net realisable value. Cost comprises direct materials, direct labour and an appropriate proportion of variable and fixed overhead expenditure. Items considered obsolete are carried at nil value. Costs of purchased inventory are determined after deducting rebates and discounts. Cost of major components of stock in trade is determined on following basis:

Raw material	Annual average basis
Packing material	Annual average basis
Work in process	Estimated manufacturing cost
Stores, spares and loose tools	Annual average basis
Finished goods	Annual average manufacturing cost

- Judgments and estimates

Net realizable value is estimated selling price in ordinary course of business less estimated costs of production and estimated costs necessary to make the sale. A review is made on each reporting date on inventories for excess inventories, obsolescence and declines in net realizable value and an allowance is recorded against the inventory balances for any such declines.

4.4 Share capital

Ordinary shares are classified as equity and recognized at their face value. Transaction costs (net of tax) directly attributable to the issuance of ordinary shares are recognized as a deduction from equity in statement of changes in equity.

4.5 Earnings per share (EPS)

The company presents basic and diluted earning per share (EPS) for its ordinary shares. Basis EPS is calculated by dividing the profit or loss attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period. Diluted EPS is determined by adjusting the profit or loss attributable to ordinary shareholders and the weighted average number of ordinary shares outstanding for the effects for all dilutive potential ordinary shares.

4.6 Dividend distribution and other appropriations to ordinary shareholders

- Dividend to ordinary shareholders is recognized as a deduction from retained earnings in statement of changes in equity and as a liability, to the extent it is unclaimed/unpaid, in the Company's financial statements in the year in which the dividends are declared and other appropriations are recognized in the period in which these are approved.
- However, if these are approved after the reporting period but before the financial statement are authorized for issue, disclosure is made in the financial statements as subsequent events after the reporting date.

4.7 Lease liability and right-of-use asset (ROUA)

- At inception of a contract, the Company assesses whether a contract is, or contains, a lease based on whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Lease terms are negotiated on an individual basis and contain a wide range of different terms and conditions.

RTM

Liven Pharma Limited

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2026

- Leases are recognized as a right-of-use asset and a corresponding liability at the date at which the leased asset is available for use by the Company.
- The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease, or if that rate cannot be readily determined, the Company's incremental borrowing rate.
- Lease payments included in measurement of lease liability comprise:
 - Fixed lease payments, including in-substance fixed payments, less any lease incentives receivable;
 - Variable lease payments that depend on an index or rate, initially measured using the index or rate at the commencement date;
 - The amount expected to be payable by the lessee under residual value guarantees;
 - The exercise price of purchase options, if the lessee is reasonably certain to exercise the options; and
 - Payments of penalties for terminating the lease, if the lease term reflects the exercise of an option to terminate the lease.
- The lease liability is subsequently measured at amortized cost using the effective interest rate method whereby the carrying amount of lease liability is increased to reflect the interest thereon and decreased to reflect lease payments made. Interest is recognized in profit or loss.
- Lease liability is remeasured whenever:
 - The lease term has changed or there is a significant event or change in circumstances resulting in a change in the assessment of exercise of a purchase option, in which case the lease liability is remeasured by discounting the revised lease payments using a revised discount rate;
 - The lease payments change due to changes in an index or rate or a change in expected payment under a guaranteed residual value, in which cases the lease liability is remeasured by discounting the revised lease payments using an unchanged discount rate, unless the lease payments change is due to a change in a floating interest rate, in which case a revised discount rate is used; or
 - A lease contract is modified and the lease modification is not accounted for as a separate lease, in which case the lease liability is remeasured based on the lease term of the modified lease by discounting the revised lease payments using a revised discount rate at the effective date of the modification.
- When the lease liability is remeasured, a corresponding adjustment is made to the carrying amount of the related right-of-use asset, except where the carrying amount of right-of-use asset is reduced to zero. In that case, any adjustment exceeding the carrying amount of the right-of-use asset is recognized in profit or loss.
- Variable rents that do not depend on an index or rate are not included in the measurement of the lease liability and the right-of-use asset. The related payments are recognized as an expense in the period in which the event or condition that triggers those payments occurs.
- The Company has elected to apply the practical expedient not to recognize right-of-use asset and lease liabilities for short term leases that have a lease term of 12 months or less and leases of low-value assets. The Company recognizes the lease payments associated with these leases as an operating expense on a straight-line basis over the term of the lease unless another systematic basis is more representative of the time pattern in which economic benefits from the leased assets are consumed.
- The right-of-use asset is initially measured based on the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentive received.

Ritmy

Liven Pharma Limited

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2026

- Subsequent to initial recognition, a right-of-use asset is measured at cost less accumulated depreciation and accumulated impairment losses, if any. Depreciation is recognized on right of use building and motor vehicle using straight line method and reducing balance method respectively, over the shorter of lease term and useful life of the right-of-use asset, unless the lessor transfers ownership of the underlying asset to the Company by the end of lease term or the cost of the right-of-use asset reflects that the Company will exercise a purchase option. In that case, the right-of-use asset is depreciated at rates specified in note 5 over the useful life of the underlying asset, which is determined on the same basis as those of operating fixed assets. In addition, the right-of-use asset is adjusted for certain remeasurements of the related lease liability.

4.8 Employee benefits

4.8.1 Short-term employee benefits

The Company recognizes the undiscounted amount of short term employee benefits to be paid in exchange for services rendered by employees as a liability after deducting amount already paid and as an expense in profit or loss unless it is included in the cost of inventories or property and equipment as permitted or required by the approved accounting and reporting standards as applicable in Pakistan. If the amount paid exceeds the undiscounted amount of benefits, the excess is recognized as an asset to the extent that the prepayment would lead to a reduction in future payments or cash refund.

4.8.2 Post-employment benefits - Defined contribution plan

A defined contribution plan is a post-employment benefit plan under which an entity pays fixed contribution into a separate entity and will have no legal or constructive obligation to pay further amounts. Obligations for contributions to defined contribution plans are recognized as an employee benefit expense in the statement of comprehensive income when they are due. Prepaid contributions are recognized as an asset to the extent that a cash refund or a reduction in future payments is available.

The Company operates a un-recognized provident fund scheme for its permanent employees. Contributions to fund are made on monthly basis by the Company and employee at the rate of 5% of the gross salary. The Company's contributions are recognized as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as an asset.

4.9 Taxation

4.9.1 Current

- The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the end of the reporting period. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.

4.9.2 Deferred

- Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes after considering, the effective rate of tax which is equal to enacted rate of tax as determined in approach (b) to the guide issued by ICAP. However, deferred tax liabilities are not recognised if they arise from the initial recognition of goodwill. Deferred income tax is also not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the end of the reporting period and are expected to apply when the related deferred income tax asset is realised or the deferred income tax liability is settled.

Attny

Liven Pharma Limited

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED JUNE 30, 2026

- In this regard, the effects on deferred taxation of the portion of income that is subject to final tax regime is also considered in accordance with the treatment prescribed in "Technical Release - 27" by The Institute of Chartered Accountants of Pakistan.
- Deferred tax assets are recognised for deductible temporary differences and unused tax losses and credits only if it is probable that future taxable amounts will be available to utilise those temporary differences and unused tax losses and credits.
- Current and deferred tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, the tax is also recognised in other comprehensive income or directly in equity, respectively.

- Judgment and estimates

Significant judgment is required in determining the income tax expenses and corresponding provision for tax. There are many transactions and calculations for which the ultimate tax determination is uncertain as these matters are being contested at various legal forums. The Company recognizes liabilities for anticipated tax issues based on estimates of whether additional taxes will be due. Where the final tax outcome of these matters is different from the amounts that were initially recorded, such differences will impact the current and deferred tax assets and liabilities in the period in which such determination is made.

- Further, the carrying amount of deferred tax assets is reviewed at each reporting date and is adjusted to reflect the current assessment of future taxable profits. If required, carrying amount of deferred tax asset is reduced to the extent that it is no longer probable that sufficient taxable profits to allow the benefit of part or all of that recognised deferred tax asset to be utilised. Any such reduction shall be reversed to the extent that it becomes probable that sufficient taxable profit will be available.

- Off-setting

Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets and liabilities and when the deferred tax balances relate to the same taxation authority. Current tax assets and tax liabilities are offset where the entity has a legally enforceable right to offset and intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

4.9.3 Levy

The tax charged under Income Tax Ordinance, 2001 which is not based on taxable income or any amount paid / payable in excess of the calculation based on taxable income, which is not adjustable against the future tax liability, is classified as levy in the statement of profit or loss and other comprehensive income as these levies fall under the scope of IFRIC 21/IAS 37.

4.10 Trade and other payables

- Liabilities for trade and other payables are carried at cost which is the fair value of the consideration to be paid in the future for goods and services received, whether or not billed to the Company.

4.11 Foreign currency transactions and translations

Transactions in foreign currencies are translated into Pak Rupees at the foreign exchange rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the statement of financial position date are translated into Pak Rupees at the foreign exchange rate prevailing at that date. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translations at the year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the statement of profit or loss."

Rtney

Liven Pharma Limited

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2026

4.12 Revenue from contracts with customers

The Company recognizes revenue when it transfers control over goods to its customers, being when the products are delivered to the customer and there is no unfulfilled obligation that could effect the customer's acceptance of the product. Revenue is recognized at an amount that reflects the consideration, to which the Company expects to be entitled in exchange for transferring of goods to its customers net of discount and sales related indirect taxes. The sales related indirect taxes are regarded as collected on behalf of statutory authorities. The Company generates revenue by supplying products to the customers, including export product

- Revenue from domestic sale of goods is recognised at a point in time when control of goods is transferred to the customer which coincides with the delivery of goods.

- Exports sales are recognised as revenue when invoiced with the transfer of control of goods, which coincides either with the date of bill of lading or upon delivery to customer or its representatives, based on term of arrangements.

- Interest income is recognised on accrual basis.

The transaction price for products are agreed under the contracts with customers.

Sales return is the obligation to refund some or all of the consideration received (or receivable) from the customer and is measured at the amount the Company ultimately expects it will have to return to the customer.

The normal credit term is 30 to 90 days upon delivery. The company considers whether there are other promises in the contract that are separate performance obligations to which a portion of the transaction price needs to be allocated. In determining the transaction price for the sale of goods, the company considers the effects of variable consideration, the existence of significant financing components, non-cash consideration, and consideration payable to the customer.

4.13 Other revenue

- Return on bank deposits and short term investments is recognised at amortized cost and are accounted for using the effective interest rate method.
- All the other revenues are recorded on accrual basis.

4.14 Trade debts

Trade receivables are recognised initially at the amount of consideration that is unconditional, unless they contain significant financing components when these are recognised at fair value. They are subsequently measured at amortised cost using the effective interest method, less loss allowance.

4.15 Borrowing costs

Borrowing costs are recognized as an expense in the period in which they are incurred except where such costs are directly attributable to the acquisition, construction or production of a qualifying asset in which such costs are capitalized as part of the cost of that asset. Borrowing costs includes exchange differences arising from foreign currency borrowings to the extent these are regarded as an adjustment to borrowing costs and net gain / loss on the settlement of derivatives hedging instruments.

4.16 Cash and cash equivalents

- For the purposes of statement of cash flows, cash and cash equivalents comprise cash, balances with banks on current and deposit accounts.

4.17 Provisions

Provisions for legal claims and good obligations are recognized when the Company has a present legal or constructive obligation as a result of past events, it is probable that an outflow of resources will be required to settle the obligation and the amount can be reliably estimated. Provisions are not recognized for future operating losses.

Where there are a number of similar obligations, the likelihood that an outflow will be required in settlement is determined by considering the class of obligations as a whole. A provision is recognized even if the likelihood of an outflow with respect to any one item included in the same class of obligations may be small.

R17/26

Liven Pharma Limited

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2026

Provisions are measured at the present value of management's best estimate of the consideration required to settle the present obligation at the reporting date, taking into account the risk and uncertainties surrounding the obligation. Where a provision is measured using cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows calculated using pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the liability. The increase in the provision due to the passage of time is recognized as interest expense.

4.18 Contingencies and commitments

4.18.1 Contingencies

4.18.1.1 Contingent assets

- Contingent assets are disclosed when the Company has a possible asset that arises from past events and whose existence will only be confirmed by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Company. Contingent assets are not recognized until their realization becomes virtually certain.

4.18.1.2 Contingent liabilities

Contingent liabilities are not accounted for in the financial statements unless these are actual liabilities and are only disclosed when:

- a) there is a possible obligation that arises from past events and whose existence will be confirmed only by the occurrence or non occurrence of one or more uncertain future events not wholly within the control of the Company; or
- b) there is present obligation that arises from past events but it is not probable that an outflow of resources embodying economic benefits will be required to settle the obligation or the amount of the obligation cannot be measured with sufficient reliability.

In event the outflow of resources associated with a contingent liability is assessed as probable, and if the size of the outflow can be reliably estimated, a provision is recognized in the financial statements.

4.18.2 Commitments

The Company discloses nature, term, aggregate amount and variable components of commitments at the balance sheet date which are not yet incurred including contractual obligations with suppliers of goods and capital assets for future purchases, lease commitments, guarantees, unused letters of credit and other commitments.

4.19 Financial instruments

Financial assets and financial liabilities are recognized when an entity becomes a party to the contractual provisions of the instruments. A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

4.19.1 Financial assets

a) Initial recognition and measurement

- Financial assets are classified, at initial recognition, as subsequently measured at amortized cost, fair value through other comprehensive income (OCI), and fair value through profit or loss.
- The classification of financial assets at initial recognition depends on the financial asset's contractual cash flow characteristics and the Company's business model for managing them. With the exception of trade receivables that do not contain a significant financing component or for which the Company has applied the practical expedient, the Company initially measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs. Trade receivables that do not contain a significant financing component or for which the Company has applied the practical expedient are measured at the transaction price determined under IFRS 15.

Ritney

Liven Pharma Limited

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED JUNE 30, 2026

- In order for a financial asset to be classified and measured at amortized cost or fair value through OCI, it needs to give rise to cash flows that are "solely payments of principal and interest (SPPI)" on the principal amount outstanding. This assessment is referred to as the SPPI test and is performed at an instrument level.
 - The Company's business model for managing financial assets refers to how it manages its financial assets in order to generate cash flows. The business model determines whether cash flows will result from collecting contractual cash flows, selling the financial assets, or both.
 - Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trades) are recognized on the trade date, i.e., the date that the Company commits to purchase or sell the asset.
- (b) **Subsequent measurement**
- For purposes of subsequent measurement, financial assets are classified in following categories:
 - (i) Financial assets at amortized cost (debt instruments)
 - (ii) Financial assets at fair value through OCI with recycling of cumulative gains and losses (debt instruments)
 - (iii) Financial assets designated at fair value through OCI with no recycling of cumulative gains and losses upon derecognition (equity instruments)
 - (iv) Financial assets at fair value through profit or loss
- (i) **Financial assets at amortized cost (debt instruments)**
- This category is the most relevant to the Company. The Company measures financial assets at amortized cost if both of the following conditions are met:
 - The financial asset is held within a business model with the objective to hold financial assets in order to collect contractual cash flows; and
 - The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.
 - Financial assets at amortized cost are subsequently measured using the effective interest rate (EIR) method and are subject to impairment. Gains and losses are recognized in profit or loss when the asset is derecognized, modified or impaired.
- (ii) **Financial assets at fair value through OCI (debt instruments)**
- The Company measures debt instruments at fair value through OCI if both of the following conditions are met:
 - (i) The financial asset is held within a business model with the objective of both holding to collect contractual cash flows and selling; and
 - (ii) The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.
 - For debt instruments at fair value through OCI, interest income, foreign exchange revaluation and impairment losses or reversals are recognized in the statement of profit or loss and computed in the same manner as for financial assets measured at amortized cost. The remaining fair value changes are recognized in OCI. Upon derecognition, the cumulative fair value change recognized in OCI is recycled to profit or loss.
- (iii) **Financial assets designated at fair value through OCI (equity instruments)**
- Upon initial recognition, the Company can elect to classify irrevocably its equity investments as equity instruments designated at fair value through OCI when they meet the definition of equity under "IAS 32 Financial Instruments: Presentation" and are not held for trading. The classification is determined on an instrument-by-instrument basis.

RTB

Liven Pharma Limited

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2026

- Gains and losses on these financial assets are never recycled to profit or loss. Dividends are recognized as other income in the statement of profit or loss when the right of payment has been established, except when the Company benefits from such proceeds as a recovery of part of the cost of the financial asset, in which case, such gains are recorded in OCI. Equity instruments designated at fair value through OCI are not subject to impairment assessment.
- (iv) **Financial assets at fair value through profit or loss**
 - These are financial assets which have not been classified as 'financial assets at amortized cost' or as 'financial assets at fair value through other comprehensive income', are mandatorily measured at fair value through profit or loss or for which the Company makes an irrevocable election at initial recognition to designate as 'financial asset at fair value through profit or loss' if doing so eliminates or significantly reduces a measurement or recognition inconsistency.
 - Financial assets at fair value through profit or loss are carried in the statement of financial position at fair value with net changes in fair value recognized in the statement of profit or loss.
 - This category includes derivative instruments and listed equity investments which the Company had not irrevocably elected to classify at fair value through OCI. Dividends on listed equity investments are also recognized as other income in the statement of profit or loss when the right of payment has been established.
 - A derivative embedded in a hybrid contract, with a financial liability or non-financial host, is separated from the host and accounted for as a separate derivative if: the economic characteristics and risks are not closely related to the host; a separate instrument with the same terms as the embedded derivative would meet the definition of a derivative; and the hybrid contract is not measured at fair value through profit or loss. Embedded derivatives are measured at fair value with changes in fair value recognized in profit or loss. Reassessment only occurs if there is either a change in the terms of the contract that significantly modifies the cash flows that would otherwise be required or a reclassification of a financial asset out of the fair value through profit or loss category.
- (c) **Derecognition**
 - A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognized when:
 - (i) The rights to receive cash flows from the asset have expired.
 - (ii) The Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement; and either
 - (a) the Company has transferred substantially all the risks and rewards of the asset, or
 - (b) the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.
 - When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if, and to what extent, it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Company continues to recognize the transferred asset to the extent of its continuing involvement. In that case, the Company also recognizes an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained.
 - Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Company could be required to repay.

R. B. B. B.

Liven Pharma Limited

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2026

(d) Impairment of financial assets

- The Company recognizes an allowance for expected credit losses (ECLs) for all debt instruments not held at fair value through profit or loss. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.
- Life time ECLs are the ECLs that results from all possible defaults events over the expected life of a financial instrument. 12 month ECLs are portion of ECL that result from default events that are possible within 12 months after the reporting date.
- For trade receivables and contract assets, the Company applies a simplified approach in calculating ECLs. Therefore, the Company does not track changes in credit risk, but instead recognizes a loss allowance based on lifetime ECLs at each reporting date. The Company has established a provision matrix that is based on its historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment.
- For debt instruments at amortized cost (other than trade receivables and contract assets) and fair value through OCI, the Company applies the low credit risk simplification. At every reporting date, the Company evaluates whether the debt instrument is considered to have low credit risk using all reasonable and supportable information that is available without undue cost or effort. In making that evaluation, the Company reassesses the internal credit rating of the debt instrument. In addition, the Company considers that there has been a significant increase in credit risk when contractual payments are more than 90 days past due.
- The Company's debt instruments at fair value through OCI that are considered to be low credit risk investments. It is the Company's policy to measure ECLs on such instruments on a 12-month basis. However, when there has been a significant increase in credit risk since origination, the allowance will be based on the lifetime ECL. The Company uses the ratings from the Good Credit Rating Agency both to determine whether the debt instrument has significantly increased in credit risk and to estimate ECLs.
- The Company considers a financial asset in default when contractual payments are 90 days past due. However, in certain cases, the Company may also consider a financial asset to be in default when internal or external information indicates that the Company is unlikely to receive the outstanding contractual amounts in full before taking into account any credit enhancements held by the Company. A financial asset is written off when there is no reasonable expectation of recovering the contractual cash flows.

4.19.2 Financial liabilities

(a) Initial recognition and measurement

- Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, and financial liabilities at amortized cost, as appropriate.
- All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

(b) Subsequent measurement

- The measurement of financial liabilities depends on their classification, as described below:

(i) Financial liabilities at fair value through profit or loss

- Financial liabilities at fair value through profit or loss include financial liabilities held for trading and financial liabilities designated upon initial recognition as at fair value through profit or loss.
- Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term. Separated embedded derivatives are also classified as held for trading unless they are designated as effective hedging instruments.
- Gains or losses on liabilities held for trading are recognized in the statement of profit or loss.

R. Prasad

Liven Pharma Limited

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2026

- Financial liabilities designated upon initial recognition at fair value through profit or loss are designated at the initial date of recognition, and only if the criteria in IFRS 9 are satisfied. The Company has not designated any financial liability as at fair value through profit or loss.
- Financial liabilities designated upon initial recognition at fair value through profit or loss are designated at the initial date of recognition, and only if the criteria in IFRS 9 are satisfied. The Company has not designated any financial liability as at fair value through profit or loss.
- (ii) **Financial liabilities at amortized cost (loans and borrowings)**
 - This is the category most relevant to the Company. After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortized cost using the effective interest rate (EIR) method. Gains and losses are recognized in profit or loss when the liabilities are derecognized as well as through the EIR amortization process.
 - Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortization is included as finance costs in the statement of profit or loss.
 - This category generally applies to interest-bearing loans and borrowings.
- (c) **Derecognition**
 - A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognized in the statement of profit or loss.
- 4.20 **Share based payments**
 - For equity-settled share-based payment transactions, the entity measures the goods or services received, and the corresponding increase in equity, directly, at the fair value of the goods or services received, unless that fair value cannot be estimated reliably. If the entity cannot estimate reliably the fair value of the goods or services received, the entity shall measure their value, and the corresponding increase in equity, indirectly, by reference to the fair value of the equity instruments granted.
- 4.21 **Segment reporting**
 - Segment reporting is based on the operating segments that are reported in the manner consistent with internal reporting of the Company. An operating segment is a component of the Company that engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses that relate to transactions with any of the Company's other components. An operating segment's operating results are reviewed regularly by the Chief Executive Officer to make decisions about resources to be allocated to the segment and assess its performance and for which discrete financial information is available.
 - Segment results and assets include items directly attributable to a segment as well as those that can be allocated on a reasonable basis.
- 4.22 **Loan and borrowing**

Loans and borrowings, except for loan from directors and sponsors which are repayable at the Company's discretion and are not payable on demand, are classified as 'financial liabilities at amortized cost'. On initial recognition, these are measured at cost, being fair value at the date the liability is incurred, less attributable transaction costs. Subsequent to initial recognition, these are measured at amortized cost with any difference between cost and value at maturity recognized in the profit or loss over the period of the borrowings on an effective interest basis.

Loan from directors and sponsors which are repayable at the Company's discretion and are not payable on demand are stated in the statement of financial position at cost and presented as equity in accordance with guidance provided in Technical Release 32 'Accounting Directors' Loan' issued by the Institute of Chartered Accountants of Pakistan.

Romy

Liven Pharma Limited

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED JUNE 30, 2026

4.23 Contract liabilities

A contract liability is the obligation to transfer goods or services to a customer for which the Company has received consideration from the customer. If a customer pays consideration before the Company transfers goods or services to the customer, a contract liability is recognised when the payment is made. Contract liabilities are recognised as revenue when the Company performs under the contract.

4.24 Contract assets

Contract assets arise when the Company performs its performance obligations by transferring goods to a customer before the customer pays its consideration or before payment is due.

RMey

Liven Pharma Limited **NOTES TO THE FINANCIAL STATEMENTS** **FOR THE YEAR ENDED JUNE 30, 2026**

5 PROPERTY, PLANT AND EQUIPMENT

Owned assets
Leased assets

Note	2026 (Rupees)	2025 (Rupees)
5.1	913,317,992	658,835,218
5.1	4,846,726	7,677,162
	918,164,718	666,512,380

Description	COST					Rate %	DEPRECIATION					WDV As on June 30, 2026
	As on July 01, 2025	Additions	Transfer	Revaluation surplus	Disposals		As on July 01, 2025	Transfer	Disposals	Charge for the year	As on June 30, 2026	
	Rupees						Rupees					
Owned assets												
Freehold land	105,750,000	-	-	42,300,000	-	-	-	-	-	-	-	148,050,000
Buildings on freehold land	247,954,713	-	-	78,443,215	-	5%	49,745,045	-	-	5,910,483	59,655,528	266,742,460
Plant and machinery	400,628,718	5,362,590	-	115,290,675	-	3%	64,122,058	-	-	10,170,325	74,292,383	446,989,510
Laboratory equipment	13,354,026	-	-	-	-	20%	13,354,026	-	-	782,123	10,065,523	3,168,485
Office equipment	542,044	470,088	-	-	-	20%	9,303,410	-	-	163,347	285,350	726,782
Generators	1,360,590	-	-	-	-	20%	182,003	-	-	361,965	3,520,725	12,142,503
Furniture and fixture	6,778,413	-	-	8,884,815	-	10%	3,158,700	-	-	100,769	869,475	273,628
Computer and accessories	911,103	231,000	-	-	-	30%	767,705	-	-	4,559,685	9,783,751	34,803,571
Motor vehicles	11,010,653	23,598,307	12,942,332	3,876,221	(6,798,191)	20%	44,629,322	8,344,845	(4,315,611)	-	-	-
Total owned asset	783,200,170	29,661,895	12,942,332	248,784,926	(6,798,191)		129,364,953	8,344,845	(4,315,611)	26,068,854	159,483,140	913,317,992
Leased assets												
Building	-	2,878,456	-	-	-	33%	-	-	-	159,970	159,970	2,716,466
Motor vehicles	15,741,332	-	(12,942,332)	-	-	20%	8,064,170	(8,344,845)	-	952,435	671,780	2,127,240
Total leased assets	15,741,332	2,879,456	(12,942,332)	-	-		8,064,170	(8,344,845)	-	1,112,405	831,750	4,846,726
Total 2026	803,941,502	32,541,351	-	248,784,926	(6,798,191)		137,429,123	-	(4,315,611)	27,201,359	160,314,870	918,164,718

Description	COST					Rate %	DEPRECIATION					WDV As on June 30, 2025
	As on July 01, 2024	Additions	Transfer	Disposals	As on June 30, 2025		As on July 01, 2024	Transfer	Disposals	Charge for the year	As on June 30, 2025	
	Rupees						Rupees					
Owned assets												
Freehold land	105,750,000	-	-	-	105,750,000	-	-	-	-	-	-	105,750,000
Buildings on freehold land	247,954,713	-	-	-	247,954,713	5%	39,312,957	-	-	10,432,068	49,745,045	188,203,668
Plant and machinery	388,591,774	11,697,244	-	-	400,628,718	3%	53,991,269	-	-	10,130,800	64,122,058	336,505,666
Laboratory equipment	13,354,026	-	-	-	13,354,026	20%	8,313,256	-	-	590,151	9,303,410	2,580,616
Office equipment	273,241	368,700	-	-	542,044	20%	135,151	-	-	46,832	182,003	290,041
Generators	1,360,590	-	-	-	1,360,590	20%	798,274	-	-	112,445	906,119	451,281
Furniture and fixture	6,778,413	-	-	-	6,778,413	10%	2,756,576	-	-	402,184	3,158,700	3,619,633
Computer and accessories	911,103	-	-	-	911,103	30%	766,249	-	-	61,406	767,705	143,398
Motor vehicles	140,528	10,870,125	-	-	11,010,653	20%	77,168	-	-	1,699,685	1,176,853	9,833,501
Total owned asset	765,364,101	22,836,069	-	-	788,300,170		106,688,889	-	-	23,276,063	129,364,953	658,835,218
Leased assets												
Motor vehicles	12,942,332	2,788,000	-	-	15,741,332	20%	6,669,692	-	-	1,394,478	8,064,170	7,677,162
Total leased assets	12,942,332	2,789,000	-	-	15,741,332		6,669,692	-	-	1,394,478	8,064,170	7,677,162
Total 2025	778,306,433	25,625,069	-	-	803,941,502		113,358,581	-	-	24,670,541	137,429,123	666,512,380

5.1 Revalued freehold land, buildings on freehold land, vehicles (owned), furniture and fixtures and plant and machinery

Had there been no revaluation, the carrying values of the freehold land, buildings freehold land, vehicles (owned), furniture and fixtures and plant and machinery would have been Rs. 38,044,355, Rs. 13,071,695, Rs. 30,983,103, Rs. 2,951,858 and Rs. 52,353,313 respectively.

The forced sale value of the revalued of freehold land, buildings on freehold land, vehicles (owned), furniture and fixtures and plant and machinery has been assessed at Rs. 111,037,500, Rs. 200,056,800, Rs. 26,147,678, Rs. 9,106,877 and Rs. 335,242,133 respectively. The forced sale value is 75% of revalued amount.

5.2 Fair value measurements under revaluation model for property, plant and equipment

Previous revaluation was carried out in the year 2021 by Messrs Anderson Consulting (Private) Limited. During the year, the fair value measurement of the Company's freehold land, buildings on freehold land, vehicles (owned), furniture and fixtures and plant and machinery as at June 30, 2026 was performed by Messrs Appraiser Services, who are independent valuers not related to the Company. Messrs Appraiser Services are listed on approved panel of valuers issued by Pakistan Bank's Association (Panel I, II, III) and they have appropriate qualifications and recent experience in the fair value measurement of properties in the relevant locations.

5.3 The freehold land included in property, plant and equipment is situated at 49-KM, Multan Road, Phool Nagar, District Kasur, and comprises an area of 21 kanals and 3 marlas. The building included in property, plant and equipment is constructed on the said freehold land.

Rebec

Liven Pharma Limited

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2026

- 5.4 The title of the freehold land included in the Company's owned assets is currently in the name of directors of the company, Mr. Kaashif Hussain (CEO) and Mr. Atif Hussain (Director). The land is provided as security against financing (refer to note 16) and lien is marked, the title will be transferred after loan is settled and lien is removed.

	Note	2026 (Rupees)	2025 (Rupees)
5.5 Depreciation on owned assets has been allocated as follows:			
Cost of sales	26	23,962,608	22,060,552
Administrative and general expenses	27	1,444,462	1,215,511
Selling and distribution expenses	28	681,884	-
Total depreciation		26,088,954	23,276,063
5.6 Depreciation on leased assets has been allocated as follows:			
Cost of sales	26	857,192	1,255,030
Administrative and general expenses	27	127,237	139,448
Selling and distribution expenses	28	127,976	-
Total depreciation		1,112,405	1,394,478
5.7 The Company has lease contracts for motor vehicle and a building, each with a lease term of three years.			
5.8 The lease terms of certain motor vehicles has expired. During the year, two of these vehicles were disposed of, with legal title transferred directly to the buyers, while two others were classified to owned assets, for which the Company has applied for No Objection Certificates (NOCs).			
5.9 Amounts recognised in the statement of profit or loss:			
Depreciation charge of right-of-use assets	5.6	1,112,405	1,394,478
Expense relating to variable lease payments		-	-
Total amount recognised in statement of profit or loss		1,112,405	1,394,478

6 INTANGIBLE ASSETS

Intangible assets - Definite useful life

6.1	4,796,922	8,440,679
	4,796,922	8,440,679

6.1 Intangible assets - Definite useful life

Reconciliation of the carrying amounts at the beginning and end of the year is as follows:

Particulars	2026		
	ERP system	Patents	Total
	Rupees		
Cost	6,426,000	10,000,000	16,426,000
Accumulated amortization	(5,485,321)	(2,500,000)	(7,985,321)
Net book value - July 01, 2025	940,679	7,500,000	8,440,679
Opening net book value	940,679	7,500,000	8,440,679
Additions during the year	-	-	-
Amortization for the year	(310,424)	(3,333,333)	(3,643,757)
Net book value - June 30, 2026	630,255	4,166,667	4,796,922
Cost	6,426,000	10,000,000	16,426,000
Accumulated amortization	(5,795,745)	(5,833,333)	(11,629,078)
Net book value - June 30, 2026	630,255	4,166,667	4,796,922
Rate of amortization	33%	33%	
Method of amortization	Diminishing balance method	Straight line basis	
Remaining useful life	-	1 year 3 months	

Particulars	2025		
	ERP system	Patents	Total
	Rupees		
Cost	6,426,000	-	6,426,000
Accumulated amortization	(5,022,002)	-	(5,022,002)
Net book value - July 01, 2024	1,403,998	-	1,403,998
Opening net book value	1,403,998	-	1,403,998
Additions during the year	-	10,000,000	10,000,000
Amortization for the year	(463,319)	(2,500,000)	(2,963,319)
Net book value - June 30, 2025	940,679	7,500,000	8,440,679
Cost	6,426,000	10,000,000	16,426,000
Accumulated amortization	(5,485,321)	(2,500,000)	(7,985,321)
Net book value - June 30, 2025	940,679	7,500,000	8,440,679
Rate of amortization	33%	33%	
Method of amortization	Diminishing balance method	Straight line basis	
Remaining useful life	-	2 years 3 months	

Ritny

Liven Pharma Limited
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED JUNE 30, 2026

	Note	2026 (Rupees)	2025 (Rupees)
6.2 The amortization charge for the year has been allocated as follows:			
Administrative and general expenses	27	3,643,757	2,963,319
7 TRADE DEBTS			
Unsecured, considered good			
Local trade debts		2,465,678	8,359,176
Unsecured, considered doubtful			
Local trade debts		107,446,762	114,182,549
Less: bad debt write-off		-	(25,924,389)
		109,912,440	96,617,336
Less: Allowance for expected credit loss	7.1	(98,796,898)	(87,214,758)
		11,115,542	9,402,578
7.1 Movement of allowance for expected credit losses of trade receivables			
Balance as at July 1		87,214,758	-
Charge for the year	29	11,582,140	87,214,758
Amounts written off		-	-
Balance as at June 30		98,796,898	87,214,758
7.2 After considering past experience, current conditions and forecasts, there is indication of shortfall in contractual cash flows of trade debts, therefore, expected credit loss is charged for the year.			
7.3 Age analysis of trade receivables:			

Liven Pharma Limited
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED JUNE 30, 2026

	Note	2026 (Rupees)	2025 (Rupees)
9.1 Income tax refundable			
Balance as on July 01,		-	-
Paid during the year		2,538,190	777,526
Less: adjusted against levies		(1,804,731)	(777,526)
Balance as on June 30,	18.7	<u>733,459</u>	<u>-</u>
10 PREPAYMENTS, DEPOSITS AND ADVANCES			
Advance to supplier	10.1 & 10.4	1,974,498	6,513,199
Advance to staff against expenses	10.1	469,177	65,592
Advance to Drug Regulatory Authority of Pakistan	10.2	2,819,670	-
Security deposits	10.3	634,500	703,565
Accrued markup on short term investments		863,273	-
Prepaid insurance		<u>16,543</u>	<u>57,371</u>
		<u>6,777,661</u>	<u>7,339,727</u>
10.1 The Company has written off certain long-outstanding balances considered non-recoverable. These include advances to supplier amounting to Rs. Nil (2025: Rs. 1,612,137/-) and advances to staff amounting to Rs. Nil (2025: Rs. 2,121,500/-).			
10.2 This represents fees paid to Drug Regulatory Authority of Pakistan (DRAP) for products registration against which registration certificates were not issued till reporting date.			
10.3 This represents security deposits with SNGPL amounting to Rs. 315,000 (2025: Rs. 315,000), WAPDA Rs. 14,500 (2025: Rs. 14,500), Gulab Devi Hospital Rs. 100,000 (2025: 100,000), and various government institutions Rs. Nil (2025: 249,065).			
10.4 Movement of advance to suppliers			
Gross balance		7,134,607	8,125,336
Impairment charge for the year	10.5	(5,160,109)	-
Amounts written off		-	(1,612,137)
Balance as at June 30		<u>1,974,498</u>	<u>6,513,199</u>
10.5 Movement of provision for impairment on advance to suppliers			
Balance as at July 1		-	-
Impairment charge for the year	29	5,160,109	1,612,137
Amounts written off		-	(1,612,137)
Balance as at June 30		<u>5,160,109</u>	<u>-</u>
11 SHORT-TERM INVESTMENTS			
Short term investments		<u>163,300,000</u>	<u>-</u>
		<u>163,300,000</u>	<u>-</u>
11.1 The company has invested these funds in special sharikah certificate agreements of Meezan Bank Limited having tenure of one month. This investment carries markup as prescribed by bank which ranges from 9.6% to 10.5% per annum (2025: Nil).			
12 CASH AND BANK BALANCES			
Cash in hand		7,290,628	7,838,947
Cash at bank:			
-current account		29,321	25,532
-saving accounts	12.2	<u>10,930,945</u>	<u>19,917</u>
		<u>18,250,894</u>	<u>7,884,396</u>
12.1 Cash and cash equivalents included in the statement of cash flows comprise the following:			
Cash and bank balances		18,250,894	7,884,396
Cash and cash equivalents as per statement of cash flows		<u>18,250,894</u>	<u>7,884,396</u>
12.2 The average RACC rate as prescribed by banks ranges from 0.13% to 10.00 per annum% (2025: 5.87% to 10.01%) per annum.			
12.3 Certain banks accounts of the Company having aggregate closing balance of Rs. 2,767 (2025: 45,449) are in the name of Liven Pharmaceuticals (Private) Limited.			

R. Hameed

Liven Pharma Limited
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED JUNE 30, 2026

	Note	2026 (Rupees)	2025 (Rupees)
14.1	Net amount transferred to accumulated profit on account of Incremental depreciation Deferred tax on incremental depreciation	- -	- -
14.2	Incremental depreciation represents difference between actual depreciation on revalued property and equipment and equivalent depreciation based on historical cost of property and equipment.		
14.3	On the effective date of the merger, the revaluation surplus balance was transferred to retained earnings prior to adjusting it against the merger-related expenses.		
14.4	Restriction on distribution The surplus on revaluation of property and equipment is a capital reserve, and is not available for distribution to the shareholders in accordance with section 241 of Company Act, 2017.		
15 LEASE LIABILITIES			
Present value of minimum lease payments against right of use asset	15.1	4,018,195	1,836,591
Less: Current maturity		(1,679,816)	(588,723)
		2,338,379	1,247,868
15.1	Reconciliation:		
Opening balance		1,836,591	395,413
Additions		2,879,456	2,799,000
Interest expense charged during the year		291,290	109,403
Lease rental payments made during the year		(989,142)	(1,467,225)
		4,018,195	1,836,591
Current maturity presented under current liabilities		(1,679,816)	(588,723)
Present value of minimum lease payments		2,338,379	1,247,868
15.2	Maturity analysis of lease liabilities		
- The future minimum lease payments to which the Company is committed under the agreement will be due as follows:			
Minimum lease payments:			
Not later than 1 year		1,907,124	815,383
Later than 1 year but not later than 5 years		2,903,640	1,426,920
Later than 5 years		-	-
		4,810,764	2,242,303
Finance cost allocated to future years		(792,569)	(405,712)
Present value of minimum lease payments		4,018,195	1,836,591
15.3	The total cash outflows relating to leases during the year amounted to Rs. 989,142/- (2025: Rs. 1,467,225/-).		
15.4	Interest expense amounting Rs. 291,290/- (2025: Rs. 109,403/-) is charged to statement of profit or loss.		
15.5	This represent liabilities against right-of-use assets of the Company for lease contract of motor vehicle and building. The rentals are payable in advance on monthly basis over a tenor of 3 years. The cash outflows are discounted at lessee's incremental borrowing rate of 15.03% per annum (6 month KIBOR +3% risk spread) at the date of inception of lease contract for motor vehicle and lessee's incremental borrowing rate of 14.84% per annum (1 year KIBOR +2.5% risk spread) at the date of inception of lease contract for building. The Company has the option to transfer the ownership of the motor vehicle in its name upon completion of the lease term.		
16 LONG TERM FINANCING			
<i>From banking companies - secured</i>			
Long term finances	16.1	5,018,728	7,596,321
Less: current portion shown under current liabilities	22	(2,498,256)	(2,498,256)
Non-current portion		2,520,472	5,098,065
16.1	The Company obtained long term finance facility of Rs 8.038 million from Bank Al Habib Limited in 2025 under Term Finance Facility. The mark-up payments under this facility are calculated on the basis of 6 months KIBOR plus 3% and is paid on monthly basis.		

R. B. B. B.

Liven Pharma Limited

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2026

The loan was secured against:

1st hypo charge over current assets of the company for Rs 21.33M, registered with SECP.
 TRM of Rs 500,000 and EM for Rs 100M over industrial property situated at hadbast mouza kamongal, 49 KM lahore multan road, adjacent nishat chunian mills / millat battery, tehsil pattoki district kasur vide khasra no 2405, 2401, 2400 measuring 21 kanal 03 marlas owned by Mr. Atif Siddique and Mr. Kaashif Hussain Siddique (Directors of the Company) having market value of Rs. 102M and forced sale value of Rs 83M (Land market value of Rs 29M and forced sale value of Rs 24M) valued by Harvester Services Private Ltd dated 22-06-2021. (building on freehold land market value Rs 73M and forced sale value Rs 58M).
 Personal guarantees of the directors of the Company.
 Trust receipt.
 30% Security Deposit for LF-I, LF-II and TF-III.
 Vehicles registered in the name of Bank Al Habib Limited duly insured LF-I and II.
 Specific charge over vehicles registered with SECP for Rs 3.183M for LF-I.
 Specific charge over vehicles registered with SECP for Rs 3.633M for LF-II.
 30% Down Payment.
 Specific charge over Generator registered with SECP for Rs.600,000 for TF-II.
 Specific charge over vehicle registered with SECP for Rs.1.940M for TF-III.
 20% cash margin or as per SBP directive whichever is higher.
 Lien over shipping documents.
 Accepted draft.
 Truck receipt.

17 DEFERRED TAXATION

The deferred tax assets and the deferred tax liabilities relate to income tax in the same jurisdiction, and the law allows net settlement. Therefore, they have been offset in the statement of financial position as follows:

	Note	2026 (Rupees)	2025 (Rupees)
Deferred tax liability on taxable temporary differences		199,745,873	144,882,727
Deferred tax asset on deductible temporary differences		(42,426,348)	(25,855,978)
Deferred tax asset on tax losses and credits		(42,867,787)	(26,753,984)
Deferred tax liability - net		<u>114,451,738</u>	<u>92,272,765</u>

17.1 The management of the Company has recognised deferred tax asset as sufficient taxable profits are expected to be available to set off net deductible temporary differences in the foreseeable future.

17.2 Recognized deferred tax assets and liabilities are attributable to the following:

Movement in deferred tax for the year	Balance as at July 01, 2025	Recognized in profit or loss	Recognized in equity	Recognized in OCI	Balance as at June 30, 2026
	(Rupees)				
Deferred tax liability on taxable temporary					
- Property and equipment	144,659,230	(5,100,493)	-	59,883,529	199,442,265
- Intangibles	223,497	80,110	-	-	303,607
	<u>144,882,727</u>	<u>(5,020,383)</u>	<u>-</u>	<u>59,883,529</u>	<u>199,745,873</u>
Deferred tax asset on deductible temporary differences:					
- Lease Liabilities	(532,611)	(632,665)	-	-	(1,165,277)
- Allowance for expected credit loss	(25,292,280)	(3,358,821)	-	-	(28,651,100)
- Provision for obsolete stock	-	(10,660,461)	-	-	(10,660,461)
- Impairment on advances to supplier	-	(1,496,432)	-	-	(1,496,432)
- Worker welfare fund payable	(9,227)	(9,055)	-	-	(18,282)
- Provident fund payable	(21,860)	(412,936)	-	-	(434,796)
On tax losses and credits:					
- Unabsorbed tax losses and depreciation	-	(10,309,436)	-	-	(10,309,436)
- Brought forward business losses	(25,163,084)	(1,959,565)	-	-	(27,122,649)
- Equity issuance cost	-	-	(2,522,220)	-	(2,522,220)
- Minimum tax credit	(1,590,899)	(1,322,582)	-	-	(2,913,481)
	<u>(52,609,962)</u>	<u>(30,161,953)</u>	<u>(2,522,220)</u>	<u>-</u>	<u>(85,294,135)</u>
	<u>92,272,765</u>	<u>(35,182,336)</u>	<u>(2,522,220)</u>	<u>59,883,529</u>	<u>114,451,738</u>

Rmcey

Liven Pharma Limited

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2026

Movement in deferred tax for the year	Balance as at July 01, 2024	Recognized in profit or loss	Recognized in equity	Recognized in OCI	Balance as at June 30, 2025
Deferred tax liability on taxable temporary					
- Property and equipment	-	144,659,230	-	-	144,659,230
- Intangibles	-	223,497	-	-	223,497
	-	144,882,727	-	-	144,882,727
Deferred tax asset on deductible temporary differences:					
- Lease Liabilities	-	(532,611)	-	-	(532,611)
- Allowance for expected credit loss	-	(25,292,280)	-	-	(25,292,280)
- Worker welfare fund payable	-	(9,227)	-	-	(9,227)
- Provident fund payable	-	(21,860)	-	-	(21,860)
On tax losses and credits:					
- Unabsorbed tax losses and depreciation	-	-	-	-	-
- Brought forward business losses	-	(25,163,084)	-	-	(25,163,084)
- Minimum tax credit	-	(1,590,899)	-	-	(1,590,899)
	-	(52,609,962)	-	-	(52,609,962)
	-	92,272,765	-	-	92,272,765

- 17.3 Deferred tax liability has been recognized after netting off the deferred tax asset arising from accumulated tax losses, as it is considered probable that the Company will generate sufficient taxable profits in future years to utilize these losses.
- 17.4 Tax losses amounting Rs. 6,503,603/- Rs. 17,511,850/-, Rs. 15,226,362/-, Rs. 13,787,237/- and Rs. 49,194,636/- will expire in year 2027, 2028, 2029, 2030 and 2031 respectively. Loss related to tax depreciation of Rs. 35,549,781 will be carry forward for indefinite period.
- 17.5 There is no change in the corporate income tax rate for the year. Deferred tax assets and liabilities on temporary differences are measured at effective rate of 29% (2025: 29%).

	Note	2026 (Rupees)	2025 (Rupees)
18 TRADE AND OTHER PAYABLES			
Trade creditors	18.1	25,750,836	25,452,121
Accrued liabilities	18.2	34,043,083	19,865,385
Advance against sale of vehicles		7,231,600	-
Advance from customer	18.9	8,468,973	14,085,993
Withholding income tax payable		3,187,007	768,372
Sales tax payable		57,452	44,588
Audit fee payable		771,750	517,500
Provident fund payable	18.3 & 18.6	2,816,771	140,971
Levies payable	18.7	-	813,373
Workers' welfare fund payable	18.8	63,043	31,818
		82,390,515	61,720,121

- 18.1 During the year, trade creditors amounting Rs. 1,722,383 (2025: Nil) have been written back.
- 18.2 Accrued liabilities include salaries payable to chief executive and director amounting Rs. 26,188,348 (2025: Rs. 17,758,577).
- 18.3 **Provident fund payable**
- | | | |
|------------------------------------|------------------|----------------|
| Opening balance | 140,971 | - |
| Add: Contribution for the year | 2,503,766 | 131,185 |
| Add: Interest charged for the year | 172,034 | 9,786 |
| Less: Payment made | - | - |
| Closing balance | 2,816,771 | 140,971 |
- 18.4 The Company has not opened a separate bank account for depositing the contributions of provident fund. Further, these funds have not been invested as per requirements of Companies Act, 2017.
- 18.5 The Company has accounted for interest on employee provident fund payable at rates ranging from 10.74% to 12.98% per annum (2025: 7.46%) to compensate the loss suffered by the employees due to non-investment of funds.
- 18.6 This include provident fund payable to chief executive and director amounting Rs. 783,120 (2025: 15,582) and Rs. 783,120 (2025: 15,582) respectively.



Liven Pharma Limited

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2026

	Note	2026 (Rupees)	2025 (Rupees)
18.7 Movement of levies payable			
Opening balance		813,373	-
Add: charge for the year	32	1,322,582	1,590,899
Add: prior year charge	32	76,924	-
Less: adjusted against advance tax	9.1	(1,804,731)	(777,526)
Less: paid during the year		(408,148)	-
Closing balance		-	813,373
18.8 Movement in workers' welfare fund during the year			
As at July 01		31,818	-
Add: charge for the year	29	26,452	31,818
Add: additional charge on unpaid balance	30	4,773	-
Less: payments made during the year		-	-
As at June 30		63,043	31,818
18.8.1 An additional surcharge of 15% per annum is charged on the unpaid balance of workers' welfare fund.			
18.9 Advance from customer amounting Rs. 13,692,058 (2025: 140,494) has been recognized in revenue during the year.			
19 LOAN FROM RELATED PARTIES			
<i>Unsecured</i>			
Loan from director		15,282,580	14,047,263
		15,282,580	14,047,263
19.1 Loan from directors			
Mr. Kaashif Hussain Siddique	19.2.1	15,027,580	14,047,263
Mr. Atif Hussain Siddique	19.2.2	255,000	-
		15,282,580	14,047,263
19.2.1 This represents unsecured and interest-free loan amounting Rs. 15,027,580 (2025: Rs. 14,047,263) obtained from Mr. Kaashif Hussain Siddique, Chief Executive of the Company to meet working capital requirements. The loan is repayable on demand.			
19.2.2 This represents unsecured and interest-free loan amounting Rs. 255,000 (2025: Nil) obtained from Mr. Atif Hussain Siddique, director of the Company to meet working capital requirements. The loan is repayable on demand.			
20 RUNNING FINANCE			
<i>From banking companies - Secured</i>			
Running finance	20.1	9,117,046	11,185,166
		9,117,046	11,185,166
20.1 This represents short term financing having sanctioned limit of Rs. 13 million obtained by the Company from Bank Al Habib Limited.			
20.2 The facility is to be adjusted within 90 days from the operating cash flows of the Company. This carries markup at the rate of 3 month KIBOR + 3% per annum. The markup is settled quarterly in arrears. This loan is secured against collaterals as mentioned in note 16.1.			
21 MARK UP ACCRUED			
Markup accrued on running finance	20	287,891	325,745
Markup accrued on long term financing	16	16,854	60,275
		304,745	386,020
22 CURRENT PORTION OF LONG TERM LIABILITIES			
Current portion of lease liabilities	15	1,679,816	588,723
Current portion of long term financing	16	2,498,256	2,498,256
		4,178,072	3,086,979
23 PROVISION FOR TAXATION			
The current tax liability at the period end represents net balance of:			
Provision for current income tax		-	-
Less: adjusted against advance tax		-	-
		-	-

Liven Pharma Limited

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2026

24 CONTINGENCIES AND COMMITMENTS

24.1 Contingencies

- There are no contingencies to report as at the reporting date (June 30, 2025: Nil).

24.2 Commitments

- There are no commitments to report as at the reporting date except as disclosed in note 15.2. (June 30, 2025: Nil).

	Note	2026 (Rupees)	2025 (Rupees)
25 SALES - NET			
Local sales - gross		93,922,352	130,680,311
Less: trade discount		(1,347,440)	(2,983,199)
Less: sales tax		(916,558)	(425,163)
Total local sales - net		91,658,354	127,271,949
Export sales		14,148,201	-
Sales - net		105,806,555	127,271,949
26 COST OF SALES			
Raw material consumed	26.1	37,296,921	64,433,028
Packing material consumed	26.2	15,676,906	7,915,315
Stores, spares and loose tools consumed		16,880	545,790
Lab material consumed		1,813,045	273,793
Salaries, wages and benefits	26.3	11,281,320	14,093,412
Fuel and power		919,237	4,983,187
Vehicle running expenses		132,563	73,151
Repair and maintenance		1,391,724	1,103,557
Other manufacturing overheads		4,561,940	1,283,692
Depreciation on property, plant and equipment- owned assets	5.5	23,962,608	22,060,552
Depreciation on right of use asset	5.6	857,192	1,255,030
		97,910,336	118,020,509
Work in process			
Opening stock	8	26,888,118	29,712,611
Closing stock	8	(7,607,371)	(26,888,118)
Net change in work in process		19,280,747	2,824,493
Cost of goods manufactured		117,191,082	120,845,002
Finished goods			
Opening stock	8	19,389,515	7,857,681
Closing stock	8.1	(57,419,659)	(19,389,515)
Net change in finished goods		(38,030,144)	(11,531,834)
Total cost of sales		79,160,938	109,313,168
26.1 Raw material consumed			
Opening stock	8	65,875,646	73,912,343
Add: purchases		22,815,402	56,396,331
		88,691,048	130,308,674
Less: closing stock	8	(51,394,127)	(65,875,646)
Raw material consumed during the year		37,296,921	64,433,028
26.2 Packing material consumed			
Opening stock	8	9,633,794	10,203,984
Add: purchases		18,234,442	7,345,124
		27,868,236	17,549,108
Less: closing stock	8	(12,191,330)	(9,633,794)
Raw material consumed during the year		15,676,906	7,915,315
26.3	This includes provident fund contribution amounting Rs. 266,994 (2025: Rs. 37,287).		

RHacy

Liven Pharma Limited
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED JUNE 30, 2026

	Note	2026 (Rupees)	2025 (Rupees)
27 ADMINISTRATIVE AND GENERAL EXPENSES			
Directors' remuneration	27.3	15,348,811	14,475,850
Salaries, allowances and benefits	27.2	6,923,267	1,653,187
Vehicle running and maintenance		510,859	281,268
Communication		100,855	184,981
Fee and subscription		1,279,077	16,427,722
Rent		-	91,667
Printing and stationary		185,217	710,671
Travelling and conveyance		1,363,622	228,476
Repair and maintenance		612,730	2,138,696
Legal and professional charges		1,934,198	239,369
Fuel and power		1,896,082	3,429,812
Auditor's remuneration	27.4	661,750	517,500
Insurance		104,301	88,881
Amortization on intangible assets	6.2	3,643,757	2,963,319
Cleaning and sanitary		132,545	129,272
Entertainment		477,212	-
Medical expenses		216,318	-
Donation	27.5	750,639	-
CSR expenses		-	844,642
Depreciation on property, plant and equipment- owned assets	5.5	1,444,462	1,215,511
Depreciation on right of use asset	5.6	127,237	139,448
Listing expense	27.1	-	327,803,230
		37,712,939	373,563,504
27.1	This represented impact of net liabilities of Landmark Spinning Mills Limited acquired and the fair value of deemed shares issued to its shareholders in previous year, as a result of merger, recognized as a listing expense in accordance with applicable financial reporting framework.		
27.2	This includes provident fund contribution amounting Rs. 264,889 (2025: Rs. 8,842).		
27.3	This include provident fund contribution amounting to Rs. 720,000 (2025: Rs. 14,500).		
27.4	Auditors' remuneration		
		461,750	367,500
		50,000	50,000
		50,000	50,000
		50,000	50,000
		50,000	-
		-	-
		661,750	517,500
27.5	This includes donation given to Hopewell foundation amounting Rs. 610,000 (2025: Nil).		
28 SELLING AND DISTRIBUTION EXPENSES			
Salaries, allowances and benefits	28.1	7,034,790	8,657,598
Boarding, lodging and travelling		42,400	2,254,161
Fuel and power		589,203	1,016,616
Seminars and training		-	1,659,431
Advertisement		1,031,857	3,257,214
Freight charges		197,690	198,019
Fee and subscription		56,000	197,210
Legal and professional		-	72,842
Depreciation on property, plant and equipment- owned assets		681,884	-
Depreciation on right of use asset		127,976	-
Other miscellaneous selling expenses		-	293,581
		9,761,800	17,606,673
28.1	This includes provident fund contribution amounting Rs. Nil (2025: Rs. 4,964).		

Arora

Liven Pharma Limited
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED JUNE 30, 2026

	Note	2026 (Rupees)	2025 (Rupees)
29 OTHER EXPENSES			
Workers' Welfare Fund (WWF)	18.8	26,452	31,818
Bad debts written off	7 & 10.1	-	29,658,026
Allowance for expected credit loss	7.1	11,582,140	87,214,758
Provision for obsolete stock	8.2	36,760,211	-
Provision for impairment on advance to supplier	10.5	5,160,109	-
Penalties and deductions		173,197	-
Foreign exchange loss - net		69,595	-
		<u>53,771,704</u>	<u>116,904,602</u>
30 FINANCE COSTS			
Finance charges on lease liabilities	15.1	291,290	109,403
Additional charge on unpaid balance of WWF	18.8	4,773	-
Markup on running finance		950,156	386,364
Markup on long term financing		1,034,755	221,335
Interest expense on provident fund	18.3	172,034	9,786
Bank charges		86,503	58,786
		<u>2,539,511</u>	<u>785,675</u>
31 OTHER INCOME			
Profit on bank deposits		1,356,570	305,814
Markup on short term investments		4,473,947	-
Liabilities written back	18	1,722,383	-
Gain on disposal of property plant and equipment		4,665,920	-
		<u>12,218,820</u>	<u>305,814</u>
32 LEVIES			
Minimum tax u/s 113	32.1	1,322,582	1,590,899
Minimum tax u/s 154 - prior year		76,924	-
		<u>1,399,506</u>	<u>1,590,899</u>
32.1	This represents portion of minimum tax paid under section 113 of Income Tax Ordinance (ITO, 2001), representing levy in terms of requirements of IFRIC 21/IAS 37.		
32.2	Reconciliation of current tax charge charged as per tax laws for the year, with current tax recognised in the profit and loss account, is as follows:		
		1,322,582	1,590,899
Current tax liability for the year as per applicable tax laws			
Portion of current tax liability as per tax laws, representing income tax under IAS 12		-	-
Portion of current tax computed as per tax laws, representing levy in terms of requirements of IFRIC 21/IAS 37		(1,322,582)	(1,590,899)
Difference		<u>-</u>	<u>-</u>
33 TAXATION			
Current tax			
- Charge for the year		-	-
Deferred tax			
-Adjustment attributable to origination and reversal of temporary differences		(35,182,336)	92,272,765
		<u>(35,182,336)</u>	<u>92,272,765</u>
33.1	Reconciliation of tax expense and product of accounting profit multiplied by the applicable tax rate and numerical reconciliation between the average tax rate and the applicable tax rate is not provided due to the applicability of minimum turnover tax (2025: minimum turnover tax).		
	Note	2026	2025 Restated
34 LOSS PER SHARE - BASIC AND DILUTED			
Net loss for the year attributable to ordinary shareholders (Rupees)		(31,138,687)	(584,459,523)
Weighted average number of ordinary shares outstanding during the year (Number)		111,624,523	82,155,399
Loss per share (Rupees)		<u>(0.28)</u>	<u>(7.11)</u>

R. M. M.

Liven Pharma Limited

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED JUNE 30, 2026

- 34.1 Due to issuance of right shares during the year, the basic and diluted loss per share of the current and prior year has been adjusted for the said issue as per the requirements of IAS 33.
- 34.2 There is no difference between basic and diluted loss per share as the Company has not issued any instruments carrying options which would have an impact on loss per share when exercised.

35 TRANSACTIONS WITH RELATED PARTIES

The related parties comprise of associated companies/undertakings, directors of the Company and key management personnel. Remuneration of key management personnel is disclosed in note 36 to these financial statements. Details of transactions with related parties during the year other than those which have been disclosed elsewhere in these financial statements are stated below:

Name of related party	Nature of relationship	Transaction Details	2026	2025
			Rupees	Rupees
Key Management Personnel:				
Mr. Kaashif Hussain Siddiquie	- Chief Executive & Shareholder - Percentage shareholding 43.29% (2025: 43.48%)	Expense incurred on behalf of	1,388,465	14,047,263
		Loan repaid	408,148	-
		Right shares issued during the year	91,949,150	-
		Shares issued against loan from director	-	71,250,000
Mr. Atif Hussain Siddiquie	-Director & Shareholder - Percentage shareholding 43.18% (2025: 43.48%)	Expense incurred on behalf of	255,000	-
		Right shares issued during the year	91,438,820	-
		Shares issued against loan from director	-	71,250,000

ATD

LIVEN PHARMA LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2026

36 REMUNERATION OF CHIEF EXECUTIVE OFFICER, DIRECTORS AND EXECUTIVES

	2026				2025			
	CEO	Directors	Executives	Total	CEO	Directors	Executives	Total
	Rupees.....				Rupees.....			
Remuneration	7,200,000	7,200,000	6,127,748	20,527,748	7,241,350	7,220,000	1,380,000	15,841,350
Retirement benefits	360,000	360,000	300,897	1,020,897	-	-	-	-
Bonus	-	-	-	-	-	-	-	-
Any other benefits	104,289	124,522	-	228,811	7,250	7,250	-	14,500
Total	7,664,289	7,684,522	6,428,645	21,777,456	7,248,600	7,227,250	1,380,000	15,855,850
No. of persons	1	1	3	5	1	1	1	3

36.1 Chief Executive, Director Human Resource, Executive Director Sales and Regional Managers Sales are entitled to use the Company maintained cars.

36.2 Directors' remuneration represents remuneration of Director Human Resource (Firdous Shakir - relative of Chief Executive).

37 FINANCIAL INSTRUMENT BY CATEGORY

	Note	2026		2025	
		Maturity upto one year	Maturity after one year	Maturity upto one year	Maturity after one year
		Rupees			
		Non mark-up bearing			
Financial assets					
At amortized cost					
Trade debts	7	11,115,542	-	9,402,578	-
Security deposits	10	634,500	-	703,565	-
Accrued markup on short term investments	10	863,273	-	-	-
Cash and bank balances	12	7,319,949	-	7,864,479	-
		19,933,264	-	17,970,622	-
		Mark-up bearing			
At amortized cost					
Short term investment	11	163,300,000	-	-	-
Cash and bank balances	12	10,930,945	-	19,917	-
		174,230,945	-	19,917	-
		Non mark-up bearing			
Financial liabilities					
At amortized cost					
Loan from related parties	19	15,282,580	-	14,047,263	-
Trade creditors	18	25,750,836	-	25,452,121	-
Accrued liabilities	18	34,043,083	-	19,865,385	-
Audit fee payable	18	771,750	-	517,500	-
Mark up accrued	21	304,745	-	386,020	-
		76,152,994	-	60,268,289	-
		Mark-up bearing			
At amortized cost					
Lease liabilities	15	1,679,816	2,338,379	588,723	1,247,868
Provident fund payable	18	2,816,771	-	140,971	-
Long term financing	16	2,498,256	2,520,472	2,498,256	5,098,065
Running finance	20	9,117,046	-	11,185,166	-
		16,111,889	4,858,851	14,413,116	6,345,933
		92,264,883	4,858,851	74,681,405	6,345,933

Atty

LIVEN PHARMA LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2026

	Note	2026 Rupees	2025 Rupees
38 FINANCIAL INSTRUMENTS			
The gross carrying amounts of the Company's financial instruments by class and category are as follows:			
38.1 Financial assets			
- Financial assets - at amortized cost			
Trade debts	7	11,115,542	9,402,578
Prepayments, deposits and advances	10	1,497,773	703,565
Short term investments	11	163,300,000	-
Cash and bank balances	12	18,250,894	7,884,396
		194,164,209	17,990,539
38.2 Financial liabilities - at amortized cost			
Lease liabilities	15	4,018,195	1,836,591
Long term financing	16	5,018,728	7,596,321
Loan from related party	20	15,282,580	14,047,263
Trade and other payables	18	63,382,440	45,975,977
Running finance	20	9,117,046	11,185,166
Mark up accrued	21	304,745	386,020
		97,123,734	81,027,338

39 FINANCIAL RISK MANAGEMENT

- The Company's activities expose it to a variety of financial risks: credit risk, liquidity risk and market risk (including currency risk, interest rate risk and price risk).
- The Board of Directors has the overall responsibility for establishment and oversight of risk management framework. The Board of Directors has developed a risk policy that sets out fundamentals of risk management framework. The risk policy focuses on unpredictability of financial markets, the Company's exposure to risk of adverse effects thereof and objectives, policies and processes for measuring and managing such risks. The management team of the Company is responsible for administering and monitoring the financial and operational financial risk management throughout the Company in accordance with the risk management framework.
- The Company's exposure to financial risks, the way these risks affect the financial position and performance, and forecast transactions of the Company and the manner in which such risks are managed is as follows:

39.1 Credit Risk

- Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations. The maximum exposure to credit risk is equal to the carrying amount of financial assets.

39.1.1 Exposure to credit risk

- Credit risk principally arises from debt instruments held by the Company as at the reporting date. The maximum exposure to credit risk as at the reporting date is as follows:

Financial assets at amortized cost	2026	2025
	Rupees	
Trade debts	11,115,542	9,402,578
Prepayments, deposits and advances	1,497,773	703,565
Short term investments	163,300,000	-
Bank balances	10,960,266	45,449
	186,873,581	10,151,592

(a) Trade debts

These include customers which are counter parties to trade debts. The Company is exposed to credit risk in respect of trade debts. The analysis of ages of trade debts of the Company as at the reporting date is as follows:

R. P. Singh

LIVEN PHARMA LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2026

- Aging analysis of the trade debts

	Exposure at default	Expected credit loss	Expected credit loss rate
	Rupees		%
30-Jun-26			
Not yet past due			
0 - 30 days	1,541,585	-	0%
Past due but not impaired			
31 to 90 days	924,093	-	0%
Past due and impaired			
91 to 180 days	10,624,861	2,656,215	25%
181 to 270 days	1,362,437	681,219	50%
271 to 365 days	260,383	260,383	100%
365 days above	95,199,081	95,199,081	100%
	109,912,440	98,796,898	
30-Jun-25			
Not yet past due			
0 - 30 days	7,797,027	-	0%
Past due but not impaired			
31 to 90 days	562,149	-	0%
Past due and impaired			
91 to 180 days	790,878	197,720	25%
181 to 270 days	900,487	450,244	50%
271 to 365 days	6,394,070	6,394,070	100%
365 days above	80,172,725	80,172,725	100%
	96,617,336	87,214,758	

An impairment analysis is performed at reporting date using a provision matrix to measure expected credit losses. The provision rates are based on days past due for groupings of various parties with similar loss pattern (i.e., by type and rating). The calculation reflects the probability weighted outcome, the time value of money and reasonable and supportable information that is available at the reporting date about past events, current conditions and forecast of future economic conditions. The maximum exposure to credit risk at the reporting date of carrying value of each class of financial assets. The Company does not hold collateral as security. The information about the credit risk exposure on the Company's advances and other receivables using the provision matrix is given above.

(b) Bank balances and short term investments

- The bankers of the Company have reasonably high credit ratings as determined by various independent credit rating agencies. Considering their strong financial standing, management does not expect any credit loss. The external credit ratings of the Company's banks are as follows:

Bank name	Credit rating agency	Short Term	Long Term	— Rupees —	
Meezan Bank Limited	VIS	A-1+	AAA	10,715,280	19,917
Meezan Bank Limited	VIS	A-1+	AAA	163,300,000	-
United bank Limited	PACRA	A-1+	AAA	215,666	-
Bank Alfalah Limited	PACRA	A-1+	AAA	26,700	-
Bank Al Habib	PACRA	A-1+	AAA	2,620	25,532

(c) Prepayments, deposits and advances

This includes security deposits placed with government institutions and a hospital amounting to Rs. 634,500 (2025: Rs. 703,565), which are considered to have low credit risk, and accrued mark-up on short-term investments amounting to Rs. 863,273 (2025: Rs. Nil). The credit ratings of the banks and financial institutions concerned are given in note 39.1.1(b)

39.1.2 Concentrations of credit risk

- The Company determines concentrations of credit risk by type of counterparty. Maximum exposure to credit risk, as at the reporting date, by type of counterparty is as follows:

Q. Husey

LIVEN PHARMA LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2026

Financial assets at amortized cost	2026	2025
	Rupees	
Customers	11,115,542	9,402,578
Deposits with government institutions and hospital	634,500	703,565
Banking companies and financial institutions	175,123,539	7,884,396
	186,873,581	17,990,539

- There were 2 customer (2025: Nil) with balance exceeding 10% of total amounts of trade receivable.

39.2 Liquidity risk management

- Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due.

39.2.1 Liquidity risk management

- The Company's approach to managing liquidity risk is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation. The Company manages liquidity risk maintaining adequate reserves, banking facilities and by continuously monitoring forecast and actual cashflows, and by matching the maturity profiles of financial assets and liabilities. There were no changes in the Company's approach to liquidity risk management during the year.

39.2.2 Exposure to liquidity risk

- The following table presents the Company's remaining contractual maturity for its non-derivative financial liabilities with agreed repayment periods. The analysis have been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the Company can be required to pay.

As at June 30, 2026	Carrying Amount	Contractual Cash Flows	Less than One Year	More than one year to five years	More than five years	Total
	Rupees					
Financial Liabilities						
<i>Interest bearing</i>						
Lease liabilities	4,018,195	4,810,764	1,907,124	2,903,640	-	4,810,764
Long term financing	5,018,728	5,035,582	2,515,110	2,520,472	-	5,035,582
Running finance	9,117,046	9,404,937	9,404,937	-	-	9,404,937
Mark up accrued	304,745	304,745	304,745	-	-	304,745
Trade and other payables	2,816,771	2,816,771	2,816,771	-	-	2,816,771
<i>Non-interest bearing</i>						
Loan from related parties	15,282,580	15,282,580	15,282,580	-	-	15,282,580
Trade and other payables	60,565,669	60,565,669	60,565,669	-	-	60,565,669
Total	97,123,734	98,221,048	92,796,936	5,424,112	-	98,221,048

As at June 30, 2025	Carrying Amount	Contractual Cash Flows	Less than One Year	More than one year to five years	More than five years	Total
	Rupees					
Financial Liabilities						
<i>Interest bearing</i>						
Lease liabilities	1,836,591	2,242,303	815,383	1,426,920	-	2,242,303
Long term financing	7,596,321	7,656,596	2,558,531	5,098,065	-	7,656,596
Running finance	11,185,166	11,510,911	11,510,911	-	-	11,510,911
Mark up accrued	386,020	386,020	386,020	-	-	386,020
Trade and other payables	140,971	140,971	140,971	-	-	140,971
<i>Non-interest bearing</i>						
Loan from related parties	14,047,263	14,047,263	14,047,263	-	-	14,047,263
Trade and other payables	45,835,006	45,835,006	45,835,006	-	-	45,835,006
Total	81,027,338	81,819,070	75,294,085	6,524,985	-	81,819,070

- It is not expected that the cash flows included in the maturity analysis could occur significantly earlier or at significantly different amounts.

Attney

LIVEN PHARMA LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2026

39.3 Market risk

- Market risk is the risk that changes in market prices, such as currency risk, interest rates and equity prices will affect the Company's income or the value of its holdings of the financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimizing return.

39.3.1 Currency risk

- Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. Currency risk arises mainly from future commercial transactions or receivables and payables that exist due to transactions in foreign currencies.

As at reporting date the Company is not exposed to currency risk as there are no foreign receivables / payables. Accordingly no currency rate sensitivity analysis has been presented.

39.3.2 Other price risk

- Other price risk represents the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices (other than those arising from interest rate risk or currency risk), whether those changes are caused by factors specific to the individual financial instrument or its issuer, or factors affecting all similar financial instrument traded in the market. The Company is not exposed to other price risk.

39.3.3 Interest rate risk

- Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates.

(a) Interest rate risk management

- The Company manages interest rate risk by analyzing its interest rate exposure on a dynamic basis. Cash flow interest rate risk is managed by simulating various scenarios taking into consideration refinancing, renewal of existing positions and alternative financing. Based on these scenarios, the Company calculates impact on profit after taxation and equity of defined interest rate shift, mostly 100 basis points. There were no changes in Company's approach to interest rate risk management during the year.

(b) Interest rate risk exposure

Particulars	2026	2025	2026	2025
	Effective markup rate %		Carrying value in Rupees	
Financial asset				
Variable rate instruments				
Short term investments	9.6% to 10.50%	-	163,300,000	-
Cash and bank balances	0.13% to 10%	5.87% to 10.01%	10,930,945	19,917
Financial liabilities				
Variable rate instruments				
Lease Liabilities	14.07% to 14.46%	15.03%	4,018,195	1,836,591
Long term finances	13.49% to 15.56%	14.13% to 22.39%	5,018,728	7,596,321
Provident fund payable	10.74% to 12.98%	7.46%	2,816,771	140,971
Running finance	13.63% to 14.79%	14.15% to 19.13%	9,117,046	11,185,166
			9,036,923	9,432,912

(c) Interest bearing financial instruments

- The effective interest rates for interest bearing financial instruments are mentioned in relevant notes to the financial statements. The Company's interest rate profile of financial instruments as at the reporting date is as follows:

RH/cey

LIVEN PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED JUNE 30, 2026

Particulars	2026		
	Exposed to Yield / Interest risk	Not exposed to Yield / Interest rate risk	Total
	Rupees		
Financial assets as per statement of financial position			
Trade debts	-	11,115,542	11,115,542
Prepayments, deposits and advances	-	1,497,773	1,497,773
Short term investments	163,300,000	-	163,300,000
Cash and bank balances	10,930,945	7,319,949	18,250,894
Total	174,230,945	19,933,264	194,164,209
Financial liabilities as per statement of financial position			
Loan from related parties	-	15,282,580	15,282,580
Trade and other payables	2,816,771	60,565,669	63,382,440
Lease liabilities	4,018,195	-	4,018,195
Long term financing	5,018,728	-	5,018,728
Running finance	9,117,046	-	9,117,046
Mark up accrued	-	304,745	304,745
Total	20,970,740	76,152,994	97,123,734

Particulars	2025		
	Exposed to Yield / Interest risk	Not exposed to Yield / Interest rate risk	Total
	Rupees		
Financial assets as per statement of financial position			
Trade debts	-	9,402,578	9,402,578
Prepayments, deposits and advances	-	703,565	703,565
Cash and bank balances	19,917	7,864,479	7,884,396
Total	19,917	17,970,622	17,990,539
Financial liabilities as per statement of financial position			
Loan from related parties	-	14,047,263	14,047,263
Trade and other payables	140,971	45,835,006	45,975,977
Lease liabilities	1,836,591	-	1,836,591
Long term financing	7,596,321	-	7,596,321
Running finance	11,185,166	-	11,185,166
Mark up accrued	-	386,020	386,020
Total	20,759,049	60,268,289	81,027,338

(d) Fair value sensitivity analysis for fixed rate instruments

- The Company does not account for any fixed rate financial assets and liabilities at fair value through profit or loss. Therefore, a change in interest rate at the reporting date would not affect profit or loss of the Company.

(e) Cash flow sensitivity analysis for variable rate instruments

- If interest rate had been 1% higher/ lower with all other variable held constant, loss before taxation for the year would have been lower/ higher by Rs. 1,532,602/- (2025: Rs.207,391/-)

R. Ramesh

LIVEN PHARMA LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2026

40 FAIR VALUE ESTIMATION

- Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

40.1 Fair value hierarchy

- The Company has established a fair value hierarchy that categorises into three levels the inputs to valuation techniques used to measure fair value.
- Level Quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices).
- Level Inputs for the asset or liability that are not based on observable market data (that is, unobservable inputs).
- The Company recognizes transfers between levels of the fair value hierarchy at the end of the reporting period during which the transfer has occurred.
- The Company's policy for determining when transfers between levels in the hierarchy have occurred includes monitoring of the following factors:
 - changes in market and trading activity (e.g. significant increases / decreases in activity)
 - changes in inputs used in valuation techniques (e.g. inputs becoming / ceasing to be observable in the market)

40.2 Non-financial assets measured at fair value

40.2.1 Recurring fair value measurements

For non-financial assets that are recognized in the financial statements at fair value on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by re-assessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

Fair value measurement using			
Quoted price in active market	Significant observable inputs	Significant unobservable inputs	Total
(Level 1)	(Level 2)	(Level 3)	
-----Rupees-----			

June 30, 2026

Revalued property, plant and equipment

Freehold land	-	148,050,000	-	148,050,000
Buildings on freehold land	-	-	266,742,400	266,742,400
Plant and machinery	-	-	446,989,510	446,989,510
Furniture and fixture	-	-	12,142,503	12,142,503
Motor vehicles	-	34,863,571	-	34,863,571
	-	182,913,571	725,874,413	908,787,984

June 30, 2025

Revalued property, plant and equipment

Freehold land	-	105,750,000	-	105,750,000
Buildings on freehold land	-	-	198,209,668	198,209,668
Plant and machinery	-	-	336,506,660	336,506,660
Furniture and fixture	-	-	3,619,653	3,619,653
Motor vehicles	-	9,833,801	-	9,833,801
	-	115,583,801	538,335,981	653,919,782

Retained

LIVEN PHARMA LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2026

40.2.2 Valuation techniques used to derive level 2 and level 3 fair values

The Company obtains independent valuations for its certain classes of property, plant and equipment at least every three years. At the end of each reporting period, the management updates its assessment of the fair value of each asset mentioned above, taking into account the most recent independent valuation. The management determines an asset's value within a range of reasonable fair value estimates. Level 2 fair value of freehold land has been derived using a sales comparison approach. Sale prices of comparable land in close proximity are adjusted for differences in key attributes such as location and size of the property. Level 3 fair value of building on freehold land has been determined using a depreciated replacement cost approach, whereby, current cost of construction of a similar building in a similar location has been adjusted using a suitable depreciation rate to arrive at present market value. Level 3 fair value of plant and machinery has been determined using a depreciated replacement cost approach, whereby, the current replacement cost of items of similar make/origin, capacity and level of technology has been adjusted using a suitable depreciation rate on account of normal wear and tear. Level 3 fair value of furniture and fixtures has been determined using a depreciated replacement cost approach. Level 2 fair value of motor vehicles has been derived using a sales comparison approach. Sales prices of comparable motor vehicles in identical circumstances are adjusted for differences in key attributes such as condition of vehicles.

Description	2026	2025	Significant unobservable inputs	Quantitative data / range and relationship to the fair value
	Rupees	Rupees		
Buildings on freehold land	266,742,400	198,209,668	Cost of construction of a new similar building. Suitable depreciation rate to arrive at depreciated replacement value.	The market value has been determined by using a suitable depreciation factor on cost of constructing a similar new building. Higher, the estimated cost of construction of a new building, higher the fair value. Further, higher the depreciation rate, the lower the fair value of the building.
Plant and machinery	446,989,510	336,506,660	Cost of acquisition of similar plant and machinery with similar level of technology. Suitable depreciation rate to arrive at depreciated replacement value.	The market value has been determined by using cost of acquisition of similar plant and machinery with similar level of technology and applying a suitable depreciation factor based on remaining useful lives of plant and machinery. The higher the cost of acquisition of similar plant and machinery, higher the fair value of plant and machinery. Further, higher the depreciation rate, the lower the fair value of plant and machinery.
Furniture and fixture	12,142,503	3,619,653	Cost of acquisition of similar furniture and fixture with similar level of specifications. Suitable depreciation rate to arrive at depreciated replacement value.	The market value has been determined by using cost of acquisition of similar furniture and fixture with similar level of specifications and applying a suitable depreciation factor based on remaining useful lives of plant and machinery. The higher the cost of acquisition of similar furniture and fixture, higher the fair value of plant and machinery. Further, higher the depreciation rate, the lower the fair value of furniture and fixture.

Attorney

LIVEN PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED JUNE 30, 2026

	Note	2026 Rupees	2025 Rupees
40.2.3 Reconciliation of Level 3 fair values			
Opening balance			
-Buildings on freehold land		198,209,668	208,641,756
-Plant and machinery		336,506,660	334,940,215
-Furniture and fixture		3,619,653	4,021,837
		<u>538,335,981</u>	<u>547,603,808</u>
Add: Purchases		5,362,500	11,697,244
Less: Sales		-	-
Add: Revaluation surplus recongnized in other comprehensive income		202,618,705	-
Less: Depreciation expense recongnized in profit or loss		<u>(20,442,773)</u>	<u>(20,965,071)</u>
Closing balance		<u>725,874,413</u>	<u>538,335,981</u>

40.2.4 Non-recurring fair value measurements

There are no non-recurring fair value measurements as at the reporting date.

40.2.5 Financial instruments measured at fair value

As at June 30, 2026, all financial assets and financial liabilities are carried at amortised cost which is approximate to their fair value.

41 CAPITAL RISK MANAGEMENT

- The Company's policy is to maintain an efficient capital base so as to maintain investor, creditor and market confidence and to sustain the future development of the Company's business. The Board of Directors monitors the Return on Capital Employed, which the Company defines as operating income divided by total capital employed. The Board of Directors also monitors the level of dividends to ordinary shareholders.
- The Company's objectives when managing capital are:
 - a) to safeguard its ability to continue as a going concern, so that it can continue to provide returns for shareholders and benefits for other stakeholders; and
 - b) to provide an adequate return to shareholders.
- The Company manages the capital structure in the context of economic conditions and the risk characteristics of the underlying assets. In order to maintain or adjust the capital structure, the Company may, for example, adjust the amount of dividends paid to shareholders, issue new shares, if possible, selling surplus property, plant and equipment without affecting the optimal production and operating level and regulating its dividend payout thus maintaining smooth capital management.
- In line with the industry norms, the Company monitors capital on the basis of the gearing ratio.

- As at the reporting date, the gearing ratio of the Company was worked out as under:

Total borrowings	A	33,741,294	35,051,361
Less: Cash and bank balances	B	(18,250,894)	(7,884,396)
Net debt	C=A-B	15,490,400	27,166,965
Total Equity	D	985,458,014	633,860,394
Total capital Employed	E=C+D	1,000,948,414	661,027,359
Gearing ratio	F=C/E	1.55%	4.11%

41.1 Total debt includes long term financing, loan from related parties, running finance, lease liabilities and markup accrued.

41.2 The total equity includes share capital and reserves of the Company. Total capital employed includes total equity plus debt.

41.3 The Company is not subject to externally imposed capital requirements. There were no changes in the Company's approach to capital management during the year.

RTM

LIVEN PHARMA LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2026

42 CHANGES FROM FINANCING CASH FLOWS

Particulars - June 30, 2026	Issued, subscribed and paid up capital	Long term financing	Lease liabilities	Loan from related parties	Running finance
	Rupees				
As at beginning of the year	930,403,670	7,596,321	1,836,591	14,047,263	11,185,167
Addition of liability during the year	-	-	2,879,456	-	-
Repayment of liability	-	(2,577,593)	(989,142)	-	-
Amount paid during the year by the Company	-	-	-	(408,148)	(92,847,335)
Amount received during the year by the Company	-	-	-	1,643,465	90,779,215
Amount received through issuance of right shares	200,000,000	-	-	-	-
Non-cash items					
Expenses paid by the related party on behalf of Company	-	-	-	-	-
Cancellation of share capital of LPL as per scheme of share arrangement	-	-	-	-	-
Deemed issue of shares to shareholders of LSML as per scheme of share arrangement	-	-	-	-	-
Issuance of shares to shareholders of LPL as per scheme of share arrangement	-	-	-	-	-
Adjusted against issuance of share	-	-	-	-	-
Lease liabilities extinguished	-	-	291,290	-	-
Interest on lease liabilities	-	-	-	-	-
Current maturity presented under current liabilities	-	-	-	-	-
As at end of the year	1,130,403,670	5,018,728	4,018,195	15,282,580	9,117,047

Particulars - June 30, 2025	Issued, subscribed and paid up capital	Long term financing	Lease liabilities	Loan from related parties	Running finance
	Rupees				
As at beginning of the year	400,000	1,358,000	395,413	142,500,000	12,656,065
Addition of liability during the year	-	6,680,000	2,799,000	-	-
Repayment of liability	-	(441,679)	(1,467,225)	-	-
Amount paid during the year by the Company	-	-	-	-	(156,143,152)
Amount received during the year by the Company	-	-	-	-	154,672,254
Non-cash items					
Expenses paid by the related party on behalf of Company	-	-	-	14,047,263	-
Cancellation of share capital of LPL as per scheme of share arrangement	-	-	-	-	-
Deemed issue of shares to shareholders of LSML as per scheme of share arrangement	121,237,000	-	-	-	-
Issuance of shares to shareholders of LPL as per scheme of share arrangement	808,766,670	-	-	-	-
Adjusted against issuance of share	-	-	-	(142,500,000)	-
Lease liabilities extinguished	-	-	-	-	-
Interest on lease liabilities	-	-	109,403	-	-
Current maturity presented under current liabilities	-	-	-	-	-
As at end of the year	930,403,670	7,596,321	1,836,591	14,047,263	11,185,167

43 ENTITY-WIDE INFORMATION AND DISCLOSURES

- For management purposes, the activities of the Company are recognized into one operating segment, i.e. manufacturing and selling of pharmaceutical products. The Company operates in the said reportable operating segment based on the nature of the product, risk and return, organizational and management structure and internal financial reporting systems. Accordingly, the figures reported in these financial statements relate to the Company's only one reportable segment. The Company-wide disclosures regarding the reportable segments are as follows:

	Note	2026 Rupees	2025 Rupees
43.1 Information about products			
- Medicine		105,806,555	127,271,949
		<u>105,806,555</u>	<u>127,271,949</u>
43.2 Information about major customers			
- 2 Customers (2025: Nil)		58.98%	0.00%
43.3 Information about geographical areas			
- Revenue			
Pakistan (Domicile country)		91,658,354	127,271,949
Yemen		14,148,201	-
		<u>105,806,555</u>	<u>127,271,949</u>

Rkheer

LIVEN PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED JUNE 30, 2026

- All non-current assets of the Company are located in Pakistan as at the reporting date.

44 PLANT CAPACITY AND PRODUCTION

	2026 No. of units	2025 No. of units
Installed capacity	12,000,000	12,000,000
Actual production	721,676	882,914

44.1 The capacity and production of the Company's plant are indeterminable as these are multi-product and involve varying processes of manufacture.

45 DETAILS OF FACILITIES UN-AVAILED ARE AS FOLLOWS:

Facility	Purpose	Bank	Total amount	Unavailed amount (2026)	Unavailed amount (2025)
.....Rupees.....					
Running Finance	To meet working capital requirements	Al Habib Bank Limited	13,000,000	3,882,954	1,911,733
Finance Against Trust Receipt	For retirement of shipping documents under LC sight & bank contract registered through BAHLL	Al Habib Bank Limited	3,000,000	3,000,000	3,000,000
Lease Finance	For the purpose of brand new non-commercial vehicles of local manufacturer	Al Habib Bank Limited	1,872,000	-	-
Term Finance	For purchase of brand new locally manufactured commercial vehicle	Al Habib Bank Limited	1,086,404	-	-
Term Finance	For purchase of brand new balister packing machine for the use of company	Al Habib Bank Limited	4,639,000	-	-
Term Finance	For purchase of brand new machinery for the use of company	Al Habib Bank Limited	1,870,917	-	-
Letter of Credit	To import pharma raw material	Al Habib Bank Limited	62,000,000	62,000,000	62,000,000

Note 2026 2025
 Rupees Rupees

46 SHARIAH COMPLIANT DISCLOSURE

46.1 In accordance with the requirements of the Securities and Exchange Commission of Pakistan (SECP) vide SRO 1278(I) / 2024 dated August 15, 2024. The Company has disclosed its assets, liabilities, income and expenditure related to financing, investments and other income/expenses etc. between shariah and conventional elements as follows:

Statement of Financial Position - liability side

Mark-up accrued on conventional loans	21	304,745	386,020
Financing obtained as per islamic mode		-	-

Statement of Financial Position - asset side

Short term shariah compliant investments	11	163,300,000	-
Shariah compliant bank deposits, bank balances	12	10,715,280	19,917

Statement of comprehensive income

Revenue earned from a shariah-compliant business segment	25	105,806,555	127,271,949
Break-up of late payments or liquidated damages		-	-
Gain or loss or dividend earned on shariah compliant investments or share of profit from shariah-compliant associates		-	-

Attestation

LIVEN PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED JUNE 30, 2026

	Note	2026 Rupees	2025 Rupees
Profit earned from Shariah-compliant bank deposits, bank balances, or TDRs	31	4,532,221	305,814
Exchange gain/(loss) earned from actual currency	29	(69,595)	-
Exchange gains earned using conventional derivative financial instruments		-	-
Profit paid on Islamic mode of financing		-	-
Total interest earned on any conventional loan or advance		-	-

	2026Rupees.....			2025Rupees.....		
	Non-shariah	Shariah compliant	Total	Non-shariah	Shariah compliant	Total
Statement of comprehensive income - other income (note 31)						
Profit on bank deposits	1,298,296	58,274	1,356,570	-	305,814	305,814
Income from short term investment	-	4,473,947	4,473,947	-	-	-
Liabilities written back	-	1,722,383	1,722,383	-	-	-
Gain on disposal of property plant and equipment	-	4,665,920	4,665,920	-	-	-
	1,298,296	10,920,524	12,218,820	-	305,814	305,814

46.2 The Company has no insurance relationships with takaful operators and their windows.

46.3 Relationship with Shariah-compliant financial institutions, including banks (have been disclosed in respective notes to the financial statements) is as follows:

Name	Relationship
Meezan Bank Limited	Short term investment and bank balances

47 **NUMBER OF EMPLOYEES**

- The total number of persons employed as at the year end date and the average number of employees during the year are as follows:

	2026	2025
	(Numbers)	
Total employees		
Number of employees as at June 30,	39	41
Average number of employees during the year	43	60
Factory employees		
Number of employees as at June 30,	25	24
Average number of employees during the year	25	33

48 **CORRESPONDING FIGURES**

- Corresponding figures have been rearranged and reclassified, wherever considered necessary, for the purposes of better presentation and to comply with requirements of accounting and reporting standards (IFRSs) and requirements of the 4th schedule of the Companies Act, 2017, the effects of which are not considered material.

- Advance from customer amounting Rs. 13,246,564 previously classified in trade creditors, has been reclassified and shown in advance from customer.

Rthika

LIVEN PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED JUNE 30, 2026

49 AUTHORIZATION OF FINANCIAL STATEMENTS

49.1 These financial statements were approved and authorized for issue on October 02, 2026 by the Board of Directors of the Company.



Chief Executive



Director



Chief Financial Officer